|
Cayman Islands
(State or other jurisdiction of
incorporation or organization) |
| |
6770
(Primary Standard Industrial
Classification Code Number) |
| |
N/A
(I.R.S. Employer
Identification Number) |
|
|
Joel L. Rubinstein
White & Case LLP 1221 Avenue of the Americas New York, New York 10020 (212) 819-8200 |
| |
Jessica Zhou
White & Case 16th Floor, York House The Landmark, 15 Queen’s Road Central Central, Hong Kong (852) 2822 8725 |
| |
Mitchell S. Nussbaum, Esq.
Loeb & Loeb LLP 345 Park Avenue New York, NY 10154 (212) 407-4000 |
| |
Janeane R. Ferrari, Esq.
Loeb & Loeb LLP 345 Park Avenue New York, NY 10154 (212) 407-4000 |
|
|
Large accelerated filer
☐
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☒
|
| |
Smaller reporting company
☒
|
|
| | | |
Emerging growth company
☒
|
|
| | |
Assuming No
Redemptions (Shares) |
| |
%
Ownership |
| |
Assuming
Interim Redemptions(1) (Shares) |
| |
%
Ownership |
| |
Assuming
Maximum Redemptions(2) (Shares) |
| |
%
Ownership |
| ||||||||||||||||||
DiaCarta Equity Holders(3)
|
| | | | 46,000,000 | | | | | | 47.1% | | | | | | 46,000,000 | | | | | | 59.7% | | | | | | 46,000,000 | | | | | | 76.6% | | |
HH&L Class A ordinary shares
|
| | | | 41,400,000 | | | | | | 42.4% | | | | | | 20,700,000 | | | | | | 26.9% | | | | | | 3,718,907 | | | | | | 6.2% | | |
HH&L Class B ordinary shares
|
| | | | 10,350,000 | | | | | | 10.6% | | | | | | 10,350,000 | | | | | | 13.4% | | | | | | 10,350,000 | | | | | | 17.2% | | |
Pro forma common stock outstanding at September 30, 2022
|
| | | | 977,500,000 | | | | | | 100% | | | | | | 77,050,000 | | | | | | 100% | | | | | | 60,068,907 | | | | | | 100% | | |
| | |
Assuming No
Redemptions (Shares) |
| |
%
Ownership |
| |
Assuming
Interim Redemptions(1) (Shares) |
| |
%
Ownership |
| |
Assuming
Maximum Redemptions(2) (Shares) |
| |
%
Ownership |
| ||||||||||||||||||
DiaCarta Equity Holders(3)
|
| | | | 46,000,000 | | | | | | 47.1% | | | | | | 46,000,000 | | | | | | 59.7% | | | | | | 46,000,000 | | | | | | 76.6% | | |
HH&L Class A ordinary shares
|
| | | | 41,400,000 | | | | | | 42.4% | | | | | | 20,700,000 | | | | | | 26.9% | | | | | | 3,718,907 | | | | | | 6.2% | | |
HH&L Class B ordinary shares
|
| | | | 10,350,000 | | | | | | 10.6% | | | | | | 10,350,000 | | | | | | 13.4% | | | | | | 10,350,000 | | | | | | 17.2% | | |
Pro forma common stock outstanding at September 30, 2022
|
| | | | 977,500,000 | | | | | | 100% | | | | | | 77,050,000 | | | | | | 100% | | | | | | 60,068,907 | | | | | | 100% | | |
| | |
Page
|
| |||
| | | | 38 | | | |
| | | | 62 | | | |
| | | | 64 | | | |
| | | | 67 | | | |
| | | | 69 | | | |
| | | | 71 | | | |
| | | | 72 | | | |
| | | | 171 | | | |
| | | | 179 | | | |
| | | | 215 | | | |
| | | | 216 | | | |
| | | | 223 | | | |
| | | | 225 | | | |
| | | | 237 | | | |
| | | | 239 | | | |
| | | | 241 | | | |
| | | | 248 | | | |
| | | | 249 | | | |
| | | | 266 | | | |
| | | | 278 | | | |
| | | | 295 | | | |
| | | | 304 | | | |
| | | | 350 | | | |
| | | | 368 | | | |
| | | | 375 | | | |
| | | | 380 | | | |
| | | | 383 | | | |
| | | | 387 | | | |
| | | | 390 | | | |
| | | | 394 | | | |
| | | | 395 | | | |
| | | | 396 | | | |
| | | | 397 | | | |
| | | | 398 | | | |
| | | | 399 | | | |
| | | | 400 | | | |
| | | | 401 | | | |
| | | | 402 | | | |
| | | | F-1 | | | |
| | | | A-1 | | |
| | |
Page
|
| |||
| | | | B-1 | | | |
| | | | C-1 | | | |
| | | | D-1 | | | |
| | | | E-1 | | | |
| | | | F-1 | | | |
| | | | G-1 | | | |
| | | | H-1 | | | |
| | | | I-1 | | | |
| | | | J-1 | | | |
| | | | K-1 | | |
| | |
Assuming No
Redemptions (Shares) |
| |
%
Ownership |
| |
Assuming
Interim Redemptions(1) (Shares) |
| |
%
Ownership |
| |
Assuming
Maximum Redemptions(2) (Shares) |
| |
%
Ownership |
| ||||||||||||||||||
DiaCarta Equity Holders holding Ordinary Shares
|
| | | | 25,617,380 | | | | | | 19.9% | | | | | | 25,617,380 | | | | | | 23.7% | | | | | | 25,617,380 | | | | | | 28.1% | | |
DiaCarta Equity Holders
holding DiaCarta Series A Preference Shares |
| | | | 6,788,217 | | | | | | 5.3% | | | | | | 6,788,217 | | | | | | 6.3% | | | | | | 6,788,217 | | | | | | 7.5% | | |
DiaCarta Equity Holders
holding DiaCarta Series B Preference Shares |
| | | | 10,962,622 | | | | | | 8.5% | | | | | | 10,962,622 | | | | | | 10.1% | | | | | | 10,962,622 | | | | | | 12.0% | | |
Holders of DiaCarta PubCo
Options(3) |
| | | | 2,312,806 | | | | | | 1.8% | | | | | | 2,312,806 | | | | | | 2.1% | | | | | | 2,312,806 | | | | | | 2.5% | | |
Holders of Converted DiaCarta PubCo
Warrants(4) |
| | | | 301,700 | | | | | | 0.2% | | | | | | 301,700 | | | | | | 0.3% | | | | | | 301,700 | | | | | | 0.3% | | |
HH&L Class A ordinary shares
|
| | | | 41,400,000 | | | | | | 32.2% | | | | | | 20,700,000 | | | | | | 19.2% | | | | | | 3,718,903 | | | | | | 4.1% | | |
HH&L Class B ordinary shares
|
| | | | 10,350,000 | | | | | | 8.0% | | | | | | 10,350,000 | | | | | | 9.6% | | | | | | 10,350,000 | | | | | | 11.4% | | |
Holders of HH&L public warrants(5)
|
| | | | 20,700,000 | | | | | | 16.1% | | | | | | 20,700,000 | | | | | | 19.2% | | | | | | 20,700,000 | | | | | | 22.7% | | |
Holders of HH&L private placement warrants(5)
|
| | | | 10,280,000 | | | | | | 8.0% | | | | | | 10,280,000 | | | | | | 9.5% | | | | | | 10,280,000 | | | | | | 11.3% | | |
Pro forma common stock outstanding at September 30, 2022
|
| | | | 128,730,000 | | | | | | 100% | | | | | | 99,750,000 | | | | | | 100% | | | | | | 91,031,628 | | | | | | 100% | | |
| | |
Cayman Constitutional Documents
|
| |
Proposed Organizational Documents
|
|
Authorized Shares (Advisory Organizational Documents Proposal 5A) | | |
The Cayman Constitutional Documents authorize 555,000,000 shares, divided into 500,000,000 HH&L Class A ordinary shares, 50,000,000 HH&L Class B ordinary shares and 5,000,000 HH&L Preference Shares.
|
| | The Proposed Organizational Documents authorize shares, consisting of shares of DiaCarta PubCo common stock and shares of DiaCarta PubCo preferred stock. | |
| | | See paragraph 5 of the Existing Memorandum. | | | See Article IV of the Proposed Certificate of Incorporation. | |
Authorize the Board of Directors to Issue Preferred Shares Without Shareholder Consent (Advisory Organizational Documents Proposal 5B) | | | The Cayman Constitutional Documents authorize the issuance of 5,000,000 HH&L Preference Shares with such designation, rights and preferences as may be determined from time to time by HH&L Board. Accordingly, HH&L Board is empowered under the Cayman Constitutional Documents, without shareholder approval, to issue preference shares with dividend, liquidation, redemption, voting or other rights which could adversely affect the voting power or other rights of the holders of ordinary shares (except to the extent it may affect the ability of HH&L to carry out a conversion of HH&L Class B ordinary shares on the Closing Date, as contemplated by the Existing Articles). | | | The Proposed Organizational Documents authorize the Board to issue all or any shares of preferred stock in one or more series and to fix for each such series such voting powers, full or limited, and such designations, preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as the Board may determine. | |
| | | See paragraph 5 of the Existing Memorandum and Article 3 of the Existing Articles. | | | See Article V, subsection B of the Proposed Certificate of Incorporation. | |
Classified Board (Advisory Organizational Documents Proposal 5C) | | | The Cayman Constitutional Documents provide that the HH&L Board shall be composed of one class. | | | The Proposed Organizational Documents provide that the Board be divided into three classes with only one class of directors being elected in each year and each class serving a three-year term. | |
| | | See Article 28.2 of the Existing Articles. | | | See Article VII of the Proposed Certificate of Incorporation. | |
| | |
Cayman Constitutional Documents
|
| |
Proposed Organizational Documents
|
|
Removal of Directors (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents provide that before a Business Combination, holders of Class B ordinary shares may by an Ordinary Resolution remove any director, and that after a Business Combination, shareholders may by an Ordinary Resolution remove any director. | | | The Proposed Organizational Documents provide that, subject to the special rights of the holders of any series of preferred stock to elect directors, any director may be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least a majority of the voting power of all of the then outstanding shares of voting stock entitled to vote generally in the election of directors, voting together as a single class. | |
| | | See Article 31 of the Cayman Constitutional Documents. | | | See Article VII of the Proposed Certificate of Incorporation. | |
Adoption of Supermajority Vote Requirement to Amend the Proposed Organizational Documents (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents provide that amendments to change HH&L’s name, to alter or add to the existing articles or certain sections of the existing memorandum with respect to any objects, powers or other matters specified therein or to reduce its share capital or any capital redemption reserve fund may be made by a special resolution under Cayman Islands law, being the affirmative vote of holders of a majority of at least two-thirds of the HH&L shares represented in person or by proxy and entitled to vote thereon and who vote at a quorate general meeting. | | | The Proposed Organizational Documents require the affirmative vote of at least two-thirds of the voting power of the outstanding shares to (i) adopt, amend or repeal the Proposed Bylaws, and to (ii) amend, alter, repeal or rescind Articles VII, VIII, IX, X, XI, XII and XIII of the Proposed Certificate of Incorporation. | |
| | | See Article 18.3 of the Cayman Constitutional Documents. | | | See Article XIII of the Proposed Certificate of Incorporation and Article X of the Proposed Bylaws. | |
Company Name (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents provide that the name of the company is “HH&L Acquisition Co.” | | | The Proposed Organizational Documents provide that the name of the corporation will be “DiaCarta, Inc.” | |
| | | See paragraph 1 of the Existing Memorandum. | | | See Article I of the Proposed Certificate of Incorporation. | |
| | |
Cayman Constitutional Documents
|
| |
Proposed Organizational Documents
|
|
Perpetual Existence (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents provide that if HH&L does not consummate a business combination (as defined in the Cayman Constitutional Documents) by 24 months from the consummation of the IPO, or such later time as the shareholders may approve in accordance with the Existing Articles, HH&L will cease all operations except for the purposes of winding up and will redeem the public shares and liquidate HH&L’s trust account. | | | The Proposed Organizational Documents do not include any provisions relating to DiaCarta PubCo’s ongoing existence; the default under the DGCL will make DiaCarta PubCo’s existence perpetual. | |
| | | See Article 51.7 of the Cayman Constitutional Documents. | | | Default rule under the DGCL. | |
Action by Written Consent of Shareholders (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents permit shareholders to approve amendments to Article 31.1 by unanimous written resolution. | | | The Proposed Organizational Documents require stockholders to take action at an annual or special meeting and prohibit stockholder action by written consent in lieu of a meeting. | |
| | | | | | See Article VIII of the Proposed Certificate of Incorporation. | |
Exclusive Forum (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents do not contain a provision adopting an exclusive forum for certain shareholder litigation. | | | The Proposed Organizational Documents adopt Delaware as the exclusive forum for certain stockholder litigation and the federal district courts of the United States for causes of action brought to enforce any liability or duty created by the Securities Act, the Exchange Act, or any other claim for which the federal courts of the United States have exclusive jurisdiction. | |
| | | | | | See Article XII of the Proposed Certificate of Incorporation. | |
Takeovers by Interested Stockholders (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents do not provide restrictions on takeovers of HH&L by a related shareholder following a business combination. | | | The Proposed Organizational Documents will have DiaCarta PubCo elect not to be governed by Section 203 of the DGCL relating to takeovers by interested stockholders but will provide other similar restrictions regarding takeovers by interested stockholders. | |
| | | | | | See Article X of the Proposed Certificate of Incorporation. | |
| | |
Cayman Constitutional Documents
|
| |
Proposed Organizational Documents
|
|
Provisions Related to Status as Blank Check Company (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents include various provisions related to HH&L’s status as a blank check company prior to the consummation of a business combination. | | | The Proposed Organizational Documents do not include such provisions related to HH&L’s status as a blank check company, which no longer will apply upon consummation of the Merger, as HH&L will cease to be a blank check company at such time. | |
| | |
Assuming No
Redemptions (Shares) |
| |
%
Ownership |
| |
Assuming
Interim Redemptions(1) (Shares) |
| |
%
Ownership |
| |
Assuming
Maximum Redemptions(2) (Shares) |
| |
%
Ownership |
| ||||||||||||||||||
DiaCarta Equity Holders holding Ordinary Shares
|
| | | | 25,617,380 | | | | | | 19.9% | | | | | | 25,617,380 | | | | | | 23.7% | | | | | | 25,617,380 | | | | | | 28.1% | | |
DiaCarta Equity Holders
holding DiaCarta Series A Preference Shares |
| | | | 6,788,217 | | | | | | 5.3% | | | | | | 6,788,217 | | | | | | 6.3% | | | | | | 6,788,217 | | | | | | 7.5% | | |
DiaCarta Equity Holders
holding DiaCarta Series B Preference Shares |
| | | | 10,962,622 | | | | | | 8.5% | | | | | | 10,962,622 | | | | | | 10.1% | | | | | | 10,962,622 | | | | | | 12.0% | | |
Holders of DiaCarta PubCo
Options(3) |
| | | | 2,312,806 | | | | | | 1.8% | | | | | | 2,312,806 | | | | | | 2.1% | | | | | | 2,312,806 | | | | | | 2.5% | | |
Holders of Converted DiaCarta PubCo Warrants(4)
|
| | | | 301,700 | | | | | | 0.2% | | | | | | 301,700 | | | | | | 0.3% | | | | | | 301,700 | | | | | | 0.3% | | |
HH&L Class A ordinary shares
|
| | | | 41,400,000 | | | | | | 32.2% | | | | | | 20,700,000 | | | | | | 19.2% | | | | | | 3,718,903 | | | | | | 4.1% | | |
HH&L Class B ordinary shares
|
| | | | 10,350,000 | | | | | | 8.0% | | | | | | 10,350,000 | | | | | | 9.6% | | | | | | 10,350,000 | | | | | | 11.4% | | |
Holders of HH&L public warrants(5)
|
| | | | 20,700,000 | | | | | | 16.1% | | | | | | 20,700,000 | | | | | | 19.2% | | | | | | 20,700,000 | | | | | | 22.7% | | |
Holders of HH&L private placement warrants(5)
|
| | | | 10,280,000 | | | | | | 8.0% | | | | | | 10,280,000 | | | | | | 9.5% | | | | | | 10,280,000 | | | | | | 11.3% | | |
Pro forma common stock outstanding at September 30, 2022
|
| | | | 128,730,000 | | | | | | 100% | | | | | | 99,750,000 | | | | | | 100% | | | | | | 91,031,628 | | | | | | 100% | | |
| | |
Assuming No
Redemption |
| |
Assuming
Interim Redemption(1) |
| |
Assuming
Maximum Redemption |
| |||||||||
(in millions)
|
| | | | | | | | | | | | | | |||||
Sources | | | | | | | | | | | | | | | |||||
Proceeds from Trust Account
|
| | | $ | 414,000,000 | | | | | $ | 207,000,000 | | | | | $ | 40,000,000 | | |
DiaCarta’s Equity(2)
|
| | | | 460,000,000 | | | | | | 460,000,000 | | | | | | 460,000,000 | | |
Sponsor Shares
|
| | | | 103,500,000 | | | | | | 103,500,000 | | | | | | 103,500,000 | | |
Total Sources
|
| | | $ | 977,500,000 | | | | | $ | 770,500,000 | | | | | $ | 603,500,000 | | |
| | |
Assuming No
Redemption |
| |
Assuming
Interim Redemption(1) |
| |
Assuming
Maximum Redemption |
| |||||||||
(in millions)
|
| | | | | | | | | | | | | | |||||
Uses | | | | | | | | | | | | | | | |||||
Cash on Balance Sheet
|
| | | $ | 394,000,000 | | | | | $ | 187,000,000 | | | | | $ | 20,000,000 | | |
DiaCarta’s Equity(2)
|
| | | | 460,000,000 | | | | | | 460,000,000 | | | | | | 460,000,000 | | |
Sponsor Shares
|
| | | | 103,500,000 | | | | | | 103,500,000 | | | | | | 103,500,000 | | |
Transaction costs(3)
|
| | | | 20,000,000 | | | | | | 20,000,000 | | | | | | 20,000,000 | | |
Total Uses
|
| | | $ | 977,500,000 | | | | | $ | 770,500,000 | | | | | $ | 603,500,000 | | |
|
| | |
For the Nine
Months Ended September 30, 2022 (unaudited) |
| |
For the Year
Ended December 31, 2021 |
| |
For the Period
from September 4, 2020 (inception) through December 31, 2020 |
| |||||||||
Statement of Operations Data: | | | | | | | | | | | | | | | | | | | |
General and administrative expenses
|
| | | $ | 2,499,624 | | | | | $ | 1,640,492 | | | | | $ | 12,681 | | |
Administrative expenses – related party
|
| | | | 135,000 | | | | | | 165,000 | | | | | | — | | |
Loss from operations
|
| | | | (2,634,624) | | | | | | (1,805,492) | | | | | | (12,681) | | |
Other income (expense): | | | | | | | | | | | | | | | | | | | |
Change in fair value of derivative warrant liabilities
|
| | | | 16,419,400 | | | | | | 3,923,200 | | | | | | — | | |
Financing cost – derivative warrant liabilities
|
| | | | — | | | | | | (821,170) | | | | | | — | | |
Income from investments held in Trust Account
|
| | | | 2,493,903 | | | | | | 23,891 | | | | | | — | | |
Net income (loss)
|
| | | | 16,278,679 | | | | | | 1,320,429 | | | | | | (12,681) | | |
Basic and diluted weighted average shares outstanding
of Class A ordinary shares |
| | | | 41,400,000 | | | | | | 36,976,438 | | | | | | — | | |
Basic and diluted net income (loss) per ordinary share,
Class A |
| | | $ | 0.31 | | | | | $ | 0.03 | | | | | $ | — | | |
Basic weighted average shares outstanding of Class B ordinary shares
|
| | | | 10,350,000 | | | | | | 10,205,753 | | | | | | 9,000,000 | | |
Diluted weighted average shares outstanding of Class B ordinary shares
|
| | | | 10,350,000 | | | | | | 10,350,000 | | | | | | 9,000,000 | | |
Basic and diluted net income (loss) per ordinary share,
Class B |
| | | $ | 0.31 | | | | | $ | 0.03 | | | | | $ | (0.00) | | |
| | |
September 30,
2022 (Unaudited) |
| |
December 31,
|
| ||||||||||||
| | |
2021
|
| |
2020
|
| ||||||||||||
Balance Sheet Data: | | | | | | | | | | | | | | | | | | | |
Assets | | | | | | | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | | | | | | | |
Cash
|
| | | $ | 293,137 | | | | | $ | 399,935 | | | | | $ | 6,410 | | |
Prepaid expenses
|
| | | | 137,676 | | | | | | 326,283 | | | | | | 17,000 | | |
Total current assets
|
| | | | 430,813 | | | | | | 726,218 | | | | | | 23,410 | | |
Deferred offering costs
|
| | | | — | | | | | | — | | | | | | 439,752 | | |
Investments held in Trust Account
|
| | | | 416,517,794 | | | | | | 414,023,891 | | | | | | — | | |
Total Assets
|
| | | $ | 416,948,607 | | | | | $ | 414,750,109 | | | | | $ | 463,162 | | |
| | |
September 30,
2022 (Unaudited) |
| |
December 31,
|
| ||||||||||||
| | |
2021
|
| |
2020
|
| ||||||||||||
Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Equity (Deficit):
|
| | | | | | | | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 135,297 | | | | | $ | 176,063 | | | | | $ | 116,374 | | |
Accrued expenses
|
| | | | 2,733,810 | | | | | | 988,825 | | | | | | 194,520 | | |
Accounts payable – related party
|
| | | | 300,000 | | | | | | 165,000 | | | | | | — | | |
Working Capital Loan – related party
|
| | | | 500,000 | | | | | | — | | | | | | 139,949 | | |
Total current liabilities
|
| | | | 3,669,107 | | | | | | 1,329,888 | | | | | | 450,843 | | |
Derivative warrant liabilities
|
| | | | 929,400 | | | | | | 17,348,800 | | | | | | — | | |
Deferred underwriting commissions
|
| | | | 14,490,000 | | | | | | 14,490,000 | | | | | | — | | |
Total liabilities
|
| | | | 19,088,507 | | | | | | 33,168,688 | | | | | | 450,843 | | |
Commitments and Contingencies | | | | | | | | | | | | | | | | | | | |
Class A ordinary shares subject to possible redemption,
$0.0001 par value; 41,400,000 and 0 shares at $10.06 and $10.00 per share redemption value as of September 30, 2022 and December 31, 2021, respectively |
| | | | 416,417,794 | | | | | | 414,000,000 | | | | | | — | | |
Shareholders’ Equity (Deficit): | | | | | | | | | | | | | | | | | | | |
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding
|
| | | | — | | | | | | — | | | | | | — | | |
Class A ordinary shares, $0.0001 par value; 500,000,000
shares authorized; no non-redeemable shares issued and outstanding at December 31, 2021 and 2020 |
| | | | — | | | | | | — | | | | | | — | | |
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 10,350,000 shares issued and outstanding at December 31, 2021 and 2020(1)
|
| | | | 1,035 | | | | | | 1,035 | | | | | | 1,035 | | |
Additional paid-in capital
|
| | | | — | | | | | | — | | | | | | 23,965 | | |
Accumulated deficit
|
| | | | (18,558,729) | | | | | | (32,419,614) | | | | | | (12,681) | | |
Total shareholders’ equity (deficit)
|
| | | | (18,557,694) | | | | | | (32,418,579) | | | | | | 12,319 | | |
Total Liabilities, Class A Ordinary shares Subject to
Possible Redemption and Shareholders’ Equity (Deficit) |
| | | $ | 416,948,607 | | | | | $ | 414,750,109 | | | | | $ | 463,162 | | |
|
| | |
For the Nine
months Ended September 30, 2022 |
| |
For the Year
Ended December 31, 2021 |
| |
For the Year
Ended December 31, 2020 |
| |||||||||
Statement of Operations Data: | | | | | | | | | | | | | | | | | | | |
Revenues
|
| | | $ | 18,332,240 | | | | | $ | 41,501,568 | | | | | $ | 14,445,079 | | |
Cost of Revenues
|
| | | | 10,722,756 | | | | | | 13,426,619 | | | | | | 8,629,681 | | |
Gross Profit
|
| | | | 7,609,484 | | | | | | 28,074,949 | | | | | | 5,815,398 | | |
Operating Expenses: | | | | | | | | | | | | | | | | | | | |
Selling and marketing expenses
|
| | | | 1,855,147 | | | | | | 1,820,038 | | | | | | 1,182,573 | | |
General and administrative expenses
|
| | | | 3,889,301 | | | | | | 3,824,924 | | | | | | 2,566,119 | | |
Research and development expenses
|
| | | | 4,868,430 | | | | | | 5,179,766 | | | | | | 4,841,818 | | |
Total Operating Expenses
|
| | | | 10,612,878 | | | | | | 10,824,728 | | | | | | 8,590,510 | | |
Income(Loss) from Operations
|
| | | | (3,003,394) | | | | | | 17,250,221 | | | | | | (2,775,112) | | |
Interest income(expense), net
|
| | | | 123,371 | | | | | | (701,630) | | | | | | (336,222) | | |
Investment loss
|
| | | | (140,787) | | | | | | (10,370) | | | | | | 88,764 | | |
Other income(expense), net
|
| | | | (319,626) | | | | | | 600,405 | | | | | | 848,784 | | |
Total Other income (expense)
|
| | | | (337,042) | | | | | | (111,595) | | | | | | 601,326 | | |
Income (Loss) before Income Taxes
|
| | | | (3,340,436) | | | | | | 17,138,626 | | | | | | (2,173,786) | | |
Income Taxes
|
| | | | (403,192) | | | | | | (5,328,468) | | | | | | (44,195) | | |
Net Income (Loss)
|
| | | $ | (2,937,244) | | | | | $ | 11,810,158 | | | | | $ | (2,217,981) | | |
Less: net income attributable to noncontrolling interests
|
| | | | — | | | | | | — | | | | | | 34,463 | | |
Net Income (Loss) attributable to DiaCarta
|
| | | | (2,937,244) | | | | | | 11,810,158 | | | | | | (2,183,518) | | |
Foreign currency translation adjustments
|
| | | | (622,386) | | | | | | 290,631 | | | | | | 472,844 | | |
Total Comprehensive Income (Loss)
|
| | | $ | (3,559,630) | | | | | $ | 12,100,789 | | | | | $ | (1,745,137) | | |
Less: comprehensive loss attributable to non-controlling interest
|
| | | | — | | | | | | — | | | | | | 34,463 | | |
Comprehensive Income (Loss) attributable to DiaCarta
|
| | | | (3,559,630) | | | | | | 12,100,789 | | | | | | (1,710,674) | | |
Net Loss Per Common Share | | | | | | | | | | | | | | | | | | | |
Basic
|
| | | | (0.10) | | | | | | 0.41 | | | | | | (0.08) | | |
Diluted
|
| | | | (0.10) | | | | | | 0.25 | | | | | | (0.08) | | |
| | |
For the Nine
months Ended September 30, 2022 |
| |
For the Year
Ended December 31, 2021 |
| |
For the Year
Ended December 31, 2020 |
| |||||||||
Weighted Average Number of Common Shares Outstanding:
|
| | | | | | | | | | | | | | | | | | |
Basic
|
| | | | 28,469,472 | | | | | | 28,469,472 | | | | | | 28,469,472 | | |
Diluted
|
| | | | 28,469,472 | | | | | | 49,370,099 | | | | | | 28,469,472 | | |
|
| | |
As of
|
| |||||||||||||||
| | |
September 30,
2022 |
| |
December 31,
2021 |
| |
December 31,
2020 |
| |||||||||
Balance Sheet Data: | | | | | | | | | | | | | | | | | | | |
Assets | | | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 4,243,524 | | | | | $ | 22,644,119 | | | | | $ | 9,595,487 | | |
Short-term investments
|
| | | | 10,916,415 | | | | | | — | | | | | | — | | |
Accounts receivable, net
|
| | | | 4,071,378 | | | | | | 6,219,331 | | | | | | 3,898,667 | | |
Advances to suppliers
|
| | | | 20,153 | | | | | | 147,642 | | | | | | 199,777 | | |
Inventories, net
|
| | | | 1,451,085 | | | | | | 1,198,578 | | | | | | 1,069,717 | | |
Prepaid income taxes
|
| | | | 2,484,630 | | | | | | — | | | | | | — | | |
VAT recoverables
|
| | | | 139,260 | | | | | | 244,755 | | | | | | 406,467 | | |
Prepayments
|
| | | | 240,577 | | | | | | 248,854 | | | | | | 63,187 | | |
Loan due from a related party
|
| | | | 288,255 | | | | | | 223,219 | | | | | | — | | |
Other current assets
|
| | | | 239,345 | | | | | | 243,635 | | | | | | 236,458 | | |
Total Current Assets
|
| | | | 24,094,622 | | | | | | 31,170,133 | | | | | | 15,469,760 | | |
Property and equipment, net
|
| | | | 2,535,658 | | | | | | 2,491,126 | | | | | | 2,722,681 | | |
Intangible assets, net
|
| | | | 9,070 | | | | | | 10,529 | | | | | | 12,261 | | |
Operating lease right-of-use asset
|
| | | | 7,432,419 | | | | | | 8,997,758 | | | | | | 2,838,822 | | |
Finance lease assets
|
| | | | 22,596 | | | | | | 53,024 | | | | | | 101,807 | | |
Deferred tax assets
|
| | | | 2,389,240 | | | | | | 2,389,240 | | | | | | 4,893,834 | | |
Loan due from a related party
|
| | | | 1,419,836 | | | | | | 1,114,145 | | | | | | 757,992 | | |
Other asset
|
| | | | 42,125 | | | | | | 42,125 | | | | | | 417,727 | | |
Total Non-current Assets
|
| | | | 13,850,944 | | | | | | 15,097,947 | | | | | | 11,745,124 | | |
Total Assets
|
| | | $ | 37,945,566 | | | | | $ | 46,268,080 | | | | | $ | 27,214,884 | | |
Liabilities and Shareholders’ Equity | | | | | | | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 4,588,796 | | | | | $ | 5,339,633 | | | | | $ | 3,994,768 | | |
Accrued liabilities and other payables
|
| | | | 281,277 | | | | | | 543,866 | | | | | | 483,168 | | |
Loan from a shareholder
|
| | | | — | | | | | | — | | | | | | 1,188,428 | | |
Operating lease liabilities, current
|
| | | | 1,224,747 | | | | | | 1,164,841 | | | | | | 678,114 | | |
Finance lease liabilities, current
|
| | | | — | | | | | | 14,803 | | | | | | 52,363 | | |
Income tax payable
|
| | | | — | | | | | | 1,218,562 | | | | | | 15,038 | | |
Advance from customers
|
| | | | 168,366 | | | | | | 145,475 | | | | | | 1,442,124 | | |
Convertible bonds payable
|
| | | | — | | | | | | 2,152,617 | | | | | | — | | |
Total Current Liabilities
|
| | | | 6,263,186 | | | | | | 10,579,797 | | | | | | 7,854,003 | | |
Long-term loan
|
| | | | — | | | | | | — | | | | | | 463,238 | | |
Convertible bonds payable
|
| | | | — | | | | | | — | | | | | | 1,433,485 | | |
| | |
As of
|
| |||||||||||||||
| | |
September 30,
2022 |
| |
December 31,
2021 |
| |
December 31,
2020 |
| |||||||||
Lease Liabilities, non-current
|
| | | | 7,285,463 | | | | | | 9,098,024 | | | | | | 3,101,691 | | |
Finance lease liabilities, non-current
|
| | | | — | | | | | | — | | | | | | 21,099 | | |
Total Non-current Liabilities
|
| | | | 7,285,463 | | | | | | 9,098,024 | | | | | | 5,019,513 | | |
Total Liabilities
|
| | | | 13,548,649 | | | | | | 19,677,821 | | | | | | 12,873,516 | | |
Shareholders’ Equity | | | | | | | | | | | | | | | | | | | |
Ordinary shares (USD0.001 par value, 28,469,472 shares
authorized; 28,469,472 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively) |
| | | | 28,469 | | | | | | 28,469 | | | | | | 28,469 | | |
Series A non-redeemable preferred shares (USD0.001 par value, 7,543,948 shares authorized; 7,543,948 shares issued and outstanding with liquidation preference of $8,000,000 at September 30, 2022 and December 31, 2021, respectively)
|
| | | | 7,544 | | | | | | 7,544 | | | | | | 7,544 | | |
Series B non-redeemable preferred shares (USD0.001 par value, 13,646,217 shares authorized; 12,183,137 shares issued and outstanding with liquidation preference of $36,336,249, at September 30, 2022 and December 31, 2021, respectively)
|
| | | | 12,183 | | | | | | 12,183 | | | | | | 12,183 | | |
Additional paid-in capital
|
| | | | 55,385,930 | | | | | | 54,019,642 | | | | | | 53,871,540 | | |
Accumulated deficit
|
| | | | (28,688,454) | | | | | | (25,751,210) | | | | | | (37,561,368) | | |
Accumulated other comprehensive loss
|
| | | | (2,348,755) | | | | | | (1,726,369) | | | | | | (2,017,000) | | |
Total Shareholders’ Equity
|
| | | | 24,396,917 | | | | | | 26,590,259 | | | | | | 14,341,368 | | |
Total Liabilities and Shareholders’ Equity
|
| | | $ | 37,945,566 | | | | | $ | 46,268,080 | | | | | $ | 27,214,884 | | |
|
| | |
Pro Forma
Combined (Assuming No Redemptions) |
| |
Pro Forma
Combined (Assuming Interim Redemptions) |
| |
Pro Forma
Combined (Assuming Maximum Redemptions) |
| |||||||||
Summary Unaudited Pro Forma Condensed Combined | | | | | | | | | | | | | | | | | | | |
Statement of Operations Data for the Nine Months Ended September 30, 2022
|
| | | | | | | | | | | | | | | | | | |
Total revenue
|
| | | $ | 18,332,240 | | | | | $ | 18,332,240 | | | | | $ | 18,332,240 | | |
Net income
|
| | | $ | 13,741,171 | | | | | $ | 13,741,171 | | | | | $ | 13,741,171 | | |
Net income per share – basic and diluted
|
| | | $ | 0.14 | | | | | $ | 0.18 | | | | | $ | 0.23 | | |
Weighted-average shares outstanding – basic and diluted
|
| | | | 97,750,000 | | | | | | 77,050,000 | | | | | | 60,068,907 | | |
Summary Unaudited Pro Forma Condensed Combined | | | | | | | | | | | | | | | | | | | |
Statement of Operations Data for the Year Ended December 31, 2021
|
| | | | | | | | | | | | | | | | | | |
Total revenue
|
| | | $ | 41,501,568 | | | | | $ | 41,501,568 | | | | | $ | 41,501,568 | | |
Net income
|
| | | $ | 13,854,369 | | | | | $ | 13,854,369 | | | | | $ | 13,854,369 | | |
Net income per share – basic and diluted
|
| | | $ | 0.14 | | | | | $ | 0.18 | | | | | $ | 0.23 | | |
Weighted-average shares outstanding – basic and diluted
|
| | | | 97,750,000 | | | | | | 77,050,000 | | | | | | 60,068,907 | | |
Summary Unaudited Pro Forma Condensed Combined | | | | | | | | | | | | | | | | | | | |
Balance Sheet Data as of September 30, 2022
|
| | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 402,110,627 | | | | | $ | 195,110,627 | | | | | $ | 25,299,696 | | |
Total current assets
|
| | | $ | 422,099,401 | | | | | $ | 215,099,401 | | | | | $ | 45,288,470 | | |
Total assets
|
| | | $ | 435,950,345 | | | | | $ | 228,950,345 | | | | | $ | 59,139,414 | | |
Total current liabilities
|
| | | $ | 6,263,186 | | | | | $ | 6,263,186 | | | | | $ | 6,263,186 | | |
Total liabilities
|
| | | $ | 14,478,049 | | | | | $ | 14,478,049 | | | | | $ | 14,478,049 | | |
Total stockholders’ equity
|
| | | $ | 421,472,296 | | | | | $ | 214,472,296 | | | | | $ | 44,661,365 | | |
| | |
Historical
|
| |
Pro forma
|
| |
Unaudited DiaCarta
equivalent pro forma per share data(4) |
| |||||||||||||||||||||||||||||||||||||||
| | |
HH&L
|
| |
DiaCarta
|
| |
No
redemption scenario |
| |
Interim
redemption scenario |
| |
Maximum
redemption scenario |
| |
No
redemption scenario |
| |
Interim
redemption scenario |
| |
Maximum
redemption scenario |
| ||||||||||||||||||||||||
| | |
Class A
Ordinary Shares |
| |
Class B
Ordinary Shares |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||
As of and for the nine months ended September 30, 2022
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Book value per share – basic and diluted(1)
|
| | | $ | 10.01 | | | | | $ | (0.0001) | | | | | $ | 4.31 | | | | | $ | 2.78 | | | | | $ | 0.74 | | | | | $ | 4.43 | | | | | $ | 2.88 | | | | | $ | 0.78 | | |
Weighted average shares outstanding – basic and diluted
|
| | | | 41,400,000 | | | | | | 10,350,000 | | | | | | 97,750,000 | | | | | | 77,050,000 | | | | | | 60,068,907 | | | | | | 95,136,215 | | | | | | 74,436,215 | | | | | | 57,455,122 | | |
Net income (loss) per share – basic and diluted(2)
|
| | | $ | 0.31 | | | | | $ | 0.31 | | | | | $ | 0.14 | | | | | $ | 0.18 | | | | | $ | 0.23 | | | | | $ | 0.14 | | | | | $ | 0.18 | | | | | $ | 0.23 | | |
For the year ended December 31, 2021
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Weighted average shares outstanding – basic and diluted
|
| | | | 36,976,438 | | | | | | 10,350,000 | | | | | | 97,750,000 | | | | | | 77,050,000 | | | | | | 60,068,907 | | | | | | 95,136,215 | | | | | | 74,436,215 | | | | | | 57,455,122 | | |
Net income (loss) per share – basic and diluted(3)
|
| | | $ | 0.03 | | | | | $ | 0.03 | | | | | $ | 0.14 | | | | | $ | 0.18 | | | | | $ | 0.23 | | | | | $ | 0.15 | | | | | $ | 0.19 | | | | | $ | 0.25 | | |
Provisions
|
| |
Delaware
|
| |
Cayman Islands
|
|
Applicable legislation
|
| | General Corporation Law of the State of Delaware | | | The Cayman Islands Companies Act | |
General Vote Required for Combinations with Interested Stockholders/Shareholders
|
| | Generally, a corporation may not engage in a business combination with an interested stockholder for a period of three years after the time of the transaction in which the person became an interested stockholder, unless the corporation opts out of the statutory provision. | | | No similar provision | |
Appraisal Rights
|
| | Generally, a stockholder of a publicly traded corporation does not have appraisal rights in connection with a merger. Stockholders of a publicly traded corporation do, however, generally | | | Under Cayman Islands Companies Act, minority shareholders that dissent to a merger are entitled to be paid the fair market value of their shares, which, if necessary, may ultimately | |
Provisions
|
| |
Delaware
|
| |
Cayman Islands
|
|
| | | have appraisal rights in connection with a merger if they are required by the terms of a merger agreement to accept for their shares anything except: (a) shares or depository receipts of the corporation surviving or resulting from such merger; (b) shares of stock or depository receipts that will be either listed on a national securities exchange or held of record by more than 2,000 holders; (c) cash in lieu of fractional shares or fractional depository receipts described in (a) and (b) above; or (d) any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in (a), (b) and (c) above. | | | be determined by the courts of the Cayman Islands. | |
Requirements for Stockholder/ Shareholder Approval
|
| | Subject to the certificate of incorporation, stockholder approval of mergers, a sale of all or substantially all the assets of the corporation, dissolution and amendments of constitutional documents require a majority of outstanding shares; most other stockholder approvals require a majority of those present and voting, provided a quorum is present. | | | Subject to the articles of association, matters which require shareholder approval, whether under Cayman Islands statute or the company’s articles of association, are determined (subject to quorum requirements, the Cayman Islands Companies Act, applicable law and the relevant articles of association) by ordinary resolution, being the approval of the holders of a majority of the shares, who, being present in person or proxy and entitled to vote, vote at the quorate meeting of shareholders or by special resolution (such as the amendment of the company’s constitutional documents), being the approval of the holders of a majority of not less than two-thirds of the shares, who, being present in person or by proxy and entitled to vote, vote at the quorate meeting of shareholders. | |
Requirement for Quorum
|
| | Quorum is a majority of shares entitled to vote at the meeting unless otherwise set in the constitutional documents, but cannot be less than one-third of shares entitled to vote at the meeting. | | | Quorum is set in the company’s memorandum and articles of association. | |
Provisions
|
| |
Delaware
|
| |
Cayman Islands
|
|
Stockholder/Shareholder Consent to Action Without Meeting
|
| | Unless otherwise provided in the certificate of incorporation, stockholders may act by written consent. | | | Shareholder action by written resolutions (whether unanimous or otherwise) may be permitted by the articles of association. The articles of association may provide that shareholders may not act by written resolutions. | |
Inspection of Books and Records
|
| | Any stockholder may inspect the corporation’s books and records for a proper purpose during the usual hours for business. | | | Shareholders generally do not have any rights to inspect or obtain copies of the register of members or other corporate records of a company. | |
Stockholder/Shareholder Lawsuits
|
| | A stockholder may bring a derivative suit subject to procedural requirements (including adopting Delaware as the exclusive forum as per the Advisory Organizational Documents Proposal 5D). | | | In the Cayman Islands, the decision to institute proceedings on behalf of a company is generally taken by the company’s board of directors. A shareholder may be entitled to bring a derivative action on behalf of the company only in certain limited circumstances. | |
Removal of Directors;
|
| | Any director or the entire board may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except as follows: (1) unless the certificate of incorporation otherwise provides, in the case of a corporation with a classified board, stockholders may effect such removal only for cause; or (2) in the case of a corporation having cumulative voting, if less than the entire board is to be removed, no director may be removed without cause if the votes cast against such director’s removal would be sufficient to elect such director if then cumulatively voted at an election of the entire board. However, because the board of directors of DiaCarta PubCo will be classified after the Closing, pursuant to the Proposed Certificate of Incorporation, a director may be removed from office only for cause and only by the affirmative vote of at least 662∕3% of the total voting power of the outstanding shares of capital stock of the corporation entitled to vote in any annual | | | A company’s memorandum and articles of association may provide that a director may be removed for any or no reason and that, in addition to shareholders, boards may be granted the power to remove a director. | |
Provisions
|
| |
Delaware
|
| |
Cayman Islands
|
|
| | | election of directors or class of directors, voting together as a single class. | | | | |
Number of Directors
|
| | The number of directors is fixed by the by-laws, unless the certificate of incorporation fixes the number of directors, in which case a change in the number of directors shall be made only by amendment of the certificate of incorporation. The by-laws may provide that the board may increase the size of the board and fill any vacancies. | | | Subject to the memorandum and articles of association, the board may increase the size of the board and fill any vacancies. | |
Classified or Staggered Boards
|
| | Classified boards are permitted. | | | Classified boards are permitted. | |
Fiduciary Duties of Directors
|
| | Directors must exercise a duty of care and duty of loyalty and good faith to the company and its stockholders. | | |
A director owes fiduciary duties to a company, including to exercise loyalty, honesty and good faith to the company as a whole.
In addition to fiduciary duties, directors owe a duty of care, diligence and skill.
Such duties are owed to the company but may be owed directly to creditors or shareholders in certain limited circumstances.
|
|
Indemnification of Directors and Officers
|
| | A corporation is generally permitted to indemnify any person who was or is a party to any proceeding because such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another entity against expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred if the person acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal proceeding, had no reasonable cause to believe their conduct was unlawful. If the action was brought by or on behalf of the corporation, no indemnification is made when a person is adjudged liable to the corporation unless a court determines such person is fairly | | | A Cayman Islands exempted company generally may indemnify its directors or officers, except with regard to fraud or willful default. | |
Provisions
|
| |
Delaware
|
| |
Cayman Islands
|
|
| | | and reasonably entitled to indemnity for expenses the court deems proper. | | | | |
Limited Liability of Directors
|
| | Permits the limiting or eliminating of the monetary liability of a director to a corporation or its stockholders, except with regard to breaches of duty of loyalty, intentional misconduct, unlawful stock repurchases or dividends, or improper personal benefit. | | | Liability of directors may be limited, except with regard to their own fraud or willful default. | |
| | |
Cayman Constitutional Documents
|
| |
Proposed Organizational Documents
|
|
Authorized Shares (Advisory Organizational Documents Proposal 5A) | | | The Cayman Constitutional Documents authorize 555,000,000 shares, divided into 500,000,000 HH&L Class A ordinary shares, 50,000,000 HH&L Class B ordinary shares and 5,000,000 HH&L Preference Shares. | | | The Proposed Organizational Documents authorize shares, consisting of DiaCarta PubCo shares of common stock and shares of DiaCarta PubCo preferred stock. | |
| | | See paragraph 5 of the Existing Memorandum. | | | See Article IV of the Proposed Certificate of Incorporation. | |
Authorize the Board of Directors to Issue Preferred Shares Without Shareholder Consent (Advisory Organizational Documents Proposal 5B) | | | The Cayman Constitutional Documents authorize the issuance of 5,000,000 HH&L Preference Shares with such designation, rights and preferences as may be determined from time to time by HH&L Board. Accordingly, HH&L Board is empowered under the Cayman Constitutional Documents, without shareholder approval, to issue preference shares with dividend, liquidation, redemption, voting or other | | | The Proposed Organizational Documents authorize the Board to issue all or any shares of preferred stock in one or more series and to fix for each such series such voting powers, full or limited, and such designations, preferences and relative participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption | |
| | |
Cayman Constitutional Documents
|
| |
Proposed Organizational Documents
|
|
| | | rights which could adversely affect the voting power or other rights of the holders of ordinary shares (except to the extent it may affect the ability of HH&L to carry out a conversion of HH&L Class B ordinary shares on the Closing Date, as contemplated by the Existing Articles). | | | privileges and liquidation preferences, and to increase or decrease (the number of shares of any series as the Board may determine. | |
| | | See paragraph 5 of the Existing Memorandum and Article 3 of the Existing Articles. | | | See Article V, subsection B of the Proposed Certificate of Incorporation. | |
Classified Board (Advisory Organizational Documents Proposal 5C) | | | The Cayman Constitutional Documents provide that the HH&L Board shall be composed of one class. | | | The Proposed Organizational Documents provide that the Board be divided into three classes with only one class of directors being elected in each year and each class serving a three-year term. | |
| | | See Article 28 of the Existing Articles. | | | See Article VII of the Proposed Certificate of Incorporation. | |
Removal of Directors (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents provide that before a Business Combination, holders of HH&L Class B ordinary shares may remove any director, and that after a Business Combination, shareholders may by an Ordinary Resolution remove any director. | | | The Proposed Organizational Documents do not include any provisions relating to the removal of DiaCarta PubCo’s directors. The default under the DGCL is that, so long as the board is classified, the stockholders may affect the removal of directors only for cause and such removal will require the vote by the holders of a majority of the shares then entitled to vote at an election of directors. | |
| | | See Article 31 of the Cayman Constitutional Documents. | | | Default rule under the DGCL. | |
Adoption of Supermajority Vote Requirement to Amend the Proposed Organizational Documents (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents provide that amendments to change HH&L’s name, alter or add to the Existing Articles or certain sections of the Existing Memorandum with respect to any objects, powers or other matters specified therein or to reduce its share capital or any capital redemption reserve fund may be made by a special resolution under Cayman Islands law, being the affirmative vote of holders of a majority of at least | | | The Proposed Organizational Documents require the affirmative vote of at least two-thirds of the voting power of the outstanding shares to (i) adopt, amend or repeal the Proposed Bylaws, and to (ii) amend, alter, repeal or rescind Articles VII, VIII, IX, X, XI, XII and XIII of the Proposed Certificate of Incorporation.” | |
| | |
Cayman Constitutional Documents
|
| |
Proposed Organizational Documents
|
|
| | | two-thirds of the HH&L shares represented in person or by proxy and entitled to vote thereon and who vote at a quorate general meeting. | | | | |
| | | See Article 18.3 of the Cayman Constitutional Documents. | | | See Article XIII of the Proposed Certificate of Incorporation and Article X of the Proposed Bylaws. | |
Company Name (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents provide that the name of the company is “HH&L Acquisition Co.” | | | The Proposed Organizational Documents provide that the name of the corporation will be “DiaCarta, Inc.” | |
| | | See paragraph 1 of the Existing Memorandum. | | | See Article I of the Proposed Certificate of Incorporation. | |
Perpetual Existence (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents provide that if HH&L does not consummate a Business Combination (as defined in the Cayman Constitutional Documents) by 24 months from the consummation of the IPO, or such later time as the shareholders may approve in accordance with the Existing Articles, HH&L will cease all operations except for the purposes of winding up and will redeem the public shares and liquidate HH&L’s trust account. | | | The Proposed Organizational Documents do not include any provisions relating to DiaCarta PubCo’s ongoing existence; the default under the DGCL will make DiaCarta PubCo’s existence perpetual. | |
| | | See Article 51.7 of the Cayman Constitutional Documents. | | | Default rule under the DGCL. | |
Action by Written Consent of Shareholders (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents permit shareholders to approve amendments to Article 31.1 by unanimous written resolution. | | | The Proposed Organizational Documents require stockholders to take action at an annual or special meeting and prohibit stockholder action by written consent in lieu of a meeting. | |
| | | See Article 31.4 of the Cayman Constitutional Documents. | | | See Article VIII of the Proposed Certificate of Incorporation. | |
Exclusive Forum (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents do not contain a provision adopting an exclusive forum for certain shareholder litigation. | | | The Proposed Organizational Documents adopt Delaware as the exclusive forum for certain stockholder litigation and the federal district courts of the US for causes of action arising under the Securities Act. | |
| | |
Cayman Constitutional Documents
|
| |
Proposed Organizational Documents
|
|
| | | | | | See Article XII of the Proposed Certificate of Incorporation. | |
Takeovers by Interested Stockholders (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents do not provide restrictions on takeovers of HH&L by a related shareholder following a business combination. | | | The Proposed Organizational Documents will have DiaCarta PubCo elect not to be governed by Section 203 of the DGCL relating to takeovers by interested stockholders but will provide other similar restrictions regarding takeovers by interested stockholders. | |
| | | See Article 51 of the Cayman Constitutional Documents. | | | See Article X of the Proposed Certificate of Incorporation. | |
Provisions Related to Status as Blank Check Company (Advisory Organizational Documents Proposal 5D) | | | The Cayman Constitutional Documents include various provisions related to HH&L’s status as a blank check company prior to the consummation of a business combination. | | | The Proposed Organizational Documents do not include such provisions related to HH&L’s status as a blank check company, which no longer will apply upon consummation of the Merger, as HH&L will cease to be a blank check company at such time. | |
| | |
Scenario 1
Assuming No Redemption |
| |
Scenario 2
Assuming Interim 50% Redemption |
| |
Scenario 3
Assuming Maximum Redemption |
| |||||||||||||||||||||||||||
Equity Capitalization Summary
|
| |
Shares
|
| |
%
|
| |
Shares
|
| |
%
|
| |
Shares
|
| |
%
|
| ||||||||||||||||||
HH&L public stockholders
|
| | | | 41,400,000 | | | | | | 42.4% | | | | | | 20,700,000 | | | | | | 26.9% | | | | | | 3,718,907 | | | | | | 6.2% | | |
HH&L independent directors
|
| | | | 88,000 | | | | | | 0.1% | | | | | | 88,000 | | | | | | 0.1% | | | | | | 88,000 | | | | | | 0.1% | | |
Sponsor
|
| | | | 10,262,000 | | | | | | 10.5% | | | | | | 10,262,000 | | | | | | 13.3% | | | | | | 10,262,000 | | | | | | 17.1% | | |
DiaCarta stockholders
|
| | | | 46,000,000 | | | | | | 47.1% | | | | | | 46,000,000 | | | | | | 59.7% | | | | | | 46,000,000 | | | | | | 76.6% | | |
Total Common Stock
|
| | | | 97,750,000 | | | | | | 100.0% | | | | | | 77,050,000 | | | | | | 100.0% | | | | | | 60,068,907 | | | | | | 100.0% | | |
| | |
Historical
9.30.2022 |
| |
Historical
9.30.2022 |
| |
Scenario 1
Assuming no redemption of shares |
| |
Scenario 2
Assuming Interim 50% Redemptions |
| |
Scenario 3 Assuming
Maximum Redemptions with no forfeiture of HH&L Series B shares |
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
DiaCarta
|
| |
HH&L
|
| |
Transaction
Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| |
Additional
Transaction Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| |
Additional
Transaction Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| ||||||||||||||||||||||||
ASSETS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cash
|
| | | $ | 4,243,524 | | | | | $ | 293,137 | | | | | $ | 416,517,794 | | | | | | A | | | | | $ | 402,110,627 | | | | | $ | (207,000,000) | | | | | | G | | | | | $ | 195,110,627 | | | | | $ | (169,810,931) | | | | | | G | | | | | $ | 25,299,696 | | |
| | | | | | | | | | | | | | | | | (3,669,107) | | | | | | B | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | (15,274,721) | | | | | | F | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Short-term investments
|
| | | | 10,916,415 | | | | | | — | | | | | | | | | | | | | | | | | | 10,916,415 | | | | | | | | | | | | | | | | | | 10,916,415 | | | | | | | | | | | | | | | | | | 10,916,415 | | |
Accounts receivable, net
|
| | | | 4,071,378 | | | | | | — | | | | | | | | | | | | | | | | | | 4,071,378 | | | | | | | | | | | | | | | | | | 4,071,378 | | | | | | | | | | | | | | | | | | 4,071,378 | | |
Advances to suppliers
|
| | | | 20,153 | | | | | | — | | | | | | | | | | | | | | | | | | 20,153 | | | | | | | | | | | | | | | | | | 20,153 | | | | | | | | | | | | | | | | | | 20,153 | | |
Inventories, net
|
| | | | 1,451,085 | | | | | | — | | | | | | | | | | | | | | | | | | 1,451,085 | | | | | | | | | | | | | | | | | | 1,451,085 | | | | | | | | | | | | | | | | | | 1,451,085 | | |
Loan due from a related party, current
|
| | | | 288,255 | | | | | | — | | | | | | | | | | | | | | | | | | 288,255 | | | | | | | | | | | | | | | | | | 288,255 | | | | | | | | | | | | | | | | | | 288,255 | | |
Prepayments and other current assets, net
|
| | | | 3,103,812 | | | | | | 137,676 | | | | | | | | | | | | | | | | | | 3,241,488 | | | | | | | | | | | | | | | | | | 3,241,488 | | | | | | | | | | | | | | | | | | 3,241,488 | | |
Total current assets
|
| | | | 24,094,622 | | | | | | 430,813 | | | | | | 397,573,966 | | | | | | | | | | | | 422,099,401 | | | | | | (207,000,000) | | | | | | | | | | | | 215,099,401 | | | | | | (169,810,931) | | | | | | | | | | | | 45,288,470 | | |
Property and equipment, net
|
| | | | 2,535,658 | | | | | | — | | | | | | | | | | | | | | | | | | 2,535,658 | | | | | | | | | | | | | | | | | | 2,535,658 | | | | | | | | | | | | | | | | | | 2,535,658 | | |
Intangible assets, net
|
| | | | 9,070 | | | | | | — | | | | | | | | | | | | | | | | | | 9,070 | | | | | | | | | | | | | | | | | | 9,070 | | | | | | | | | | | | | | | | | | 9,070 | | |
Operating lease right-of-use
asset |
| | | | 7,432,419 | | | | | | — | | | | | | | | | | | | | | | | | | 7,432,419 | | | | | | | | | | | | | | | | | | 7,432,419 | | | | | | | | | | | | | | | | | | 7,432,419 | | |
Finance lease assets
|
| | | | 22,596 | | | | | | — | | | | | | | | | | | | | | | | | | 22,596 | | | | | | | | | | | | | | | | | | 22,596 | | | | | | | | | | | | | | | | | | 22,596 | | |
Deferred tax assets
|
| | | | 2,389,240 | | | | | | — | | | | | | | | | | | | | | | | | | 2,389,240 | | | | | | | | | | | | | | | | | | 2,389,240 | | | | | | | | | | | | | | | | | | 2,389,240 | | |
Loan due from a related
party |
| | | | 1,419,836 | | | | | | — | | | | | | | | | | | | | | | | | | 1,419,836 | | | | | | | | | | | | | | | | | | 1,419,836 | | | | | | | | | | | | | | | | | | 1,419,836 | | |
Other asset
|
| | | | 42,125 | | | | | | — | | | | | | | | | | | | | | | | | | 42,125 | | | | | | | | | | | | | | | | | | 42,125 | | | | | | | | | | | | | | | | | | 42,125 | | |
Investments held in Trust
Account |
| | | | — | | | | | | 416,517,794 | | | | | | (416,517,794) | | | | | | A | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Total assets
|
| | | $ | 37,945,566 | | | | | $ | 416,948,607 | | | | | $ | (18,943,828) | | | | | | | | | | | $ | 435,950,345 | | | | | $ | (207,000,000) | | | | | | | | | | | $ | 228,950,345 | | | | | $ | (169,810,931) | | | | | | | | | | | $ | 59,139,414 | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 4,588,796 | | | | | $ | 135,297 | | | | | $ | (135,297) | | | | | | B | | | | | $ | 4,588,796 | | | | | $ | | | | | | | | | | | $ | 4,588,796 | | | | | $ | | | | | | | | | | | $ | 4,588,796 | | | ||
Accounts payable – related
party |
| | | | — | | | | | | 300,000 | | | | | | (300,000) | | | | | | B | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Working Capital Loan – related
party |
| | | | | | | | | | 500,000 | | | | | | (500,000) | | | | | | B | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Accrued liabilities and other payables
|
| | | | 281,277 | | | | | | 2,733,810 | | | | | | (2,733,810) | | | | | | B | | | | | | 281,277 | | | | | | | | | | | | | | | | | | 281,277 | | | | | | | | | | | | | | | | | | 281,277 | | |
Operating lease liabilities, current
|
| | | | 1,224,747 | | | | | | — | | | | | | | | | | | | | | | | | | 1,224,747 | | | | | | | | | | | | | | | | | | 1,224,747 | | | | | | | | | | | | | | | | | | 1,224,747 | | |
Finance lease liabilities,
current |
| | | | — | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Income tax payable
|
| | | | — | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Advance from customers
|
| | | | 168,366 | | | | | | | | | | | | | | | | | | | | | | | | 168,366 | | | | | | | | | | | | | | | | | | 168,366 | | | | | | | | | | | | | | | | | | 168,366 | | |
Convertible bonds payable
|
| | | | — | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Total current liabilities
|
| | | | 6,263,186 | | | | | | 3,669,107 | | | | | | (3,669,107) | | | | | | | | | | | | 6,263,186 | | | | | | — | | | | | | | | | | | | 6,263,186 | | | | | | — | | | | | | | | | | | | 6,263,186 | | |
Lease Liabilities, non-current
|
| | | | 7,285,463 | | | | | | — | | | | | | | | | | | | | | | | | | 7,285,463 | | | | | | | | | | | | | | | | | | 7,285,463 | | | | | | | | | | | | | | | | | | 7,285,463 | | |
Derivative warrant liabilities
|
| | | | — | | | | | | 929,400 | | | | | | | | | | | | | | | | | | 929,400 | | | | | | | | | | | | | | | | | | 929,400 | | | | | | | | | | | | | | | | | | 929,400 | | |
Deferred underwriting commissions
|
| | | | — | | | | | | 14,490,000 | | | | | | (14,490,000) | | | | | | H | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Total liabilities
|
| | | | 13,548,649 | | | | | | 19,088,507 | | | | | | (18,159,107) | | | | | | | | | | | | 14,478,049 | | | | | | — | | | | | | | | | | | | 14,478,049 | | | | | | — | | | | | | | | | | | | 14,478,049 | | |
Commitments and contingencies
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
Historical
9.30.2022 |
| |
Historical
9.30.2022 |
| |
Scenario 1
Assuming no redemption of shares |
| |
Scenario 2
Assuming Interim 50% Redemptions |
| |
Scenario 3 Assuming
Maximum Redemptions with no forfeiture of HH&L Series B shares |
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
DiaCarta
|
| |
HH&L
|
| |
Transaction
Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| |
Additional
Transaction Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| |
Additional
Transaction Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| ||||||||||||||||||||||||
Class A ordinary shares subject
to possible redemption, $0.0001 par value; 41,400,000 shares at approximately $10.06 and $10.00 per share as of September 30, 2022 and December 31, 2021, respectively |
| | | | — | | | | | | 416,417,794 | | | | | | (416,417,794) | | | | | | D | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Stockholders’ equity (deficit): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding
|
| | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Class A ordinary shares, $0.0001
par value; 500,000,000 shares authorized; no non- redeemable shares issued or outstanding |
| | | | — | | | | | | — | | | | | | 9,775 | | | | | | E | | | | | | 9,775.00 | | | | | | (2,070) | | | | | | G | | | | | | 7,705 | | | | | | (1,698) | | | | | | G | | | | | | 6,007 | | |
Class B ordinary shares, $0.0001
par value; 50,000,000 shares authorized; 10,350,000 shares issued and outstanding at September 30, 2022 and December 31, 2021 |
| | | | — | | | | | | 1,035 | | | | | | (1,035) | | | | | | E | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Ordinary shares (USD0.001 par
value, 28,469,472 shares authorized; 28,469,472 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively) |
| | | | 28,469 | | | | | | — | | | | | | (28,469) | | | | | | E | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Series A non-redeemable preferred shares (USD0.001 par value, 7,543,948 shares authorized; 7,543,948 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively)
|
| | | | 7,544 | | | | | | — | | | | | | (7,544) | | | | | | E | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Series B non-redeemable
preferred shares (USD0.001 par value, 13,646,217 shares authorized; 12,183,137 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively) |
| | | | 12,183 | | | | | | — | | | | | | (12,183) | | | | | | E | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | — | | |
Additional paid-in capital
|
| | | | 55,385,930 | | | | | | — | | | | | | (18,558,729) | | | | | | C | | | | | | 452,499,730 | | | | | | (206,997,930) | | | | | | G | | | | | | 245,501,800 | | | | | | (169,809,233) | | | | | | G | | | | | | 75,692,567 | | |
| | | | | | | | | | | | | | | | | 416,417,794 | | | | | | D | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | 39,456 | | | | | | E | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | (15,274,721) | | | | | | F | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | 14,490,000 | | | | | | H | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Accumulated deficit
|
| | | | (28,688,454) | | | | | | (18,558,729) | | | | | | 18,558,729 | | | | | | C | | | | | | (28,688,454) | | | | | | | | | | | | | | | | | | (28,688,454) | | | | | | | | | | | | | | | | | | (28,688,454) | | |
Accumulated other comprehensive loss
|
| | | | (2,348,755) | | | | | | — | | | | | | | | | | | | | | | | | | (2,348,755) | | | | | | | | | | | | | | | | | | (2,348,755) | | | | | | | | | | | | | | | | | | (2,348,755) | | |
Total stockholders’ equity
|
| | | | 24,396,917 | | | | | | (18,557,694) | | | | | | 415,633,073 | | | | | | | | | | | | 421,472,296 | | | | | | (207,000,000) | | | | | | | | | | | | 214,472,296 | | | | | | (169,810,931) | | | | | | | | | | | | 44,661,365 | | |
Total liabilities and stockholders’ equity
|
| | | $ | 37,945,566 | | | | | $ | 416,948,607 | | | | | $ | (18,943,828) | | | | | | | | | | | $ | 435,950,345 | | | | | $ | (207,000,000) | | | | | | | | | | | $ | 228,950,345 | | | | | $ | (169,810,931) | | | | | | | | | | | $ | 59,139,414 | | |
|
| | | | | | | | | | | | | | |
Scenario 1
Assuming no redemption of shares |
| |
Scenario 2
Assuming Interim 50% Redemptions |
| |
Scenario 3
Assuming Maximum Redemptions with no forfeiture of HH&L Series B shares |
| |||||||||||||||||||||||||||||||||
| | |
DiaCarta
|
| |
HH&L
|
| |
Transaction
Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| |
Additional
Transaction Accounting Adjustments |
| |
Pro Forma
Combined |
| |
Additional
Transaction Accounting Adjustments |
| |
Pro Forma
Combined |
| ||||||||||||||||||||||||
Revenue, net
|
| | | $ | 18,332,240 | | | | | $ | — | | | | | $ | | | | | | | | | | | $ | 18,332,240 | | | | | $ | | | | | $ | 18,332,240 | | | | | $ | | | | | $ | 18,332,240 | | | |||
Cost of goods sold
|
| | | | 10,722,756 | | | | | | — | | | | | | | | | | | | | | | | | | 10,722,756 | | | | | | | | | | | | 10,722,756 | | | | | | | | | | | | 10,722,756 | | |
Gross profit
|
| | | | 7,609,484 | | | | | | — | | | | | | — | | | | | | | | | | | | 7,609,484 | | | | | | — | | | | | | 7,609,484 | | | | | | — | | | | | | 7,609,484 | | |
Operating expenses
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Selling and marketing expenses
|
| | | | 1,855,147 | | | | | | — | | | | | | | | | | | | | | | | | | 1,855,147 | | | | | | | | | | | | 1,855,147 | | | | | | | | | | | | 1,855,147 | | |
General and administrative
expenses |
| | | | 3,889,301 | | | | | | 2,634,624 | | | | | | (135,000) | | | | | | BB | | | | | | 3,630,286 | | | | | | | | | | | | 3,630,286 | | | | | | | | | | | | 3,630,286 | | |
| | | | | | | | | | | | | | | | | (2,758,639) | | | | | | CC | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development
expenses |
| | | | 4,868,430 | | | | | | — | | | | | | | | | | | | | | | | | | 4,868,430 | | | | | | | | | | | | 4,868,430 | | | | | | | | | | | | 4,868,430 | | |
Total operating expenses
|
| | | | 10,612,878 | | | | | | 2,634,624 | | | | | | (2,893,639) | | | | | | | | | | | | 10,353,863 | | | | | | — | | | | | | 10,353,863 | | | | | | — | | | | | | 10,353,863 | | |
Income (loss) from operations
|
| | | | (3,003,394) | | | | | | (2,634,624) | | | | | | 2,893,639 | | | | | | | | | | | | (2,744,379) | | | | | | — | | | | | | (2,744,379) | | | | | | — | | | | | | (2,744,379) | | |
OTHER INCOME (EXPENSE): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Change in fair value of derivative warrant
liabilities |
| | | | — | | | | | | 16,419,400 | | | | | | | | | | | | | | | | | | 16,419,400 | | | | | | | | | | | | 16,419,400 | | | | | | | | | | | | 16,419,400 | | |
Financing cost – derivative warrant liabilities
|
| | | | — | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | — | | | | | | | | | | | | — | | |
Income from investments held in Trust Account
|
| | | | — | | | | | | 2,493,903 | | | | | | (2,493,903) | | | | | | AA | | | | | | — | | | | | | | | | | | | — | | | | | | | | | | | | — | | |
Interest income (expense), net
|
| | | | 123,371 | | | | | | — | | | | | | | | | | | | | | | | | | 123,371 | | | | | | | | | | | | 123,371 | | | | | | | | | | | | 123,371 | | |
Investment income/(loss)
|
| | | | (140,787) | | | | | | — | | | | | | | | | | | | | | | | | | (140,787) | | | | | | | | | | | | (140,787) | | | | | | | | | | | | (140,787) | | |
Other (expense) income, net
|
| | | | (319,626) | | | | | | — | | | | | | | | | | | | | | | | | | (319,626) | | | | | | | | | | | | (319,626) | | | | | | | | | | | | (319,626) | | |
Total other expense, net
|
| | | | (337,042) | | | | | | 18,913,303 | | | | | | (2,493,903) | | | | | | | | | | | | 16,082,358 | | | | | | — | | | | | | 16,082,358 | | | | | | — | | | | | | 16,082,358 | | |
Income (loss) before income tax
|
| | | | (3,340,436) | | | | | | 16,278,679 | | | | | | 399,736 | | | | | | | | | | | | 13,337,979 | | | | | | — | | | | | | 13,337,979 | | | | | | — | | | | | | 13,337,979 | | |
Income tax benefit
|
| | | | (403,192) | | | | | | — | | | | | | — | | | | | | | | | | | | (403,192) | | | | | | | | | | | | (403,192) | | | | | | | | | | | | (403,192) | | |
Net income (loss)
|
| | | $ | (2,937,244) | | | | | $ | 16,278,679 | | | | | $ | 399,736 | | | | | | | | | | | $ | 13,741,171 | | | | | $ | — | | | | | $ | 13,741,171 | | | | | $ | — | | | | | $ | 13,741,171 | | |
Net income (loss) attributable to noncontrolling interest
|
| | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | — | | | | | | | | | | | | — | | | | | | | | | | | | — | | |
Net income (loss) attributable to common
stockholders |
| | | $ | (2,937,244) | | | | | $ | 16,278,679 | | | | | $ | 399,736 | | | | | | | | | | | $ | 13,741,171 | | | | | $ | — | | | | | $ | 13,741,171 | | | | | $ | — | | | | | $ | 13,741,171 | | |
COMPREHENSIVE INCOME (LOSS):
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
NET INCOME (LOSS)
|
| | | | (2,937,244) | | | | | | 16,278,679 | | | | | | 399,736 | | | | | | | | | | | | 13,741,171 | | | | | | — | | | | | | 13,741,171 | | | | | | — | | | | | | 13,741,171 | | |
OTHER COMPREHENSIVE (LOSS)
INCOME |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Foreign currency translation
adjustments |
| | | | (622,386) | | | | | | — | | | | | | — | | | | | | | | | | | | (622,386) | | | | | | — | | | | | | (622,386) | | | | | | — | | | | | | (622,386) | | |
TOTAL COMPREHENSIVE INCOME (LOSS)
|
| | | $ | (3,559,630) | | | | | | 16,278,679 | | | | | $ | 399,736 | | | | | | | | | | | $ | 13,118,785 | | | | | $ | — | | | | | $ | 13,118,785 | | | | | $ | — | | | | | $ | 13,118,785 | | |
Net loss per share – basic
|
| | | $ | (0.10) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Net loss per share – diluted
|
| | | $ | (0.10) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted net income per ordinary
share, Class A |
| | | | | | | | | $ | 0.31 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted net income per ordinary
share, Class B |
| | | | | | | | | $ | 0.31 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Pro forma weighted average number of common shares outstanding – basic and diluted
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | 97,750,000 | | | | | | | | | | | | 77,050,000 | | | | | | | | | | | | 60,068,907 | | |
Pro forma net income per share – basic and diluted
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | $ | 0.14 | | | | | | | | | | | $ | 0.18 | | | | | | | | | | | $ | 0.23 | | |
| | | | | | | | | | | | | | |
Scenario 1 Assuming
no redemption of shares |
| |
Scenario 2 Assuming
Interim 50% Redemptions |
| |
Scenario 3 Assuming
Maximum Redemptions with no forfeiture of HH&L Series B shares |
| |||||||||||||||||||||||||||||||||
| | |
DiaCarta
|
| |
HH&L
|
| |
Transaction
Accounting Adjustments |
| | | | | | | |
Pro Forma
Combined |
| |
Additional
Transaction Accounting Adjustments |
| |
Pro Forma
Combined |
| |
Additional
Transaction Accounting Adjustments |
| |
Pro Forma
Combined |
| ||||||||||||||||||||||||
Revenue, net
|
| | | $ | 41,501,568 | | | | | $ | — | | | | | $ | | | | | | | | | | | | $ | 41,501,568 | | | | | $ | | | | | $ | 41,501,568 | | | | | $ | | | | | $ | 41,501,568 | | | ||
Cost of goods sold
|
| | | | 13,426,619 | | | | | | — | | | | | | | | | | | | | | | | | | 13,426,619 | | | | | | | | | | | | 13,426,619 | | | | | | | | | | | | 13,426,619 | | |
Gross profit
|
| | | | 28,074,949 | | | | | | — | | | | | | — | | | | | | | | | | | | 28,074,949 | | | | | | — | | | | | | 28,074,949 | | | | | | — | | | | | | 28,074,949 | | |
Operating expenses
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Selling and marketing expenses
|
| | | | 1,820,038 | | | | | | — | | | | | | | | | | | | | | | | | | 1,820,038 | | | | | | | | | | | | 1,820,038 | | | | | | | | | | | | 1,820,038 | | |
General and administrative expenses
|
| | | | 3,824,924 | | | | | | 1,805,492 | | | | | | (165,000) | | | | | | BB | | | | | | 4,882,743 | | | | | | | | | | | | 4,882,743 | | | | | | | | | | | | 4,882,743 | | |
| | | | | | | | | | | | | | | | | (582,673) | | | | | | CC | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development expenses
|
| | | | 5,179,766 | | | | | | — | | | | | | | | | | | | | | | | | | 5,179,766 | | | | | | | | | | | | 5,179,766 | | | | | | | | | | | | 5,179,766 | | |
Total operating expenses
|
| | | | 10,824,728 | | | | | | 1,805,492 | | | | | | (747,673) | | | | | | | | | | | | 11,882,547 | | | | | | — | | | | | | 11,882,547 | | | | | | — | | | | | | 11,882,547 | | |
Income (loss) from operations
|
| | | | 17,250,221 | | | | | | (1,805,492) | | | | | | 747,673 | | | | | | | | | | | | 16,192,402 | | | | | | — | | | | | | 16,192,402 | | | | | | — | | | | | | 16,192,402 | | |
OTHER INCOME (EXPENSE): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Change in fair value of derivative warrant liabilities
|
| | | | — | | | | | | 3,923,200 | | | | | | | | | | | | | | | | | | 3,923,200 | | | | | | | | | | | | 3,923,200 | | | | | | | | | | | | 3,923,200 | | |
Financing cost – derivative warrant liabilities
|
| | | | — | | | | | | (821,170) | | | | | | | | | | | | | | | | | | (821,170) | | | | | | | | | | | | (821,170) | | | | | | | | | | | | (821,170) | | |
Income from investments held in Trust Account
|
| | | | — | | | | | | 23,891 | | | | | | (23,891) | | | | | | AA | | | | | | — | | | | | | | | | | | | — | | | | | | | | | | | | — | | |
Interest income (expense), net
|
| | | | (701,630) | | | | | | — | | | | | | | | | | | | | | | | | | (701,630) | | | | | | | | | | | | (701,630) | | | | | | | | | | | | (701,630) | | |
Investment income/(loss)
|
| | | | (10,370) | | | | | | — | | | | | | | | | | | | | | | | | | (10,370) | | | | | | | | | | | | (10,370) | | | | | | | | | | | | (10,370) | | |
Other (expense) income, net
|
| | | | 600,405 | | | | | | — | | | | | | | | | | | | | | | | | | 600,405 | | | | | | | | | | | | 600,405 | | | | | | | | | | | | 600,405 | | |
Total other expense, net
|
| | | | (111,595) | | | | | | 3,125,921 | | | | | | (23,891) | | | | | | | | | | | | 2,990,435 | | | | | | — | | | | | | 2,990,435 | | | | | | — | | | | | | 2,990,435 | | |
Income (loss) before income tax
|
| | | | 17,138,626 | | | | | | 1,320,429 | | | | | | 723,782 | | | | | | | | | | | | 19,182,837 | | | | | | — | | | | | | 19,182,837 | | | | | | — | | | | | | 19,182,837 | | |
Income tax expense
|
| | | | 5,328,468 | | | | | | — | | | | | | | | | | | | | | | | | | 5,328,468 | | | | | | 5,328,468 | | | | | | 5,328,468 | | | | | | | | | | | | | | |
Net income (loss)
|
| | | $ | 11,810,158 | | | | | $ | 1,320,429 | | | | | $ | 723,782 | | | | | | | | | | | $ | 13,854,369 | | | | | $ | — | | | | | $ | 13,854,369 | | | | | $ | — | | | | | $ | 13,854,369 | | |
Net income (loss) attributable to noncontrolling interest
|
| | | | — | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | | | | | | | — | | | | | | | | | | | | — | | |
Net income (loss) attributable to common stockholders
|
| | | $ | 11,810,158 | | | | | $ | 1,320,429 | | | | | $ | 723,782 | | | | | | | | | | | $ | 13,854,369 | | | | | $ | — | | | | | $ | 13,854,369 | | | | | $ | — | | | | | $ | 13,854,369 | | |
COMPREHENSIVE LOSS: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
NET LOSS
|
| | | | 11,810,158 | | | | | | 1,320,429 | | | | | | 723,782 | | | | | | | | | | | | 13,854,369 | | | | | | — | | | | | | 13,854,369 | | | | | | — | | | | | | 13,854,369 | | |
OTHER COMPREHENSIVE (LOSS) INCOME
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Foreign currency translation
adjustments |
| | | | 290,631 | | | | | | — | | | | | | — | | | | | | | | | | | | 290,631 | | | | | | — | | | | | | 290,631 | | | | | | — | | | | | | 290,631 | | |
TOTAL COMPREHENSIVE
LOSS |
| | | $ | 12,100,789 | | | | | | 1,320,429 | | | | | $ | 723,782 | | | | | | | | | | | $ | 14,145,000 | | | | | $ | — | | | | | $ | 14,145,000 | | | | | $ | — | | | | | $ | 14,145,000 | | |
Net income per share – basic
|
| | | $ | 0.41 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Net income per share – diluted
|
| | | $ | 0.25 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted net income (loss) per ordinary share, Class A
|
| | | | | | | | | $ | 0.03 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted net income (loss) per ordinary share, Class B
|
| | | | | | | | | $ | 0.03 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Pro forma weighted average number of common shares outstanding – basic and diluted
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | 97,750,000 | | | | | | | | | | | | 77,050,000 | | | | | | | | | | | | 60,068,907 | | |
Pro forma net loss per share – basic and diluted
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | $ | 0.14 | | | | | | | | | | | $ | 0.18 | | | | | | | | | | | $ | 0.23 | | |
| | |
Pro Forma
Combined (Assuming No Redemptions) |
| |
Pro Forma Combined
(Assuming Interim 50% Redemptions) |
| |
Pro Forma Combined
(Assuming Maximum Redemptions) |
| |||||||||
Summary Unaudited Pro Forma Condensed Combined | | | | | | | | | | | | | | | | | | | |
Statement of Operations Data for the Nine Months Ended September 30, 2022
|
| | | | | | | | | | | | | | | | | | |
Total revenue
|
| | | $ | 18,332,240 | | | | | $ | 18,332,240 | | | | | $ | 18,332,240 | | |
Net income
|
| | | $ | 13,741,171 | | | | | $ | 13,741,171 | | | | | $ | 13,741,171 | | |
Net income per share – basic and diluted
|
| | | $ | 0.14 | | | | | $ | 0.18 | | | | | $ | 0.23 | | |
Weighted-average shares outstanding – basic and diluted
|
| | | | 97,750,000 | | | | | | 77,050,000 | | | | | | 60,068,907 | | |
Summary Unaudited Pro Forma Condensed Combined | | | | | | | | | | | | | | | | | | | |
Statement of Operations Data for the Year Ended December 31, 2021
|
| | | | | | | | | | | | | | | | | | |
Total revenue
|
| | | $ | 41,501,568 | | | | | $ | 41,501,568 | | | | | $ | 41,501,568 | | |
Net income
|
| | | $ | 13,854,369 | | | | | $ | 13,854,369 | | | | | $ | 13,854,369 | | |
Net income per share – basic and diluted
|
| | | $ | 0.14 | | | | | $ | 0.18 | | | | | $ | 0.23 | | |
Weighted-average shares outstanding – basic and diluted
|
| | | | 97,750,000 | | | | | | 77,050,000 | | | | | | 60,068,907 | | |
Summary Unaudited Pro Forma Condensed Combined | | | | | | | | | | | | | | | | | | | |
Balance Sheet Data as of September 30, 2022 | | | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 402,110,627 | | | | | $ | 195,110,627 | | | | | $ | 25,299,696 | | |
Total current assets
|
| | | $ | 422,099,401 | | | | | $ | 215,099,401 | | | | | $ | 45,288,470 | | |
Total assets
|
| | | $ | 435,950,345 | | | | | $ | 228,950,345 | | | | | $ | 59,139,414 | | |
Total current liabilities
|
| | | $ | 6,263,186 | | | | | $ | 6,263,186 | | | | | $ | 6,263,186 | | |
Total liabilities
|
| | | $ | 14,478,049 | | | | | $ | 14,478,049 | | | | | $ | 14,478,049 | | |
Total stockholders’ equity
|
| | | $ | 421,472,296 | | | | | $ | 214,472,296 | | | | | $ | 44,661,365 | | |
Name
|
| |
Age
|
| |
Position
|
|
Kenneth W. Hitchner | | | 62 | | | chairman of the board | |
Richard Qi Li | | | 52 | | | chief executive officer & director | |
Huanan Yang | | | 38 | | | chief operating officer & director | |
Yingjie (Christina) Zhong | | | 53 | | | chief financial officer | |
Qingjun Jin | | | 65 | | | independent director | |
Dr. Jingwu Zhang Zang | | | 66 | | | independent director | |
Professor Frederick Si Hang Ma | | | 69 | | | independent director | |
Derek Nelsen Sulger | | | 50 | | | independent director | |
Individual
|
| |
Position
|
| |
Entity
|
| |
Entity’s Business
|
| |
Affiliation
|
|
Kenneth W. Hitchner
|
| | chairman of the board | | | Elements Advisors SPV | | | Investment Advisor | | | Director | |
| | | | | | Wuxi Biologics (Cayman) Inc. | | | Healthcare | | | Director | |
| | | | | | CStone Pharmaceuticals Co., Ltd. | | | Biotech & Pharmaceutical | | | Director | |
Richard Qi Li | | | chief executive officer and director of the board | | |
Chenghe Group Ltd.
|
| | Financial Services | | | Director | |
| | | | | | Chenghe Capital Asset Management Ltd. | | | Financial Services | | | Director and Designated Representative | |
| | | | | | Chenghe Acquisition Co. | | | Special Purpose Acquisition Company | | | Director | |
| | | | | | Chenghe Capital Limited Partnership | | | Financial Services | | | Limited Partner | |
| | | | | | Chenghe Investment Private Ltd | | | Asset Management | | | Director | |
| | | | | | Chenghe Investment Co. | | | Financial Services | | | Director | |
Fenglei Fang | | | chairman of the advisory board | | | HOPU Investments | | |
Assets Management
|
| | Chairman(1) | |
| | | | | | Goldman Sachs Gao Hua Securities Company Limited | | | Financial Services | | | Director | |
| | | | | | Beijing Gaohua Securities Company | | | Financial Services | | | Chairman | |
Individual
|
| |
Position
|
| |
Entity
|
| |
Entity’s Business
|
| |
Affiliation
|
|
| | | | | | Limited | | | | | | | |
| | | | | | Phoenix Media Investment (Holdings) Limited | | | Media | | | Director | |
Huanan Yang | | | chief operating officer and director | | | HOPU Investments | | | PE Investments | | | Executive Director | |
| | | | | |
China Tea Co., Ltd.
|
| | Tea Products | | | Director | |
| | | | | | COFCO Fortune Co., Ltd. | | | Food Products | | | Director | |
Qingjun Jin | | |
independent director
|
| | King & Wood Mallesons | | | Legal Services | | | Senior Partner | |
| | | | | | Goldstream Investment Limited | | |
Technology Services
|
| | Director | |
| | | | | | Shenzhen Cheng Chung Design Co., Ltd. | | | Engineering & Construction | | | Director | |
| | | | | | Shenzhen Kingkey Smart Agriculture Times Co., Ltd. | | |
Real Estate
Owners & Developers |
| | Director | |
| | | | | | Bank of Tianjin Co., Ltd. | | | Banking | | | Director | |
| | | | | | Hengqin Life Insurance Co., Ltd. | | | Life Insurance | | | Director | |
| | | | | | Central Development Holdings Limited | | | Renewable Energy | | | Director | |
| | | | | | Sino-Ocean Group Holding Limited | | |
Real Estate
Owners & Developers |
| | Director | |
| | | | | | Times China Holdings Limited | | |
Real Estate
Owners & Developers |
| | Director | |
| | | | | | Invesco Great Wall Fund Management Co., Ltd. | | | Asset Management | | | Director | |
Dr. Jingwu Zhang Zang | | |
independent director
|
| | I-Mab | | | Biotech & Pharmaceutical | | | Chief Executive Officer & Director | |
Professor Frederick Si Hang Ma | | |
independent director
|
| | Unicorn II Holdings Limited | | | Healthcare | | | Director | |
| | | | | | Guangshen Railway Company Limited | | | Railway Transport | | | Director | |
| | | | | | COSCO Shipping Holdings Co., Ltd. | | | Shipping | | | Director | |
| | | | | | FWD Group Holdings Limited | | | Insurance | | | Director and Chairman | |
Urine Test
|
| |
Sensitivity
(%) |
| |
Specificity
(%) |
| |
Assay Platform
|
| |
Quantitative
|
| |
Regulatory
Pathway |
|
Oncuria | | |
93
|
| |
93 – 95
|
| |
Multi ELISA
|
| |
Yes
|
| |
Pending
|
|
Cytology
|
| |
13 – 48
|
| |
85 – 100
|
| |
Microscopy
|
| |
No
|
| |
FDA
|
|
UroVysion
|
| |
70 – 86
|
| |
66 – 93
|
| |
Complex FISH
|
| |
No / Yes
|
| |
FDA
|
|
BTA stat
|
| |
29 – 74
|
| |
56 – 86
|
| |
Point of Care
|
| |
No
|
| |
FDA
|
|
BladderChek
|
| |
47 – 100
|
| |
55 – 98
|
| |
Point of Care
|
| |
No
|
| |
FDA
|
|
Cxbladder ™
|
| |
82 – 95
|
| |
85 – 94
|
| |
Multi RT-PCR
|
| |
Yes
|
| |
LDT
|
|
| | | |
Gene Target
|
| |
Sensitivity (LOD)
|
| |
Instruments
|
| |
FDA EUA
|
|
| DiaCarta QuantiVirus MPXV Test Kit | | | MPXV J2L and B6R | | | 50 copies/mL or 100 TCID50/mL | | | BioRad CFX384, ABI QS5, ABI 7500Dx and Roche LC480II | | | 1/10/2023 | |
| Quest Diagnostics Quest Diagnostics Monkeypox Virus Qualitative Real-Time PCR | | | Orthopoxvirus DNA polymerase gene (E9L), monkeypox virus (clade II) TNF (Tumor Necrosis Factor receptor) gene. | | | 100 copies/mL for MPXV; 250 copies/mL for OPXV | | | ABI 7500 Real-Time PCR or ABI 7500 Fast Real- Time PCR instruments | | | 9/7/2022 | |
| Abbott Alinity m MPXV | | | Dual target assay | | | 200 copies/mL | | | Alinity m System | | | 10/7/2022 | |
| ThermoFisher TaqPath Monkeypox/Orthopox Virus DNA Kit | | | monkeypox virus (MPXV), non- variola Orthopoxvirus (OPXV) targets | | | 100 GCE/mL for MPXV and 250 GCE/mL for OPXV | | | ABI QS5 Dx Real-Time PCR System, 96- well; ABI QS 7 Flex Real-Time PCR System, 384- well | | | 12/13/2022 | |
| Roche cobas MPXV for use on the cobas 6800/8800 Systems (cobas MPXV) | | | MPXV F3L gene, the MPXVB21R/B22R gene | | | 57 copies/mL | | | cobas® 6800/8800 Systems | | | 12/14/2022 | |
| BD VIASURE Monkeypox virus Real Time PCR Reagents for BD MAX System | | | tumor-necrosis factor gene (G2R) and an open reading frame (F3L) of the monkeypox genome | | | 90 TCID50/mL | | | BD MAX™ System | | | 12/23/2022 | |
|
IVD Products
|
| |
Non-IVD Products
|
|
|
RadTox
(Blood-based test for personalizing radiation and chemo response) |
| |
cfDNA extraction kit
|
|
|
ColoScape
(Blood-based test for colon cancer early detection) |
| |
DiaCarta Luminometer instrument
|
|
|
Oncuria
(Blood-based test for bladder cancer early detection) |
| |
DiaCarta cfDNA blood collection tubes
|
|
|
QClamp EGFR mutations test
QuantiVirus HPV E6/E7 test |
| |
QFusion ALK test
|
|
Location
|
| |
Type of Facility
|
| |
Capacity / Utilization
|
| |
Leased or owned
|
|
Pleasanton,
California |
| | Headquarters administration, research and development, CLIA | | |
37,000 sf
Capacity of 0.5 to 1 million
|
| | Leased | |
Location
|
| |
Type of Facility
|
| |
Capacity / Utilization
|
| |
Leased or owned
|
|
| | |
labs, Manufacture, U.S. sales and marketing, distribution
Equipped with all necessary instruments and tools for manufacturing any DiaCarta molecular diagnostic IVD test kit or protein immunoassay and other IVD or RUO test kits
|
| | molecular diagnostic IVD test kits per month, depending on the configurations. Average output was 150,000test kits per month in 2021 | | | | |
Nanjing, China
|
| |
Administration, R&D labs, Manufacture, sales and marketing
Equipped with all necessary instruments and tools for manufacturing any DiaCarta molecular diagnostic IVD test kit or protein immunoassay and other IVD or RUO test kits
|
| |
70,000 sf
Capacity of 1 – 2 million molecular diagnostic IVD test kits per month, depending on the configurations. Average output was 50,000 test kits per month in 2021
|
| | Leased | |
Issued Utility Patents
|
| ||||||
Patent / Jurisdiction
|
| |
Product
|
| |
Expiration
|
|
U.S. Patent No. 9,745,633 | | |
XNA,
QClamp® KRAS Mutation Detection Test QClamp® NRAS Mutation Detection Test QClamp® EGFR Mutation Detection Test QClamp® BRAF Mutation Detection Test QClamp® JAK2 Mutation Detection Test QClamp® PIK3CA Mutation Detection Test PNA Clamp mutation Detection Tests ColoScape™ Colorectal Cancer Detection Test |
| |
August 16, 2035*
|
|
U.S. Patent No. 10,400,277 | | |
XNA,
QClamp® KRAS Mutation Detection Test QClamp® NRAS Mutation Detection Test QClamp® EGFR Mutation Detection TestQClamp® BRAF Mutation Detection TestQClamp® JAK2 Mutation Detection TestQClamp® PIK3CA Mutation Detection Test
|
| |
August 10, 2035
|
|
U.S. Patent No. 11,208,689 | | |
XNA,
QClamp® KRAS Mutation Detection Test QClamp® NRAS Mutation Detection Test QClamp® EGFR Mutation Detection TestQClamp® BRAF Mutation Detection TestQClamp® JAK2 Mutation Detection TestQClamp® PIK3CA Mutation Detection Test ColoScape™ Colorectal Cancer Detection Test |
| |
August 10, 2035
|
|
U.S. Patent No. 11,274,302 | | |
XNA,
CRISPR-Quest Gene Editing Test |
| | April 8, 2040* | |
Chinese Patent No. 109996891 | | |
XNA,
ColoScape™ Colorectal Cancer Detection Test |
| | January 5, 2038 | |
E.U .Patent No. 3494236 | | |
XNA,
ColoScape™ Colorectal Cancer Detection Test |
| | March 6, 2039 | |
U.S. Patent No. 8,404,444 | | |
SuperbDNA,
Radiation Therapy Toxicity Measurement (RadTox) |
| |
March 17, 2031*
|
|
U.S. Patent No. 9,512,471 | | |
SuperbDNA,
QuantiVirus™ HPV E6/E7 mRNA Test |
| |
August 4, 2030*
|
|
Australian Patent No. 2010356288 | | |
SuperbDNA,
QuantiVirus™ HPV E6/E7 mRNA Test |
| | June 30, 2030 | |
Canadian Patent No. 2803753 | | |
SuperbDNA,
QuantiVirus™ HPV E6/E7 mRNA Test |
| | June 30, 2030 | |
Chinese Patent No. 110404606 | | | Antigen Detection Kit | | | June 18, 2039 | |
Chinese Patent No. 110394200 | | | Syphilis detection kit convenient to use | | | June 17, 2039 | |
Chinese Patent No. 110386329 | | | Portable gene detection kit | | | | |
Pending Utility Patents | | | | | | | |
Pending US Serial
No. 16/510,870 Also published as US No. 20190330621 |
| | CRISPR-Quest Gene Editing Test | | | July 12, 2039 | |
Issued Utility Patents
|
| ||||||
Patent / Jurisdiction
|
| |
Product
|
| |
Expiration
|
|
Pending US Serial No. 17/233,423
Also published as US No. 20210332444 |
| | QuantiVirus™ SARS-CoV-2 Test Kit (RT-PCR Test – Detects 3 genes)QuantiVirus™ SARS-CoV-2 Multiplex Test Kit (RT-PCR Test – Detects 1 gene) | | | April 16, 2041 | |
Pending US Serial No. 17/184,501
Also published as US No. 20220275450 |
| |
ColoScape™ Colorectal Cancer Detection Test
|
| | January 4, 2038 | |
Pending US Serial No. 17/933,081 | | | QClamp® KRAS Mutation Detection Test QClamp® NRAS Mutation Detection Test QClamp® EGFR Mutation Detection TestQClamp® BRAF Mutation Detection TestQClamp® JAK2 Mutation Detection TestQClamp® PIK3CA Mutation Detection Test | | | September 16, 2042 | |
Pending US Serial No. 17/902,517 | | | QuantiVirus™ Anti-SARS-CoV-2 IgG Test Kit (Antibody Test) – Research Use Only | | | September 2, 2042 | |
Pending US Serial No. 17/703,874 | | | XNA, QClamp® KRAS Mutation Detection Test QClamp® NRAS Mutation Detection Test QClamp® EGFR Mutation Detection TestQClamp® BRAF Mutation Detection TestQClamp® JAK2 Mutation Detection TestQClamp® PIK3CA Mutation Detection Test | | |
August 10, 2035
|
|
Pending US Serial
No. US 17/694,608 |
| | XNA, CRISPR-Quest Gene Editing Test | | |
October 17, 2037
|
|
Pending US Serial
No.18/057,215 |
| | Antisense Gene Therapy Employing Xenonucleic Acids | | | July 23, 2041 | |
Pending US Serial
No.17/384,635 |
| |
XNA,
Lung Cancer Mutation Detection
|
| | July 23, 2041 | |
Pending US Serial
No.17/981,467 |
| | Detection Of Polynucleotides And Mutant Polynucleotide Sequences In Tissue Samples | | | July 26, 2041 | |
Pending US Serial
No.17/386,451 |
| | Molecular Clamping And Allele Specific Qpcr Technology For Kras G12c Mutation Detection | | | July 27, 2041 | |
Pending US Serial
No. 17/933,081 filed |
| |
XNA,
QClamp® KRAS Mutation Detection Test QClamp® NRAS Mutation Detection Test QClamp® EGFR Mutation Detection TestQClamp® BRAF Mutation Detection TestQClamp® JAK2 Mutation Detection TestQClamp® PIK3CA Mutation Detection Test ColoScape™ Colorectal Cancer Detection Test
|
| |
January 26, 2042
|
|
Provisional Application
No. 63/415,669 |
| | SARS-COV-2 TEST | | |
October 13, 2043
|
|
Provisional Application
No. 63/415,325 |
| | XNAs’ – All tests using XNA | | |
October 12, 2043
|
|
Provisional Application
No. 63/415,572 |
| | Xna-Based Methylation And Mutant Detection Methods For Cancer Diagnostic | | |
October 12, 2043
|
|
Provisional Application
No. 63/415,592 |
| | CRISPR Gene-Editing’s Cell Screening | | |
October 12, 2043
|
|
| Chinese Patent No. 106636323 (A) | | | SuperbDNA, | | |
February 23, 2030
|
|
| | | | Radiation Therapy Toxicity Measurement (RadTox) | | | | |
| Chinese Patent No. 215365796 (U) | | | Cell culture kit for gene sequencing | | |
February 23, 2041
|
|
| Chinese Patent No. 215156920 (U) | | | Cancer gene detection kit | | |
February 25, 2041
|
|
| Chinese Patent No. 215156919 (U) | | | T cell CAR molecular expression analysis | | |
February 25, 2041
|
|
| Chinese Patent No. 215162676 (U) | | | Nucleic acid detector for isothermal amplification and gene editing | | |
February 23, 2041
|
|
| Chinese Patent No. 215157413 (U) | | | Cancer early-stage gene detection kit | | |
February 23, 2041
|
|
| Chinese Patent No. 113897276 (A) | | | Rapid detection kit for multiple respiratory viruses, and preparation method and system thereof | | |
September 23, 2041
|
|
| Chinese Patent No. 113879682 (A) | | |
Kit for genetic colorectal cancer gene detection
ColoScape™ Colorectal Cancer Detection Test |
| |
September 19, 2041
|
|
| Chinese Patent No. 214496323 (U) | | |
Multi-gene detection kit for cancer prognosis
|
| |
February 25, 2041
|
|
| Chinese Patent No. 113025479 (A) | | | Kit for detecting cell activation antigen | | |
February 28, 2041
|
|
| Chinese Patent No. 113018568 (A) | | | Cell reinfusion device for cell biotherapy | | |
February 28, 2041
|
|
| Chinese Patent No. 210506346 (U) | | | Gun arranging device for nucleic acid extractor | | | June 11, 2039 | |
| Chinese Patent No. 210481351 (U) | | | Biosafety cabinet suitable for small-scale biological test | | | June 19, 2039 | |
| Chinese Patent No. 210410785 (U) | | | Small-dose disposable pipettor for separating serum | | | June 19, 2039 | |
| Chinese Patent No. 210410784 (U) | | | Medical examination pipette | | | June 19, 2039 | |
| Chinese Patent No. 210419913 (U) | | |
Medical biological gene component analyzer
|
| | June 19, 2039 | |
| Chinese Patent No. 210410764 (U) | | | Biosafety cabinet with gloves convenient to replace | | | June 11, 2039 | |
| Chinese Patent No. 210411178 (U) | | | Convenient-to-maintain high-speed centrifuge for biomedical test | | | June 11, 2039 | |
| Chinese Patent No. 210385691 (U) | | | Temperature control oscillator for biomedical treatment | | | June 19, 2039 | |
| Chinese Patent No. 210181290 (U) | | |
Inverted microscope for biomedical treatment
|
| | June 19, 2039 | |
| PCT/US2021/027844 into Chinese national phase | | | QuantiVirus™ SARS-CoV-2 Test Kit (RT-PCR Test – Detects 3 genes)QuantiVirus™ SARS-CoV-2 Multiplex Test Kit (RT-PCR Test – Detects 1 gene) | | | April 16, 2041 | |
|
Japanese Patent Application
No. 2022-563171 |
| | QuantiVirus™ SARS-CoV-2 Test Kit (RT-PCR Test – Detects 3 genes)QuantiVirus™ SARS-CoV-2 Multiplex Test Kit (RT-PCR Test – Detects 1 gene) | | | April 16, 2041 | |
|
European Application
No. 21 788 834.6 |
| | QuantiVirus™ SARS-CoV-2 Test Kit (RT-PCR Test – Detects 3 genes)QuantiVirus™ SARS-CoV-2 Multiplex Test Kit (RT-PCR Test – Detects 1 gene) | | | April 16, 2041 | |
|
Canadian Patent Application
No. 3175815 |
| | QuantiVirus™ SARS-CoV-2 Test Kit (RT-PCR Test – Detects 3 genes)QuantiVirus™ SARS-CoV-2 Multiplex Test Kit (RT-PCR Test – Detects 1 gene) | | | April 16, 2041 | |
U.S. Serial Number
|
| |
U.S. Reg. Number
|
| |
U.S. Trademark
|
|
90778994 | | |
6773921
|
| | QUANTIDNA | |
88875493 | | |
6237078
|
| | QUANTIVIRUS | |
88349952 | | |
6020305
|
| | VZNHEALTH | |
88088936 | | |
5900382
|
| | OPTISEQ | |
87324974 | | |
5590987
|
| | RADTOX | |
87384165 | | |
5315719
|
| | QFUSION | |
86912861 | | |
5346929
|
| | QEX | |
86658078 | | |
5096404
|
| | COLOSCAPE | |
U.S. Serial Number
|
| |
U.S. Reg. Number
|
| |
U.S. Trademark
|
|
86658907 | | |
5078947
|
| | DIMERATOR | |
85956880 | | |
4653725
|
| | QCLAMP | |
85813427 | | |
4507227
|
| | CYTOPLEX | |
| | |
For the 9 months
Ended September 30, 2022 |
| |
For the 9 months
Ended September 30, 2021 |
| |
Change
In Amount |
| |||||||||
Revenues
|
| | | $ | 18,332,240 | | | | | $ | 32,236,815 | | | | | $ | (13,904,575) | | |
Cost of Revenues
|
| | | | 10,722,756 | | | | | | 10,057,420 | | | | | | 665,336 | | |
Gross Profit
|
| | | | 7,609,484 | | | | | | 22,179,395 | | | | | | (14,569,911) | | |
Operating Expenses: | | | | | | | | | | | | | | | | | | | |
Selling and marketing expenses
|
| | | | 1,855,147 | | | | | | 1,268,160 | | | | | | 586,987 | | |
General and administrative expenses
|
| | | | 3,889,301 | | | | | | 2,681,495 | | | | | | 1,207,806 | | |
Research and development expenses
|
| | | | 4,868,430 | | | | | | 3,630,832 | | | | | | 1,237,598 | | |
Total Operating Expenses
|
| | | | 10,612,878 | | | | | | 7,580,487 | | | | | | 3,032,391 | | |
Income(Loss) from Operations
|
| | | | (3,003,394) | | | | | | 14,598,908 | | | | | | (17,602,302) | | |
Interest income(expense), net
|
| | | | 123,371 | | | | | | (527,078) | | | | | | 650,449 | | |
Investment loss
|
| | | | (140,787) | | | | | | (10,370) | | | | | | (130,417) | | |
Other Income(expense), net
|
| | | | (319,626) | | | | | | 554,597 | | | | | | (874,223) | | |
Income(Loss) before Income Taxes
|
| | | | (3,340,436) | | | | | | 14,616,057 | | | | | | (17,956,493) | | |
Income Taxes
|
| | | | 403,192 | | | | | | (4,263,379) | | | | | | 4,666,571 | | |
Net Income(Loss)
|
| | | $ | (2,937,244) | | | | | $ | 10,352,678 | | | | | | (13,289,922) | | |
| | |
For the Nine Months Ended
|
| |||||||||||||||||||||
| | |
2022
|
| |
%of
Rev |
| |
2021
|
| |
%of
Rev |
| ||||||||||||
Revenues
|
| | | $ | 18,332,240 | | | | | | | | | | | $ | 32,236,815 | | | | | | | | |
Cost of Revenue | | | | | | | | | | | | | | | | | | | | | | | | | |
Product Cost
|
| | | | 1,197,336 | | | | | | 7% | | | | | | 2,724,512 | | | | | | 8% | | |
COVID-19 Test kit and reagents
|
| | | | 1,184,921 | | | | | | 6% | | | | | | 2,297,898 | | | | | | 7% | | |
Other
|
| | | | 12,415 | | | | | | 0% | | | | | | 426,614 | | | | | | 1% | | |
Testing Service Cost
|
| | | | 9,525,420 | | | | | | 52% | | | | | | 7,332,907 | | | | | | 23% | | |
COVID-19 Tests
|
| | | | 3,760,675 | | | | | | 21% | | | | | | 1,645,791 | | | | | | 5% | | |
Oncology Tests
|
| | | | 5,598,456 | | | | | | 31% | | | | | | 5,404,358 | | | | | | 17% | | |
Other
|
| | | | 166,288 | | | | | | 1% | | | | | | 282,759 | | | | | | 1% | | |
Total Cost of Revenue
|
| | | $ | 10,722,756 | | | | | | 58% | | | | | $ | 10,057,420 | | | | | | 31% | | |
| | |
For the Year Ended
December 31, 2021 |
| |
For the Year Ended
December 31, 2020 |
| |
Change
In Amount |
| |||||||||
Revenues
|
| | | $ | 41,501,568 | | | | | $ | 14,445,079 | | | | | $ | 27,056,489 | | |
Cost of Revenues
|
| | | | 13,426,619 | | | | | | 8,629,681 | | | | | | 4,796,938 | | |
Gross Profit
|
| | | | 28,074,949 | | | | | | 5,815,398 | | | | | | 22,259,551 | | |
OPERATING EXPENSES: | | | | | | | | | | | | | | | | | | | |
Selling and marketing expenses
|
| | | | 1,820,038 | | | | | | 1,182,573 | | | | | | 637,465 | | |
General and administrative expenses
|
| | | | 3,824,924 | | | | | | 2,566,119 | | | | | | 1,258,805 | | |
Research and development expenses
|
| | | | 5,179,766 | | | | | | 4,841,818 | | | | | | 337,948 | | |
Total Operating Expenses
|
| | | | 10,824,728 | | | | | | 8,590,510 | | | | | | 2,234,218 | | |
Income(Loss) from Operations
|
| | | | 17,250,221 | | | | | | (2,775,112) | | | | | | 20,025,333 | | |
Interest income(expense), net
|
| | | | (701,630) | | | | | | (336,222) | | | | | | (365,408) | | |
Investment loss
|
| | | | (10,370) | | | | | | 88,764 | | | | | | (99,134) | | |
Other Income(expense), net
|
| | | | 600,405 | | | | | | 848,784 | | | | | | (248,379) | | |
Income(Loss) before Income Taxes
|
| | | | 17,138,626 | | | | | | (2,173,786) | | | | | | 19,312,412 | | |
Income Taxes
|
| | | | (5,328,468) | | | | | | (44,195) | | | | | | (5,284,273) | | |
Net Income(Loss)
|
| | | $ | 11,810,158 | | | | | $ | (2,217,981) | | | | | | 14,028,139 | | |
Less: net income attributable to noncontrolling interests
|
| | | | — | | | | | | 34,463 | | | | | | (34,463) | | |
Net loss attributable to DiaCarta Shareholders
|
| | | $ | 11,810,158 | | | | | $ | (2,183,518) | | | | | $ | 13,993,676 | | |
| | |
For the 12 months Ended
December 31, 2021 |
| |
For the 12 months Ended
December 31, 2020 |
| ||||||
COVID Test Products
|
| | | $ | 24,857,433 | | | | | $ | 5,078,231 | | |
COVID Test Services
|
| | | | 7,224,225 | | | | | | 1,283,702 | | |
Oncology Test Products and Services
|
| | | | 9,419,909 | | | | | | 8,083,146 | | |
Total Revenue
|
| | | | 41,501,568 | | | | | | 14,445,079 | | |
| | |
For the
year ended December 31, 2021 |
| |
For the
year ended December 31, 2020 |
| ||||||
United States
|
| | | $ | 20,834,444 | | | | | $ | 1,336,421 | | |
Foreign countries
|
| | | | (3,695,818) | | | | | | (3,510,207) | | |
| | | | $ | 17,138,626 | | | | | $ | (2,173,786) | | |
| | |
For the
year ended December 31, 2021 |
| |
For the
year ended December 31, 2020 |
| ||||||
Current tax: | | | | | | | | | | | | | |
Federal tax
|
| | | $ | 1,652,766 | | | | | $ | — | | |
State tax
|
| | | | 1,023,006 | | | | | | 15,038 | | |
Foreign tax
|
| | | | — | | | | | | — | | |
Total current tax
|
| | |
|
2,675,772
|
| | | |
|
15,038
|
| |
Deferred tax: | | | | | | | | | | | | | |
Federal tax
|
| | | | 2,372,364 | | | | | | 187,641 | | |
State tax
|
| | | | 280,332 | | | | | | (158,484) | | |
Foreign tax
|
| | | | — | | | | | | — | | |
Total deferred tax
|
| | | | 2,652,696 | | | | | | 29,157 | | |
Total provision for income taxes
|
| | | $ | 5,328,468 | | | | | $ | 44,195 | | |
| | |
For the Nine Months ended
September 30, |
| |||||||||
| | |
2022
|
| |
2021
|
| ||||||
Net cash (used in) provided by operating activities
|
| | | $ | (3,083,113) | | | | | $ | 11,241,319 | | |
Net cash used in investing activities
|
| | | | (12,543,033) | | | | | | (924,382) | | |
Net cash used in financing activities
|
| | | | (2,593,075) | | | | | | (1,278,000) | | |
Effect of exchange rate change on cash
|
| | | | (181,374) | | | | | | 18,047 | | |
Net (decrease) increase in cash
|
| | | $ | (18,400,595) | | | | | $ | 9,056,984 | | |
| | |
For the years ended
December 31, |
| |||||||||
| | |
2021
|
| |
2020
|
| ||||||
Net cash provided by (used in) operating activities
|
| | | $ | 14,960,508 | | | | | $ | (469,522) | | |
Net cash (used in) provided by investing activities
|
| | | | (830,853) | | | | | | 2,929,233 | | |
Net cash (provided by) used in financing activities
|
| | | | (1,265,874) | | | | | | 2,885,938 | | |
Effect of exchange rate change on cash
|
| | | | 184,851 | | | | | | 263,870 | | |
Net increase in cash
|
| | | $ | 13,048,632 | | | | | $ | 5,609,519 | | |
Name
|
| |
Age
|
| |
Position
|
|
Executive Officers and Directors* | | | | | | | |
Aiguo Zhang | | | 58 | | | Chief Executive Officer and Board Chairman | |
Dennis Gao | | | 55 | | | Vice President Finance and Principal Financial Officer | |
Michael Sha | | | 62 | | | Chief Technology Officer | |
Paul Okunieff | | | 65 | | | Chief Medical Officer, Director and Chairman of the Compensation Committee | |
Ram Vairavan | | | 74 | | | Senior Vice President-Commercial | |
Effie Ho | | | 54 | | | General Manager-Asia Pacific | |
Non-Executive Directors | | | | | | | |
Jack Kaye | | | 79 | | | Director, Chairman of the Audit Committee and Member of the Compensation committee | |
Kenneth W. Hitchner | | | 62 | | | Director, Member of the Audit and Nomination and Governance Committees | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Stock
Awards ($) |
| |
Non-Equity
Incentive Plan Compensation ($) |
| |
Total
($) |
| |||||||||||||||
Aiguo Zhang
Chief Executive Officer |
| | | | 2021 | | | | | | 275,000 | | | | | | — | | | | | | — | | | | | | 275,000 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
Ram Vairavan
Senior VP, Commercial |
| | | | 2021 | | | | | | 150,000 | | | | | | — | | | | | | 408,383(1) | | | | | | 558,383 | | |
Effie Ho
General Manager – Asia Pacific |
| | | | 2021 | | | | | | 165,000 | | | | | | — | | | | | | — | | | | | | 165,000 | | |
| | |
Pre-Business Combination
|
| |
Post-Business Combination
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
Assuming No
Redemption |
| |
Assuming Interim
Redemption |
| |
Assuming Maximum
Redemption with no forfeiture HH&L Class B ordinary shares |
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Name and Address of Beneficial
Owner(1)(2) |
| |
No. of
HH&L Ordinary Shares |
| |
% of
HH&L Class A Ordinary Shares |
| |
% of
HH&L Class B Ordinary Shares(3) |
| |
% of
HH&L Ordinary Shares |
| |
No. of
Shares of DiaCarta Common Stock |
| |
%
|
| |
No. of
Shares of DiaCarta Common Stock |
| |
%
|
| |
No. of
Shares of DiaCarta Common Stock |
| |
%
|
| ||||||||||||||||||||||||||||||
5% Holders | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||
HH&L Investment Co.(4)
|
| | | | 10,262,000 | | | | | | — | | | | | | 99.15% | | | | | | 19.83% | | | | | | 10,262,000 | | | | | | 10.50% | | | | | | 10262000 | | | | | | 13.32% | | | | | | 10,262,000 | | | | | | 17.08% | | |
D.E. Shaw Valence Portfolios,
L.L.C., D.E. Shaw & Co., L.L.C., D.E. Shaw & Co. and David E. Shaw(6) |
| | | | 2,398,579 | | | | | | 5.80% | | | | | | — | | | | | | 4.63% | | | | | | 2,398,579 | | | | | | 2.46% | | | | | | 2,398,579 | | | | | | 3.11% | | | | | | 2,398,579 | | | | | | 3.99% | | |
Marshall Wace LLP(7)
|
| | | | 2,311,227 | | | | | | 5.58% | | | | | | — | | | | | | 4.47% | | | | | | 2,311,227 | | | | | | 2.36% | | | | | | 2,311,227 | | | | | | 3.00% | | | | | | 2,311,227 | | | | | | 3.85% | | |
Aristeia Capital, L.L.C.(8)
|
| | | | 2,300,000 | | | | | | 5.56% | | | | | | — | | | | | | 4.44% | | | | | | 2,300,000 | | | | | | 2.35% | | | | | | 2,300,000 | | | | | | 2.99% | | | | | | 2,300,000 | | | | | | 3.83% | | |
RP Investments Advisors LP, RP Select Opportunities Master Fund Ltd., RP Debt Opportunities Fund Ltd., RP Alternative Global Bond Fund and RP SPAC
Fund(9) |
| | | | 2,100,000 | | | | | | 5.07% | | | | | | — | | | | | | 4.05% | | | | | | 2,100,000 | | | | | | 2.15% | | | | | | 2,100,000 | | | | | | 2.73% | | | | | | 2,100,000 | | | | | | 3.50% | | |
Veritas Bioscience(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 6,788,217 | | | | | | 6.94% | | | | | | 6,788,217 | | | | | | 8.81% | | | | | | 6,788,217 | | | | | | 11.30% | | |
Healthcare Industry (Cayman) Co.,
Limited(2) |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,016,984 | | | | | | 3.09% | | | | | | 3,016,984 | | | | | | 3.92% | | | | | | 3,016,984 | | | | | | 5.02% | | |
Jiankun Zhang(10)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 15,280,805 | | | | | | 15.63% | | | | | | 15,280,805 | | | | | | 19.83% | | | | | | 15,280,805 | | | | | | 25.44% | | |
Girton Water Ltd (UK)(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,734,448 | | | | | | 7.91% | | | | | | 7,734,448 | | | | | | 10.04% | | | | | | 7,734,448 | | | | | | 12.88% | | |
Directors and Executive Officers Pre-Business Combination
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||
Fenglei Fang(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Kenneth W. Hitchner(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Richard Qi Li(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Yingjie (Christina) Zhong
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Huanan Yang
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Derek Nelsen Sulger(5)
|
| | | | 22,000 | | | | | | — | | | | | | * | | | | | | * | | | | | | 22,000 | | | | | | * | | | | | | 22,000 | | | | | | * | | | | | | 22,000 | | | | | | * | | |
Qingjun Jin
|
| | | | 22,000 | | | | | | — | | | | | | * | | | | | | * | | | | | | 22,000 | | | | | | * | | | | | | 22,000 | | | | | | * | | | | | | 22,000 | | | | | | * | | |
Jingwu Zhang Zang
|
| | | | 22,000 | | | | | | — | | | | | | * | | | | | | * | | | | | | 22,000 | | | | | | * | | | | | | 22,000 | | | | | | * | | | | | | 22,000 | | | | | | * | | |
Frederick Si Hang Ma
|
| | | | 22,000 | | | | | | — | | | | | | * | | | | | | * | | | | | | 22,000 | | | | | | * | | | | | | 22,000 | | | | | | * | | | | | | 22,000 | | | | | | * | | |
All officers and directors as a
group |
| | | | 88,000 | | | | | | — | | | | | | * | | | | | | * | | | | | | 88,000 | | | | | | * | | | | | | 88,000 | | | | | | * | | | | | | 88,000 | | | | | | * | | |
Directors and Executive Officers Post-Business Combination
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||
Aiguo Zhang(10)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 15,280,805 | | | | | | 15.63% | | | | | | 15,280,805 | | | | | | 19.83% | | | | | | 15,280,805 | | | | | | 25.44% | | |
Dennis Gao(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Michael Sha(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Paul Okunieff(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,146,306 | | | | | | 3.22% | | | | | | 3,146,306 | | | | | | 4.08% | | | | | | 3,146,306 | | | | | | 5.24% | | |
Ram Vairavan(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Effie Ho(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 893,696 | | | | | | * | | | | | | 893,696 | | | | | | 1.16% | | | | | | 893,696 | | | | | | 1.49% | | |
Jack Kaye(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 17,996 | | | | | | * | | | | | | 17,996 | | | | | | * | | | | | | 17,996 | | | | | | * | | |
Kenneth W. Hitchner(2)(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
All officers and directors as a
group |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 19,338,803 | | | | | | 19.78% | | | | | | 19,338,803 | | | | | | 25.10% | | | | | | 19,338,803 | | | | | | 32.19% | | |
| | |
Delaware
|
| |
Cayman Islands
|
|
Stockholder/Shareholder Approval of Business Combinations
|
| |
Mergers generally require approval of a majority of all outstanding shares.
Mergers in which less than 20% of the acquirer’s stock is issued generally do not require acquirer stockholder approval.
Mergers in which one corporation owns 90% or more of a second corporation may be completed without the vote of the second corporation’s board of directors or stockholders.
|
| |
Mergers require a special resolution, and any other authorization as may be specified in the relevant articles of association. Parties holding certain security interests in the constituent companies must also consent.
All mergers (other than parent/subsidiary mergers) require shareholder approval — there is no exception for smaller mergers.
Where a bidder has acquired 90% or more of the shares in a Cayman Islands company, it can compel the acquisition of the shares of the remaining shareholders and thereby become the sole shareholder.
A Cayman Islands company may also be acquired through a “scheme of arrangement” sanctioned by a Cayman Islands court and approved by 50%+1 in number and 75% in value of shareholders in attendance and voting at a shareholders’ meeting.
|
|
Stockholder/Shareholder Votes for Routine Matters
|
| | Generally, approval of routine corporate matters that are put to a stockholder vote require the affirmative vote of the majority | | | Under the Cayman Islands Companies Act and Cayman Constitutional Documents, routine corporate matters may be | |
| | |
Delaware
|
| |
Cayman Islands
|
|
| | | of shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter. | | |
approved by an ordinary resolution (being a resolution passed by a simple majority of the shareholders as being entitled to do so).
vote at a meeting in person or by proxy where the articles of association permit proxies or by unanimous written resolution).
|
|
Appraisal Rights
|
| | Generally, a stockholder of a publicly traded corporation does not have appraisal rights in connection with a merger. | | | Minority shareholders that dissent from a merger are entitled to be paid the fair market value of their shares, which if necessary may ultimately be determined by the court. | |
Inspection of Books and Records
|
| | Any stockholder may inspect the corporation’s books and records for a proper purpose during the usual hours for business. | | | Shareholders generally do not have any rights to inspect or obtain copies of the register of shareholders or other corporate records of a company. | |
Stockholder/Shareholder Lawsuits
|
| | A stockholder may bring a derivative suit subject to procedural requirements (including adopting Delaware as the exclusive forum as per Advisory Organizational Documents Proposal 5D). | | | In the Cayman Islands, the decision to institute proceedings on behalf of a company is generally taken by the company’s board of directors. A shareholder may be entitled to bring a derivative action on behalf of the company, but only in certain limited circumstances. | |
Fiduciary Duties of Directors
|
| | Directors must exercise a duty of care and duty of loyalty and good faith to the company and its stockholders. | | |
A director owes fiduciary duties to a company, including to exercise loyalty, honesty and good faith to the company as a whole.
In addition to fiduciary duties, directors of HH&L owe a duty of care, diligence and skill.
Such duties are owed to the company but may be owed direct to creditors or shareholders in certain limited circumstances.
|
|
Indemnification of Directors and Officers
|
| | A corporation is generally permitted to indemnify its directors and officers acting in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation. | | | A Cayman Islands company generally may indemnify its directors or officers except with regard to fraud or willful default. | |
| | |
Delaware
|
| |
Cayman Islands
|
|
Limited Liability of Directors
|
| | Permits limiting or eliminating the monetary liability of a director to a corporation or its stockholders, except with regard to breaches of duty of loyalty, intentional misconduct, unlawful repurchases or dividends, or improper personal benefit. | | | Liability of directors may be unlimited, except with regard to their own fraud or willful default. | |
| | |
Page
|
| |||
HH& L Acquisition Co.
|
| | | | | | |
Audited Financial Statements of HH&L Acquisition Co.: | | | | | | | |
| | | | F-2 | | | |
| | | | F-3 | | | |
| | | | F-4 | | | |
| | | | F-5 | | | |
| | | | F-6 | | | |
| | | | F-7 | | | |
Financial Statements (Unaudited) | | | | | | | |
| | | | F-22 | | | |
| | | | F-23 | | | |
| | | | F-24 | | | |
| | | | F-25 | | | |
| | | | F-26 | | | |
DiaCarta, Ltd.
|
| | | | | | |
Consolidated Financial Statements | | | | | | | |
| | | | F-44 | | | |
| | | | F-45 | | | |
| | | | F-47 | | | |
| | | | F-48 | | | |
| | | | F-49 | | | |
| | | | F-51 – F-77 | | | |
Unaudited Condensed Consolidated Financial Statements | | | | | | | |
| | | | F-79 | | | |
| | | | F-81 | | | |
| | | | F-82 | | | |
| | | | F-83 | | | |
| | | | F-85 – F-99 | | |
| | |
December 31,
|
| |||||||||
| | |
2021
|
| |
2020
|
| ||||||
Assets | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | |
Cash
|
| | | $ | 399,935 | | | | | $ | 6,410 | | |
Prepaid expenses
|
| | | | 326,283 | | | | | | 17,000 | | |
Total current assets
|
| | | | 726,218 | | | | | | 23,410 | | |
Deferred offering costs
|
| | | | — | | | | | | 439,752 | | |
Investments held in Trust Account
|
| | | | 414,023,891 | | | | | | — | | |
Total Assets
|
| | | $ | 414,750,109 | | | | | $ | 463,162 | | |
Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Equity (Deficit):
|
| | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 176,063 | | | | | $ | 116,374 | | |
Accrued expenses
|
| | | | 988,825 | | | | | | 194,520 | | |
Accounts payable – related party
|
| | | | 165,000 | | | | | | — | | |
Note payable – related party
|
| | | | — | | | | | | 139,949 | | |
Total current liabilities
|
| | | | 1,329,888 | | | | | | 450,843 | | |
Derivative warrant liabilities
|
| | | | 17,348,800 | | | | | | — | | |
Deferred underwriting commissions
|
| | | | 14,490,000 | | | | | | — | | |
Total liabilities
|
| | | | 33,168,688 | | | | | | 450,843 | | |
Commitments and Contingencies | | | | | | | | | | | | | |
Class A ordinary shares subject to possible redemption, $0.0001 par value; 41,400,000 and 0 shares at $10.00 per share redemption value as of December 31, 2021 and 2020, respectively
|
| | | | 414,000,000 | | | | | | — | | |
Shareholders’ Equity (Deficit): | | | | | | | | | | | | | |
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding
|
| | | | — | | | | | | — | | |
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; no non-redeemable shares issued and outstanding at December 31, 2021 and 2020
|
| | | | — | | | | | | — | | |
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 10,350,000 shares issued and outstanding at December 31, 2021 and 2020(1)
|
| | | | 1,035 | | | | | | 1,035 | | |
Additional paid-in capital
|
| | | | — | | | | | | 23,965 | | |
Accumulated deficit
|
| | | | (32,419,614) | | | | | | (12,681) | | |
Total shareholders’ equity (deficit)
|
| | | | (32,418,579) | | | | | | 12,319 | | |
Total Liabilities, Class A Ordinary shares Subject to Possible Redemption and Shareholders’ Equity (Deficit)
|
| | | $ | 414,750,109 | | | | | $ | 463,162 | | |
| | |
For the Year Ended
December 31, 2021 |
| |
For the Period from
September 4, 2020 (inception) through December 31, 2020 |
| ||||||
General and administrative expenses
|
| | | $ | 1,640,492 | | | | | $ | 12,681 | | |
Administrative expenses – related party
|
| | | | 165,000 | | | | | | — | | |
Loss from operations
|
| | | | (1,805,492) | | | | | | (12,681) | | |
Other (expense) income: | | | | | | | | | | | | | |
Change in fair value of derivative warrant liabilities
|
| | | | 3,923,200 | | | | | | — | | |
Financing cost – derivative warrant liabilities
|
| | | | (821,170) | | | | | | — | | |
Income from investments held in Trust Account
|
| | | | 23,891 | | | | | | — | | |
Net income (loss)
|
| | | | 1,320,429 | | | | | | (12,681) | | |
Basic and diluted weighted average shares outstanding of Class A ordinary shares
|
| | | | 36,976,438 | | | | | | — | | |
Basic and diluted net income (loss) per ordinary share, Class A
|
| | | $ | 0.03 | | | | | $ | — | | |
Basic weighted average shares outstanding of Class B ordinary shares
|
| | | | 10,205,753 | | | | | | 9,000,000 | | |
Diluted weighted average shares outstanding of Class B ordinary shares
|
| | | | 10,350,000 | | | | | | 9,000,000 | | |
Basic and diluted net income (loss) per ordinary share, Class B
|
| | | $ | 0.03 | | | | | $ | (0.00) | | |
| | |
For the Year Ended December 31, 2021
|
| |||||||||||||||||||||||||||||||||||||||
| | |
Ordinary Shares
|
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Shareholders’ Equity (Deficit) |
| ||||||||||||||||||||||||||||||
| | |
Class A
|
| |
Class B
|
| ||||||||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
Balance – December 31, 2020
|
| | | | — | | | | | $ | — | | | | | | 10,350,000 | | | | | $ | 1,035 | | | | | $ | 23,965 | | | | | $ | (12,681) | | | | | $ | 12,319 | | |
Excess cash received over the fair value of the private warrants
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,084,000 | | | | | | — | | | | | | 3,084,000 | | |
Accretion to Class A ordinary share redemption amount
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (3,107,965) | | | | | | (33,727,362) | | | | | | (36,835,327) | | |
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,320,429 | | | | | | 1,320,429 | | |
Balance – December 31, 2021
|
| | | | — | | | | | $ | — | | | | | | 10,350,000 | | | | | $ | 1,035 | | | | | $ | — | | | | | $ | (32,419,614) | | | | | $ | (32,418,579) | | |
| | |
For the Period from September 4, 2020 (inception) through December 31, 2020
|
| |||||||||||||||||||||||||||||||||||||||
| | |
Ordinary Shares
|
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Shareholders’ Equity |
| ||||||||||||||||||||||||||||||
| | |
Class A
|
| |
Class B
|
| ||||||||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
Balance – September 4, 2020 (inception)
|
| | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Issuance of Class B ordinary share to Sponsor(1)
|
| | | | — | | | | | | — | | | | | | 10,350,000 | | | | | | 1,035 | | | | | | 23,965 | | | | | | — | | | | | | 25,000 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (12,681) | | | | | | (12,681) | | |
Balance – December 31, 2020
|
| | | | — | | | | | $ | — | | | | | | 10,350,000 | | | | | $ | 1,035 | | | | | $ | 23,965 | | | | | $ | (12,681) | | | | | $ | 12,319 | | |
| | |
For the Year Ended
December 31, 2021 |
| |
For the Period from
September 4, 2020 (inception) through December 31, 2020 |
| ||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | |
Net income (loss)
|
| | | $ | 1,320,429 | | | | | $ | (12,681) | | |
Adjustments to reconcile net income (loss) to net cash used in operating activities:
|
| | | | | | | | | | | | |
General and Administrative expenses paid by Sponsor
|
| | | | — | | | | | | 12,681 | | |
Income from investments held in Trust Account
|
| | | | (23,891) | | | | | | — | | |
Change in fair value of derivative warrant liabilities
|
| | | | (3,923,200) | | | | | | — | | |
Financing cost – derivative warrant liabilities
|
| | | | 821,170 | | | | | | — | | |
Changes in operating assets and liabilities: | | | | | | | | | | | | | |
Prepaid expenses
|
| | | | (309,283) | | | | | | — | | |
Accounts payable
|
| | | | 59,689 | | | | | | — | | |
Accounts payable – related party
|
| | | | 165,000 | | | | | | — | | |
Accrued expenses
|
| | | | 903,825 | | | | | | — | | |
Net cash used in operating activities
|
| | | | (986,261) | | | | | | — | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | |
Cash deposited in Trust Account
|
| | | | (414,000,000) | | | | | | — | | |
Net cash used in investing activities
|
| | | | (414,000,000) | | | | | | — | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | |
Proceeds from note payable to related party
|
| | | | — | | | | | | 6,410 | | |
Proceeds received from initial public offering, gross
|
| | | | 414,000,000 | | | | | | — | | |
Proceeds from private placement
|
| | | | 10,280,000 | | | | | | — | | |
Repayment of notes payable to related party
|
| | | | (185,116) | | | | | | — | | |
Offering costs paid
|
| | | | (8,715,098) | | | | | | — | | |
Net cash provided by financing activities
|
| | | | 415,379,786 | | | | | | 6,410 | | |
Net change in cash
|
| | | | 393,525 | | | | | | 6,410 | | |
Cash – beginning of the period
|
| | |
|
6,410
|
| | | |
|
—
|
| |
Cash – end of the period
|
| | | $ | 399,935 | | | | | $ | 6,410 | | |
Supplemental disclosure of noncash investing and financing activities:
|
| | | | | | | | | | | | |
Offering costs included in accrued expenses
|
| | | $ | 85,000 | | | | | $ | 194,520 | | |
Offering costs included in accounts payable
|
| | | $ | — | | | | | $ | 116,374 | | |
Offering costs included in notes payable
|
| | | $ | 45,167 | | | | | $ | 120,858 | | |
Deferred underwriting commissions in connection with the initial
public offering |
| | | $ | 14,490,000 | | | | | $ | — | | |
Prepaid expenses paid by Sponsor in exchange for issuance of Class B ordinary shares
|
| | | $ | — | | | | | $ | 17,000 | | |
Offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares
|
| | | $ | — | | | | | $ | 8,000 | | |
| | |
For the Year Ended
December 31, 2021 |
| |
For the Period from
September 4, 2020 (inception) through December 31, 2020 |
| ||||||||||||||||||
| | |
Class A
|
| |
Class B
|
| |
Class A
|
| |
Class B
|
| ||||||||||||
Basic and diluted net income (loss) per ordinary share: | | | | | | | | | | | | | | | | | | | | | | | | | |
Numerator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Allocation of net income (loss) – basic
|
| | | $ | 1,034,813 | | | | | $ | 285,616 | | | | | $ | — | | | | | $ | (12,681) | | |
Allocation of net income (loss) – diluted
|
| | | $ | 1,031,659 | | | | | $ | 288,770 | | | | | $ | — | | | | | $ | (12,681) | | |
Denominator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic weighted average ordinary shares outstanding
|
| | | | 36,976,438 | | | | | | 10,205,753 | | | | | | — | | | | | | 9,000,000 | | |
Diluted weighted average ordinary shares outstanding
|
| | | | 36,976,438 | | | | | | 10,350,000 | | | | | | — | | | | | | 9,000,000 | | |
Basic net income (loss) per ordinary share
|
| | | $ | 0.03 | | | | | $ | 0.03 | | | | | $ | — | | | | | $ | (0.00) | | |
Diluted net income (loss) per ordinary share
|
| | | $ | 0.03 | | | | | $ | 0.03 | | | | | $ | — | | | | | $ | (0.00) | | |
|
Gross Proceeds
|
| | | $ | 414,000,000 | | |
| Less: | | | | | | | |
|
Fair value of Public Warrants at issuance
|
| | | | (14,076,000) | | |
|
Class A ordinary share issuance costs
|
| | | | (22,759,327) | | |
| Plus: | | | | | | | |
|
Accretion of carrying value to redemption value
|
| | | | 36,835,327 | | |
|
Class A ordinary share subject to possible redemption
|
| | | $ | 414,000,000 | | |
| | |
Fair Value Measured as of December 31, 2021
|
| |||||||||||||||
Description
|
| |
Quoted Prices in
Active Markets (Level 1) |
| |
Significant Other
Observable Inputs (Level 2) |
| |
Significant Other
Unobservable Inputs (Level 3) |
| |||||||||
Assets: | | | | | | | | | | | | | | | | | | | |
Investments held in Trust Account
|
| | | $ | 414,023,891 | | | | | $ | — | | | | | $ | — | | |
Liabilities: | | | | | | | | | | | | | | | | | | | |
Derivative warrant liabilities – Public warrant
|
| | | $ | 11,592,000 | | | | | $ | — | | | | | $ | — | | |
Derivative warrant liabilities – Private warrant
|
| | | $ | — | | | | | $ | — | | | | | $ | 5,756,800 | | |
|
Derivative warrant liabilities at January 1, 2021
|
| | | $ | — | | |
|
Issuance of Public and Private Warrants – Level 3
|
| | | | 21,272,000 | | |
|
Transfer of Public Warrants to Level 1 Measurement
|
| | | | (14,076,000) | | |
|
Change in fair value of derivative warrant liabilities – Level 3
|
| | | | (1,439,200) | | |
|
Derivative warrant liabilities at December 31, 2021 – Level 3
|
| | | $ | 5,756,800 | | |
| | |
As of
December 31, 2021 |
| |||
Volatility
|
| | | | 10.00% | | |
Stock price
|
| | | $ | 9.73 | | |
Expected life of the options to convert
|
| | | | 5.61 | | |
Risk-free rate
|
| | | | 1.31% | | |
Dividend yield
|
| | | | 0% | | |
Probability of business combination
|
| | | | 90% | | |
| | |
Page
|
| |||
PART I. FINANCIAL INFORMATION | | | | | | | |
| | | | F-22 | | | |
| | | | F-22 | | | |
| | | | F-23 | | | |
| | | | F-24 | | | |
| | | | F-25 | | | |
| | | | F-26 | | |
| | |
September 30, 2022
|
| |
December 31, 2021
|
| ||||||
| | |
(Unaudited)
|
| | | | | | | |||
Assets | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | |
Cash
|
| | | $ | 293,137 | | | | | $ | 399,935 | | |
Prepaid expenses
|
| | | | 137,676 | | | | | | 326,283 | | |
Total current assets
|
| | | | 430,813 | | | | | | 726,218 | | |
Investments held in Trust Account
|
| | | | 416,517,794 | | | | | | 414,023,891 | | |
Total Assets
|
| | | $ | 416,948,607 | | | | | $ | 414,750,109 | | |
Liabilities, Class A Ordinary Shares Subject to Possible Redemption and
Shareholders’ Deficit: |
| | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 135,297 | | | | | $ | 176,063 | | |
Accounts payable – related party
|
| | | | 300,000 | | | | | | 165,000 | | |
Accrued expenses
|
| | | | 2,733,810 | | | | | | 988,825 | | |
Working capital loan – related party
|
| | | | 500,000 | | | | | | — | | |
Total current liabilities
|
| | | | 3,669,107 | | | | | | 1,329,888 | | |
Derivative warrant liabilities
|
| | | | 929,400 | | | | | | 17,348,800 | | |
Deferred underwriting commissions
|
| | | | 14,490,000 | | | | | | 14,490,000 | | |
Total liabilities
|
| | | | 19,088,507 | | | | | | 33,168,688 | | |
Commitments and Contingencies | | | | | | | | | | | | | |
Class A ordinary shares subject to possible redemption, $0.0001 par value; 41,400,000 shares at approximately $10.06 and $10.00 per share as of September 30, 2022 and December 31, 2021,
respectively |
| | | | 416,417,794 | | | | | | 414,000,000 | | |
Shareholders’ Deficit: | | | | | | | | | | | | | |
Preference shares, $0.0001 par value; 5,000,000 shares authorized; none
issued or outstanding |
| | | | — | | | | | | — | | |
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; no non-redeemable shares issued or outstanding
|
| | | | — | | | | | | — | | |
Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 10,350,000 shares issued and outstanding at September 30, 2022 and December 31, 2021
|
| | | | 1,035 | | | | | | 1,035 | | |
Additional paid-in capital
|
| | | | — | | | | | | — | | |
Accumulated deficit
|
| | | | (18,558,729) | | | | | | (32,419,614) | | |
Total shareholders’ deficit
|
| | | | (18,557,694) | | | | | | (32,418,579) | | |
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit
|
| | | $ | 416,948,607 | | | | | $ | 414,750,109 | | |
| | |
For the Three Months Ended September 30,
|
| |
For the Nine Months Ended September 30,
|
| ||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
2022
|
| |
2021
|
| ||||||||||||
General and administrative expenses
|
| | | $ | 1,395,693 | | | | | $ | 216,699 | | | | | $ | 2,499,624 | | | | | $ | 686,986 | | |
Administrative expenses – related
party |
| | | | 45,000 | | | | | | 45,000 | | | | | | 135,000 | | | | | | 120,000 | | |
Loss from operations
|
| | | | (1,440,693) | | | | | | (261,699) | | | | | | (2,634,624) | | | | | | (806,986) | | |
Other income (expenses): | | | | | | | | | | | | | | | | | | | | | | | | | |
Change in fair value of derivative
warrant liabilities |
| | | | 4,337,200 | | | | | | 12,804,600 | | | | | | 16,419,400 | | | | | | 7,021,200 | | |
Financing cost – derivative warrant liabilities
|
| | | | — | | | | | | — | | | | | | — | | | | | | (821,170) | | |
Income from investments held in Trust Account
|
| | | | 1,872,086 | | | | | | 6,360 | | | | | | 2,493,903 | | | | | | 16,040 | | |
Total other income
(expenses) |
| | | | 6,209,286 | | | | | | 12,810,960 | | | | | | 18,913,303 | | | | | | 6,216,070 | | |
Net income
|
| | | $ | 4,768,593 | | | | | $ | 12,549,261 | | | | | $ | 16,278,679 | | | | | $ | 5,409,084 | | |
Basic and diluted weighted average
shares outstanding of Class A ordinary shares |
| | | | 41,400,000 | | | | | | 41,400,000 | | | | | | 41,400,000 | | | | | | 35,485,714 | | |
Basic and diluted net income per ordinary share, Class A
|
| | | $ | 0.09 | | | | | $ | 0.24 | | | | | $ | 0.31 | | | | | $ | 0.12 | | |
Basic and diluted weighted average
shares outstanding of Class B ordinary shares |
| | | | 10,350,000 | | | | | | 10,350,000 | | | | | | 10,350,000 | | | | | | 10,157,143 | | |
Basic and diluted net income per ordinary share, Class B
|
| | | $ | 0.09 | | | | | $ | 0.24 | | | | | $ | 0.31 | | | | | $ | 0.12 | | |
| | |
For the Three and Nine Months Ended September 30, 2022
|
| |||||||||||||||||||||||||||
| | |
Class B Ordinary Shares
|
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Shareholders’ Deficit |
| ||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||
Balance – December 31, 2021
|
| | | | 10,350,000 | | | | | $ | 1,035 | | | | | $ | — | | | | | $ | (32,419,614) | | | | | $ | (32,418,579) | | |
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | 9,222,780 | | | | | | 9,222,780 | | |
Balance – March 31, 2022 (unaudited)
|
| | | | 10,350,000 | | | | | | 1,035 | | | | | | — | | | | | | (23,196,834) | | | | | | (23,195,799) | | |
Accretion of Class A ordinary shares subject to possible redemption
amount |
| | | | — | | | | | | — | | | | | | — | | | | | | (545,708) | | | | | | (545,708) | | |
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,287,306 | | | | | | 2,287,306 | | |
Balance – June 30, 2022 (unaudited)
|
| | | | 10,350,000 | | | | | | 1,035 | | | | | | — | | | | | | (21,455,236) | | | | | | (21,454,201) | | |
Accretion of Class A ordinary shares subject to possible redemption
amount |
| | | | — | | | | | | — | | | | | | — | | | | | | (1,872,086) | | | | | | (1,872,086) | | |
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | 4,768,593 | | | | | | 4,768,593 | | |
Balance – September 30, 2022
(unaudited) |
| | | | 10,350,000 | | | | | $ | 1,035 | | | | | $ | — | | | | | $ | (18,558,729) | | | | | $ | (18,557,694) | | |
| | |
For the Three and Nine Months Ended September 30, 2021
|
| |||||||||||||||||||||||||||
| | |
Class B Ordinary Shares
|
| |
Additional
Paid-In Capital |
| |
Accumulated
Deficit |
| |
Total
Shareholders’ Equity (Deficit) |
| ||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||
Balance – December 31, 2020
|
| | | | 10,350,000 | | | | | $ | 1,035 | | | | | $ | 23,965 | | | | | $ | (12,681) | | | | | $ | 12,319 | | |
Excess cash received over the fair value
of the private warrants |
| | | | — | | | | | | — | | | | | | 3,084,000 | | | | | | — | | | | | | 3,084,000 | | |
Accretion to Class A ordinary share redemption amount
|
| | | | — | | | | | | — | | | | | | (3,107,965) | | | | | | (33,727,363) | | | | | | (36,835,328) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | (4,461,996) | | | | | | (4,461,996) | | |
Balance – March 31, 2021
(unaudited) |
| | | | 10,350,000 | | | | | | 1,035 | | | | | | — | | | | | | (38,202,040) | | | | | | (38,201,005) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | (2,678,181) | | | | | | (2,678,181) | | |
Balance – June 30, 2021 (unaudited)
|
| | | | 10,350,000 | | | | | | 1,035 | | | | | | — | | | | | | (40,880,221) | | | | | | (40,879,186) | | |
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | 12,549,261 | | | | | | 12,549,261 | | |
Balance – September 30, 2021 (unaudited)
|
| | | | 10,350,000 | | | | | | 1,035 | | | | | | — | | | | | | (28,330,960) | | | | | | (28,329,925) | | |
| | |
For the Nine Months Ended September 30,
|
| |||||||||
| | |
2022
|
| |
2021
|
| ||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | |
Net income
|
| | | $ | 16,278,679 | | | | | $ | 5,409,084 | | |
Adjustments to reconcile net income to net cash used in operating activities:
|
| | | | | | | | | | | | |
Income from investments held in Trust Account
|
| | | | (2,493,903) | | | | | | (16,040) | | |
Change in fair value of derivative warrant liabilities
|
| | | | (16,419,400) | | | | | | (7,021,200) | | |
Financing cost – derivative warrant liabilities
|
| | | | — | | | | | | 821,170 | | |
Changes in operating assets and liabilities: | | | | | | | | | | | | | |
Prepaid expenses
|
| | | | 188,607 | | | | | | (379,375) | | |
Accounts payable
|
| | | | (40,766) | | | | | | 889 | | |
Accounts payable – related party
|
| | | | 135,000 | | | | | | 120,000 | | |
Accrued expenses
|
| | | | 1,744,985 | | | | | | 154,332 | | |
Net cash used in operating activities
|
| | | | (606,798) | | | | | | (911,140) | | |
Cash Flows from Investing Activities: | | | | | | | | | | | | | |
Cash deposited in Trust Account
|
| | | | — | | | | | | (414,000,000) | | |
Cash used in investing activities
|
| | | | — | | | | | | (414,000,000) | | |
Cash Flows from Financing Activities: | | | | | | | | | | | | | |
Proceeds from notes payable to related parties
|
| | | | 500,000 | | | | | | — | | |
Proceeds received from initial public offering, gross
|
| | | | — | | | | | | 414,000,000 | | |
Proceeds from private placement
|
| | | | — | | | | | | 10,280,000 | | |
Repayment of notes payable to related party
|
| | | | — | | | | | | (185,116) | | |
Offering costs paid
|
| | | | — | | | | | | (8,715,098) | | |
Net cash provided by financing activities
|
| | | | 500,000 | | | | | | 415,379,786 | | |
Net change in cash
|
| | | | (106,798) | | | | | | 468,646 | | |
Cash – beginning of the period
|
| | |
|
399,935
|
| | | |
|
6,410
|
| |
Cash – end of the period
|
| | | $ | 293,137 | | | | | $ | 475,056 | | |
Supplemental disclosure of noncash investing and financing activities: | | | | | | | | | | | | | |
Offering costs included in accrued expenses
|
| | | $ | — | | | | | $ | 85,000 | | |
Offering costs included in notes payable
|
| | | $ | — | | | | | $ | 45,167 | | |
Deferred underwriting commissions in connection with the initial public offering
|
| | | $ | — | | | | | $ | 14,490,000 | | |
| | |
For The Three Months Ended September 30,
|
| |||||||||||||||||||||
| | |
2022
|
| |
2021
|
| ||||||||||||||||||
| | |
Class A
|
| |
Class B
|
| |
Class A
|
| |
Class B
|
| ||||||||||||
Basic and diluted net income per ordinary share: | | | | | | | | | | | | | | | | | | | | | | | | | |
Numerator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Allocation of net income
|
| | | $ | 3,814,874 | | | | | $ | 953,719 | | | | | $ | 10,039,409 | | | | | $ | 2,509,852 | | |
Denominator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted weighted average ordinary shares outstanding
|
| | | | 41,400,000 | | | | | | 10,350,000 | | | | | | 41,400,000 | | | | | | 10,350,000 | | |
Basic and diluted net income per ordinary share
|
| | | $ | 0.09 | | | | | $ | 0.09 | | | | | $ | 0.24 | | | | | $ | 0.24 | | |
| | |
For The Nine Months Ended September 30,
|
| |||||||||||||||||||||
| | |
2022
|
| |
2021
|
| ||||||||||||||||||
| | |
Class A
|
| |
Class B
|
| |
Class A
|
| |
Class B
|
| ||||||||||||
Basic and diluted net income per ordinary share: | | | | | | | | | | | | | | | | | | | | | | | | | |
Numerator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Allocation of net income
|
| | | $ | 13,022,943 | | | | | $ | 3,255,736 | | | | | $ | 4,205,373 | | | | | $ | 1,203,712 | | |
Denominator: | | | | | | | | | | | | | | | | | | | | | | | | | |
Basic and diluted weighted average ordinary shares outstanding
|
| | | | 41,400,000 | | | | | | 10,350,000 | | | | | | 35,485,714 | | | | | | 10,157,143 | | |
Basic and diluted net income per ordinary share
|
| | | $ | 0.31 | | | | | $ | 0.31 | | | | | $ | 0.12 | | | | | $ | 0.12 | | |
|
Gross proceeds
|
| | | $ | 414,000,000 | | |
| Less: | | | | | | | |
|
Fair value of Public Warrants at issuance
|
| | | | (14,076,000) | | |
|
Offering costs allocated to Class A ordinary shares subject to possible redemption
|
| | | | (22,759,327) | | |
| Plus: | | | | | | | |
|
Accretion of carrying value to redemption value
|
| | | | 36,835,327 | | |
|
Class A ordinary shares subject to possible redemption – December 31, 2021
|
| | | | 414,000,000 | | |
|
Increase in redemption value of Class A ordinary shares subject to
redemption |
| | | | 545,708 | | |
|
Class A ordinary shares subject to possible redemption – June 30, 2022
|
| | | $ | 414,545,708 | | |
|
Increase in redemption value of Class A ordinary shares subject to
redemption |
| | | | 1,872,086 | | |
|
Class A ordinary shares subject to possible redemption – September 30, 2022
|
| | | $ | 416,417,794 | | |
Description
|
| |
Quoted Prices in
Active Markets (Level 1) |
| |
Significant Other
Observable Inputs (Level 2) |
| |
Significant Other
Unobservable Inputs (Level 3) |
| |||||||||
Assets: | | | | | | | | | | | | | | | | | | | |
Investments held in Trust Account
|
| | | $ | 416,517,794 | | | | | $ | — | | | | | $ | — | | |
Liabilities: | | | | | | | | | | | | | | | | | | | |
Derivative warrant liabilities – Public Warrant
|
| | | $ | 621,000 | | | | | $ | — | | | | | $ | — | | |
Derivative warrant liabilities – Private Placement
Warrant |
| | | $ | — | | | | | $ | — | | | | | $ | 308,400 | | |
Description
|
| |
Quoted Prices in
Active Markets (Level 1) |
| |
Significant Other
Observable Inputs (Level 2) |
| |
Significant Other
Unobservable Inputs (Level 3) |
| |||||||||
Assets: | | | | | | | | | | | | | | | | | | | |
Investments held in Trust Account
|
| | | $ | 414,023,891 | | | | | $ | — | | | | | $ | — | | |
Liabilities: | | | | | | | | | | | | | | | | | | | |
Derivative warrant liabilities – Public Warrant
|
| | | $ | 11,592,000 | | | | | $ | — | | | | | $ | — | | |
Derivative warrant liabilities – Private Placement
Warrant |
| | | $ | — | | | | | $ | — | | | | | $ | 5,756,800 | | |
|
Derivative warrant liabilities at December 31, 2021 – Level 3
|
| | | $ | 5,756,800 | | |
|
Change in fair value of derivative warrant liabilities – Level 3
|
| | | | (3,186,800) | | |
|
Derivative warrant liabilities at June 30, 2022 – Level 3
|
| | | $ | 2,570,000 | | |
|
Change in fair value of derivative warrant liabilities – Level 3
|
| | | | (822,400) | | |
|
Derivative warrant liabilities at June 30, 2022 – Level 3
|
| | | $ | 1,747,600 | | |
|
Change in fair value of derivative warrant liabilities – Level 3
|
| | | | (1,439,200) | | |
|
Derivative warrant liabilities at September 30, 2022 – Level 3
|
| | | $ | 308,400 | | |
|
Derivative warrant liabilities at January 1, 2021
|
| | | $ | — | | |
|
Issuance of Public and Private Warrants – Level 3
|
| | | | 21,272,000 | | |
|
Transfer of Public Warrants to Level 1 Measurement
|
| | | | (14,076,000) | | |
|
Change in fair value of derivative warrant liabilities – Level 3
|
| | | | 1,028,000 | | |
|
Derivative warrant liabilities at March 31, 2021 – Level 3
|
| | | $ | 8,224,000 | | |
|
Change in fair value of derivative warrant liabilities – Level 3
|
| | | | 822,400 | | |
|
Derivative warrant liabilities at June 30, 2021 – Level 3
|
| | | $ | 9,046,400 | | |
|
Change in fair value of derivative warrant liabilities – Level 3
|
| | | | (4,317,600) | | |
|
Derivative warrant liabilities at September 30, 2021 – Level 3
|
| | | $ | 4,728,800 | | |
| | |
September 30, 2022
|
| |
December 31, 2021
|
| ||||||
Exercise price
|
| | | $ | 11.50 | | | | | $ | 11.50 | | |
Volatility
|
| | | | 5.50% | | | | | | 10.00% | | |
Stock price
|
| | | $ | 9.94 | | | | | $ | 9.73 | | |
Expected life of the options to convert
|
| | | | 5.36 | | | | | | 5.61 | | |
Risk-free rate
|
| | | | 3.96% | | | | | | 1.31% | | |
Implied Success
|
| | | | 3.40% | | | | | | N/A | | |
| Consolidated Financial Statements | | | | | | | |
| | | | | F-44 | | | |
| | | | | F-45 | | | |
| | | | | F-47 | | | |
| | | | | F-48 | | | |
| | | | | F-49 | | | |
| | | | | F-51 – F-77 | | |
| | |
As of
December 31, 2021 |
| |
As of
December 31, 2020 |
| ||||||
Assets | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 22,644,119 | | | | | $ | 9,595,487 | | |
Accounts receivable, net
|
| | | | 6,219,331 | | | | | | 3,898,667 | | |
Advances to suppliers
|
| | | | 147,642 | | | | | | 199,777 | | |
Inventories
|
| | | | 1,198,578 | | | | | | 1,069,717 | | |
Loan to a related party, current
|
| | | | 223,219 | | | | | | — | | |
Prepayments and other current assets, net
|
| | | | 737,244 | | | | | | 706,112 | | |
Total current assets
|
| | | | 31,170,133 | | | | | | 15,469,760 | | |
Non-current assets: | | | | | | | | | | | | | |
Property, plant and equipment, net
|
| | | | 2,491,126 | | | | | | 2,722,681 | | |
Intangible assets, net
|
| | | | 10,529 | | | | | | 12,261 | | |
Operating lease right-of-use assets
|
| | | | 8,997,758 | | | | | | 2,838,822 | | |
Finance lease assets
|
| | | | 53,024 | | | | | | 101,807 | | |
Deferred tax assets, net
|
| | | | 2,389,240 | | | | | | 4,893,834 | | |
Loan to a related party
|
| | | | 1,114,145 | | | | | | 757,992 | | |
Other assets
|
| | | | 42,125 | | | | | | 417,727 | | |
Total non-current assets
|
| | | | 15,097,947 | | | | | | 11,745,124 | | |
Total assets
|
| | | $ | 46,268,080 | | | | | $ | 27,214,884 | | |
Liabilities And Shareholders’ Equity | | | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 5,339,633 | | | | | $ | 3,994,768 | | |
Accrued liabilities and other payables
|
| | | | 543,866 | | | | | | 483,168 | | |
Loan from a shareholder, current
|
| | | | — | | | | | | 1,188,428 | | |
Operating lease liabilities, current
|
| | | | 1,164,841 | | | | | | 678,114 | | |
Finance lease liabilities, current
|
| | | | 14,803 | | | | | | 52,363 | | |
Income taxes payable
|
| | | | 1,218,562 | | | | | | 15,038 | | |
Advances from customers
|
| | | | 145,475 | | | | | | 1,442,124 | | |
Convertible bond payable, current
|
| | | | 2,152,617 | | | | | | — | | |
Total current liabilities
|
| | | $ | 10,579,797 | | | | | $ | 7,854,003 | | |
| | |
As of
December 31, 2021 |
| |
As of
December 31, 2020 |
| ||||||
Liabilities And Shareholders’ Equity | | | | | | | | | | | | | |
Non-current liabilities: | | | | | | | | | | | | | |
Long-term borrowing
|
| | | $ | — | | | | | $ | 463,238 | | |
Convertible bond payable
|
| | | | — | | | | | | 1,433,485 | | |
Operating lease liabilities, non-current
|
| | | | 9,098,024 | | | | | | 3,101,691 | | |
Finance lease liabilities, non-current
|
| | | | — | | | | | | 21,099 | | |
Total non-current liabilities
|
| | | | 9,098,024 | | | | | | 5,019,513 | | |
Total liabilities
|
| | | | 19,677,821 | | | | | | 12,873,516 | | |
Shareholders’ equity: | | | | | | | | | | | | | |
Ordinary shares (USD0.001 par value, 28,469,472 shares authorized; 28,469,472 shares issued and outstanding at December 31, 2021 and 2020, respectively)
|
| | | | 28,469 | | | | | | 28,469 | | |
Series A non-redeemable preferred shares (USD0.001 par value,
7,543,948 shares authorized; 7,543,948 shares issued and outstanding with liquidation preference of $8,000,000, at December 31, 2021 and 2020, respectively) |
| | | | 7,544 | | | | | | 7,544 | | |
Series B non-redeemable preferred shares (USD0.001 par value, 13,646,217 shares authorized; 12,183,137 shares issued and Outstanding with liquidation preference of $36,336,249, at December 31, 2021 and 2020, respectively)
|
| | | | 12,183 | | | | | | 12,183 | | |
Additional paid-in capital
|
| | | | 54,019,642 | | | | | | 53,871,540 | | |
Accumulated deficit
|
| | | | (25,751,210) | | | | | | (37,561,368) | | |
Accumulated other comprehensive loss
|
| | | | (1,726,369) | | | | | | (2,017,000) | | |
Total Shareholder’s Equity
|
| | | | 26,590,259 | | | | | | 14,341,368 | | |
Total liabilities and shareholders’ equity
|
| | | $ | 46,268,080 | | | | | $ | 27,214,884 | | |
|
| | |
For the year ended
December 31, 2021 |
| |
For the year ended
December 31, 2020 |
| ||||||
Revenues
|
| | |
$
|
41,501,568
|
| | | |
$
|
14,445,079
|
| |
Cost of revenues
|
| | | | 13,426,619 | | | | | | 8,629,681 | | |
Gross profit
|
| | | | 28,074,949 | | | | | | 5,815,398 | | |
Operating expenses: | | | | | | | | | | | | | |
Selling and marketing expenses
|
| | | | 1,820,038 | | | | | | 1,182,573 | | |
General and administrative expenses
|
| | | | 3,824,924 | | | | | | 2,566,119 | | |
Research and development expenses
|
| | | | 5,179,766 | | | | | | 4,841,818 | | |
Total operating expenses
|
| | | | 10,824,728 | | | | | | 8,590,510 | | |
Income (loss) from operations
|
| | | | 17,250,221 | | | | | | (2,775,112) | | |
Interest expense, net
|
| | | | (701,630) | | | | | | (336,222) | | |
Investment (loss) / income
|
| | | | (10,370) | | | | | | 88,764 | | |
Other income, net
|
| | | | 600,405 | | | | | | 848,784 | | |
Income (loss) before income taxes provision
|
| | | | 17,138,626 | | | | | | (2,173,786) | | |
Income tax expenses
|
| | | | (5,328,468) | | | | | | (44,195) | | |
Net Income (loss)
|
| | | | 11,810,158 | | | | | | (2,217,981) | | |
Less: net loss attributable to non-controlling interest
|
| | | | — | | | | | | 34,463 | | |
Net Income (loss) Attributable To DiaCarta, Ltd shareholders
|
| | | $ | 11,810,158 | | | | | $ | (2,183,518) | | |
Other comprehensive income: | | | | | | | | | | | | | |
Foreign currency translation adjustment
|
| | | $ | 290,631 | | | | | $ | 472,844 | | |
Total comprehensive income (loss)
|
| | | | 12,100,789 | | | | | | (1,745,137) | | |
Less: comprehensive loss attributable to non-controlling interest
|
| | | | — | | | | | | 34,463 | | |
Comprehensive Income (Loss) Attributable To DiaCarta, Ltd Shareholders
|
| | | $ | 12,100,789 | | | | | $ | (1,710,674) | | |
Net income (loss) per ordinary share attributable to DiaCarta, Ltd shareholders
|
| | | | | | | | | | | | |
Basic
|
| | | $ | 0.41 | | | | | $ | (0.08) | | |
Diluted
|
| | | | 0.25 | | | | | | (0.08) | | |
Weighted average number of ordinary shares outstanding | | | | | | | | | | | | | |
Basic
|
| | | | 28,469,472 | | | | | | 28,469,472 | | |
Diluted
|
| | | | 49,370,099 | | | | | | 28,469,472 | | |
| | |
Attributable to DiaCarta, Ltd’s shareholders
|
| | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
Ordinary shares
|
| |
Series A
Preferential shares |
| |
Series B
Preferential shares |
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Accumulated
Other Comprehensive Loss |
| |
Non-
controlling interest |
| |
Total
equity |
| ||||||||||||||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2020
|
| | | | 28,469,472 | | | | | $ | 28,469 | | | | | | 7,543,978 | | | | | $ | 7,544 | | | | | | 13,646,217 | | | | | $ | 13,646 | | | | | $ | 57,431,051 | | | | | $ | (35,377,850) | | | | | $ | (2,489,844) | | | | | $ | 452,379 | | | | | $ | 20,065,395 | | |
Repurchase of Series B Preferential shares
|
| | | | — | | | | | | — | | | | | | — | | | | | | (1,463,080) | | | | | | (1,463) | | | | | | (4,362,288) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (4,363,751) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (2,183,518) | | | | | | — | | | | | | (34,463) | | | | | | (2,217,981) | | |
Buy-out of a non-controlling
interests |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (283,651) | | | | | | — | | | | | | — | | | | | | (417,916) | | | | | | (701,567) | | |
Warrants issued in connection with
convertible bond note |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,086,428 | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,086,428 | | |
Foreign currency translation adjustments
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 472,844 | | | | | | — | | | | | | 472,844 | | |
Balance as of December 31, 2020
|
| | | | 28,469,472 | | | | | $ | 28,469 | | | | | | 7,543,978 | | | | | $ | 7,544 | | | | | | 12,183,137 | | | | | $ | 12,183 | | | | | $ | 53,871,540 | | | | | $ | (37,561,368) | | | | | $ | (2,017,000) | | | | | $ | — | | | | | $ | 14,341,368 | | |
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 11,810,158 | | | | | | — | | | | | | — | | | | | | 11,810,158 | | |
Tax effect resulted from amortization of
the discount of convertible bond note |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 148,102 | | | | | | — | | | | | | — | | | | | | — | | | | | | 148,102 | | |
Foreign currency translation adjustment
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 290,631 | | | | | | — | | | | | | 290,631 | | |
Balance as of December 31, 2021
|
| | | | 28,469,472 | | | | | $ | 28,469 | | | | | | 7,543,978 | | | | | $ | 7,544 | | | | | | 12,183,137 | | | | | $ | 12,183 | | | | | $ | 54,019,642 | | | | | $ | (25,751,210) | | | | | $ | (1,726,369) | | | | | $ | — | | | | | $ | 26,590,259 | | |
| | |
For the year ended
December 31, 2021 |
| |
For the year ended
December 31, 2020 |
| ||||||
Cash Flows From Operating Activities: | | | | | | | | | | | | | |
Net income (loss)
|
| | | $ | 11,810,158 | | | | | $ | (2,217,981) | | |
Adjustments to reconcile net income (loss) to net cash provided by
(used in) operating activities: |
| | | | | | | | | | | | |
Depreciation and amortization expenses
|
| | | | 497,184 | | | | | | 428,176 | | |
Amortization of operating lease right-of-use assets
|
| | | | 1,004,855 | | | | | | 602,968 | | |
Amortization of finance lease assets
|
| | | | 48,783 | | | | | | 52,891 | | |
Interest on lease liabilities
|
| | | | 282,518 | | | | | | 198,036 | | |
Interest and amortization of convertible bond
|
| | | | 719,132 | | | | | | 280,493 | | |
Interest on shareholder loan
|
| | | | 14,287 | | | | | | 85,724 | | |
Allowance for doubtful accounts
|
| | | | (89,537) | | | | | | 215,179 | | |
Deferred tax expenses
|
| | | | 2,652,696 | | | | | | 29,157 | | |
Gain on short-term investment
|
| | | | — | | | | | | (94,228) | | |
Gain on forgiveness of PPP loan
|
| | | | (463,238) | | | | | | — | | |
Changes in assets and liabilities: | | | | | | | | | | | | | |
Accounts receivable, net
|
| | | | (2,320,664) | | | | | | (2,080,386) | | |
Inventory
|
| | | | (128,861) | | | | | | (909,235) | | |
Advances to suppliers
|
| | | | 52,135 | | | | | | 15,911 | | |
Prepayments and other current assets, net
|
| | | | (31,132) | | | | | | 8,356 | | |
Other assets
|
| | | | 375,602 | | | | | | (54,610) | | |
Accounts payable
|
| | | | 1,527,766 | | | | | | 2,173,828 | | |
Income taxes payable
|
| | | | 1,203,524 | | | | | | 14,238 | | |
Advances from customers
|
| | | | (1,296,649) | | | | | | 1,315,385 | | |
Operating lease liabilities
|
| | | | (958,749) | | | | | | (667,031) | | |
Accrued liabilities and other payables
|
| | | | 60,698 | | | | | | 133,607 | | |
Net Cash Provided by (Used In) Operating Activities
|
| | | | 14,960,508 | | | | | | (469,522) | | |
Cash Flows From Investing Activities: | | | | | | | | | | | | | |
Purchases of property, plant and equipment
|
| | | | (207,302) | | | | | | (352,282) | | |
Buy-out of non-controlling interest
|
| | | | — | | | | | | (701,567) | | |
Cash paid for short-term investments
|
| | | | — | | | | | | (5,503,896) | | |
Loan to a related party
|
| | | | (713,088) | | | | | | (362,099) | | |
Loan recovered from a third party
|
| | | | 89,537 | | | | | | — | | |
Proceeds from maturity of short-term investments
|
| | | | — | | | | | | 9,849,077 | | |
Net Cash (Used In) Provided By Investing Activities
|
| | | $ | (830,853) | | | | | $ | 2,929,233 | | |
| | |
For the year ended
December 31, 2021 |
| |
For the year ended
December 31, 2020 |
| ||||||
Cash Flows From Financing Activities: | | | | | | | | | | | | | |
Principal prepayments of finance leases
|
| | | $ | (63,159) | | | | | $ | (77,300) | | |
Repayment of loan from a shareholder
|
| | | | (1,202,715) | | | | | | — | | |
Proceeds from long-term loan
|
| | | | — | | | | | | 463,238 | | |
Proceeds from issuance of convertible bonds
|
| | | | — | | | | | | 2,500,000 | | |
Net Cash (Used In) Provided By Financing Activities
|
| | | | (1,265,874) | | | | | | 2,885,938 | | |
Effect of exchange rate changes on cash and cash equivalents
|
| | | | 184,851 | | | | | | 263,870 | | |
Net Increase in Cash and Cash Equivalents
|
| | | | 13,048,632 | | | | | | 5,609,519 | | |
Cash and cash equivalents at beginning of year
|
| | | | 9,595,487 | | | | | | 3,985,968 | | |
Cash and cash equivalents at end of year
|
| | | $ | 22,644,119 | | | | |
|
9,595,487
|
| |
Supplemental Cash Flow Information: | | | | | | | | | | | | | |
Cash paid for income taxes
|
| | | | 1,472,248 | | | | | | 800 | | |
Interest paid
|
| | | | 347,815 | | | | | | — | | |
Non-cash activities: | | | | | | | | | | | | | |
Right of use assets obtained in exchange for operating lease obligations
|
| | | | 866,625 | | | | | | 592,570 | | |
Finance lease assets obtained in exchange for finance lease obligations
|
| | | | 40,761 | | | | | | 62,469 | | |
Repurchase of Series B Preferential shares with amount due from a shareholder
|
| | | | — | | | | | | 4,309,230 | | |
Settlement of accounts payable with loan receivable from a related party
|
| | | | 182,901 | | | | | | 143,671 | | |
Entity
|
| |
Place of
incorporation |
| |
Date of
incorporation |
| |
Percentage
of ownership by the Company |
| |
Principal activities
|
|
Subsidiaries: | | | | | | | | | | | | | |
DIACARTA, INC.
(“DiaCarta USA”) |
| |
California, USA
|
| | April 21, 2011 | | |
100%
|
| | R&D, manufacture, clinical laboratory improvement amendments (CLIA) lab | |
DIACARTA, LIMITED
(“DiaCarta HK”) |
| | Hong Kong | | | July 8, 2015 | | |
100%
|
| | Holding Company | |
DIACARTA, EU, LIMITED (Ireland)
(“DiaCarta Ireland”) |
| | Ireland | | |
August 24, 2017
|
| |
100%
|
| | CE In vitro diagnostic (IVD) submissions | |
Shanghai Diji Biotech Co., Ltd.
(“Shanghai Diji” or “the WFOE”) |
| | The People’s Republic of China (“PRC” or “China”) | | | December 7, 2015 | | |
100%
|
| | Holding Company | |
Shanghai Xiete Biotech Co., Ltd.
(“Shanghai Xiete”) |
| | PRC | | | December 4, 2015 | | |
100%
|
| | Clinical services | |
Nanjing Diji Biotech Co., Ltd.
(“Nanjing Diji”) |
| | PRC | | | June 16, 2016 | | |
100%
|
| | R&D, Clinical trial activities, sales and marketing | |
Nanjing Dizhun Biotech Co., Ltd.
(“Nanjing Dizhun”) |
| | PRC | | | April 23, 2018 | | |
100%
|
| | Manufacture, import and export | |
Nanjing Diyang Biotech Co., Ltd. (“Nanjing Diyang Biotech”) | | | PRC | | | April 28, 2017 | | |
100%
|
| | R&D, clinical trial activities, sales and marketing | |
|
Leasehold improvements
|
| |
Over the shorter of the lease term or expected useful lives
|
|
|
Equipment
|
| | 2 – 5 years | |
|
Patented technology
|
| | 15.5 years | |
| | |
For the
year ended December 31, 2021 |
| |
For the
year ended December 31, 2020 |
| ||||||
Revenue | | | | | | | | | | | | | |
Service revenue
|
| | | $ | 15,277,629 | | | | | $ | 8,614,839 | | |
Product sales – kits and reagents
|
| | | | 26,223,939 | | | | | | 5,830,240 | | |
| | | | $ | 41,501,568 | | | | | $ | 14,445,079 | | |
| | |
As of
December 31, 2021 |
| |
As of
December 31, 2020 |
| ||||||
Accounts receivable
|
| | | $ | 6,452,444 | | | | | $ | 4,126,351 | | |
Less: allowance for doubtful accounts
|
| | | | (233,113) | | | | | | (227,684) | | |
Total Accounts receivable, net
|
| | | $ | 6,219,331 | | | | | $ | 3,898,667 | | |
| | |
2021
|
| |
2020
|
| ||||||
Balance as of January 1
|
| | | $ | 227,684 | | | | | $ | — | | |
Addition
|
| | | | — | | | | | | 215,179 | | |
Foreign currency translation difference
|
| | | | 5,429 | | | | | | 12,505 | | |
Balance as of December 31
|
| | | $ | 233,113 | | | | | $ | 227,684 | | |
| | |
As of
December 31, 2021 |
| |
As of
December 31, 2020 |
| ||||||
Test kits and reagents
|
| | | $ | 1,198,578 | | | | | $ | 1,069,717 | | |
| | |
As of
December 31, 2021 |
| |
As of
December 31, 2020 |
| ||||||
Equipment
|
| | | $ | 1,402,305 | | | | | $ | 1,272,298 | | |
Leasehold improvement
|
| | | | 2,408,877 | | | | | | 2,315,172 | | |
| | | | | 3,811,182 | | | | | | 3,587,470 | | |
Less: Accumulated depreciation
|
| | | | (1,320,056) | | | | | | (864,789) | | |
Total Property, plant and equipment, net
|
| | | $ | 2,491,126 | | | | | $ | 2,722,681 | | |
| | |
As of
December 31, 2021 |
| |
As of
December 31, 2020 |
| ||||||
Patented technology
|
| | | $ | 12,554 | | | | | $ | 12,261 | | |
| | | | | 12,554 | | | | | | 12,261 | | |
Less: Accumulated amortization
|
| | | | (2,025) | | | | | | — | | |
Total Intangible assets, net
|
| | | $ | 10,529 | | | | | $ | 12,261 | | |
Year
|
| | | | | | |
2022
|
| | | $ | 800 | | |
2023
|
| | | | 800 | | |
2024
|
| | | | 800 | | |
2025
|
| | | | 800 | | |
2026
|
| | | | 800 | | |
Thereafter
|
| | | | 6,529 | | |
Total
|
| | | $ | 10,529 | | |
| | |
As of
December 31, 2021 |
| |
As of
December 31, 2020 |
| ||||||
Other receivables(i)
|
| | | $ | 1,395,790 | | | | | $ | 1,451,709 | | |
VAT recoverable
|
| | | | 244,755 | | | | | | 406,467 | | |
Prepayments
|
| | | | 248,854 | | | | | | 63,187 | | |
Office rental deposits and other deposits
|
| | | | 243,635 | | | | | | 236,458 | | |
| | | | | 2,133,034 | | | | | | 2,157,821 | | |
Less: Provision against other receivables
|
| | | | (1,395,790) | | | | | | (1,451,709) | | |
Total prepayments and other current assets, net
|
| | | $ | 737,244 | | | | | $ | 706,112 | | |
| | |
2021
|
| |
2020
|
| ||||||
Balance as of January 1
|
| | | $ | 1,451,709 | | | | | $ | 1,360,625 | | |
Collections
|
| | | | (89,537) | | | | | | — | | |
Foreign currency translation difference
|
| | | | 33,618 | | | | | | 91,084 | | |
Balance as of December 31
|
| | | $ | 1,395,790 | | | | | $ | 1,451,709 | | |
| | |
As of
December 31, 2021 |
| |
As of
December 31, 2020 |
| ||||||
Salaries payable
|
| | | $ | 408,470 | | | | | $ | 318,325 | | |
Other taxes payable
|
| | | | 88,305 | | | | | | 11,964 | | |
Other payables
|
| | | | 47,091 | | | | | | 152,879 | | |
Total accrued liabilities and other payables
|
| | | $ | 543,866 | | | | | $ | 483,168 | | |
As of December 31, 2020
|
| |
Balance
|
| |
Maturity
Date |
| |
Effective Interest Rate
|
| |
Collateral/Guarantee
|
| ||||||||||||
CA Payroll protection loan(i)
|
| | | $ | 463,238 | | | | | | 2022 | | | | | | 1% | | | | | | None | | |
Type
|
| |
Number
|
| |
Issuance date
|
| |
Exercisability
|
| |
Expire date
|
| |
Termination
date |
| |
Exercise
price |
| |
Coverage
Amount |
|
Warrants
|
| |
335,289
|
| |
July 7, 2020
|
| |
Immediately
|
| |
5 years
|
| |
July 7, 2025
|
| |
$2.9825
|
| |
$1,000,000
|
|
|
Fair value of convertible note
|
| | | $ | 1,152,992 | | |
|
Fair value of warrant
|
| | | $ | 1,347,008 | | |
|
Terms of warrants
|
| |
60 months
|
| |||
|
Exercise price
|
| | | | 2.9825 | | |
|
Risk free rate of interest
|
| | | | 0.16% | | |
|
Dividend yield
|
| | | | 0.00% | | |
|
Annualized volatility of underlying stock
|
| | | | 0.512 | | |
| | |
For the
year ended December 31, 2021 |
| |
For the
year ended December 31, 2020 |
| ||||||
United States
|
| | | $ | 20,834,444 | | | | | $ | 1,336,421 | | |
Foreign countries
|
| | | | (3,695,818) | | | | | | (3,510,207) | | |
| | | | $ | 17,138,626 | | | | | $ | (2,173,786) | | |
| | |
For the
year ended December 31, 2021 |
| |
For the
year ended December 31, 2020 |
| ||||||
Current tax: | | | | | | | | | | | | | |
Federal tax
|
| | | $ | 1,652,766 | | | | | $ | — | | |
State tax
|
| | | | 1,023,006 | | | | | | 15,038 | | |
Foreign tax
|
| | | | — | | | | | | — | | |
Total current tax
|
| | | | 2,675,772 | | | | | | 15,038 | | |
Deferred tax: | | | | | | | | | | | | | |
Federal tax
|
| | | $ | 2,372,364 | | | | | $ | 187,641 | | |
State tax
|
| | | | 280,332 | | | | | | (158,484) | | |
Foreign tax
|
| | | | — | | | | | | — | | |
Total deferred tax
|
| | | | 2,652,696 | | | | | | 29,157 | | |
Total provision for income taxes
|
| | | $ | 5,328,468 | | | | | $ | 44,195 | | |
| | |
For the year
ended December 31, 2021 |
| |
For the year
ended December 31, 2020 |
| ||||||
Income (Loss) before income taxes
|
| | | $ | 17,138,626 | | | | | $ | (2,173,786) | | |
Computed income tax expense at the statutory tax rate
|
| | | | 3,599,111 | | | | | | (456,495) | | |
Additional deduction for R&D credit
|
| | | | (263,602) | | | | | | (250,361) | | |
Tax effect of state tax
|
| | | | 982,093 | | | | | | (133,652) | | |
Tax effect of non-deductible items
|
| | | | 377,656 | | | | | | 287,925 | | |
Tax effect of different tax rates in the US and the PRC
|
| | | | (120,612) | | | | | | (113,672) | | |
Change in valuation allowance
|
| | | | 581,264 | | | | | | 710,450 | | |
Other
|
| | | | 172,558 | | | | | | — | | |
Income tax expense
|
| | | $ | 5,328,468 | | | | | $ | 44,195 | | |
| | |
For the year
ended December 31, 2021 |
| |
For the year
ended December 31, 2020 |
| ||||||
Deferred tax assets: | | | | | | | | | | | | | |
Net operating loss carryforwards
|
| | | $ | 4,728,556 | | | | | $ | 6,745,528 | | |
Federal and state credits
|
| | | | 298,187 | | | | | | 943,956 | | |
Lease liabilities
|
| | | | 2,683,463 | | | | | | 958,832 | | |
Deferred revenue
|
| | | | 402,376 | | | | | | 198,086 | | |
Accrued expenses
|
| | | | 326,534 | | | | | | 160,999 | | |
Allowance for bad debts
|
| | | | 97,843 | | | | | | 95,558 | | |
Other
|
| | | | 236,647 | | | | | | 11,083 | | |
| | | | | 8,773,606 | | | | | | 9,114,042 | | |
Valuation allowance
|
| | | | (3,836,101) | | | | | | (3,171,850) | | |
Total deferred tax asset, net
|
| | | $ | 4,937,505 | | | | | $ | 5,942,192 | | |
| | |
For the year
ended December 31, 2021 |
| |
For the year
ended December 31, 2020 |
| ||||||
Deferred tax liabilities: | | | | | | | | | | | | | |
Lease assets
|
| | | | (2,370,501) | | | | | | (730,950) | | |
Depreciation
|
| | | | (65,286) | | | | | | (56,828) | | |
Convertible bond
|
| | | | (112,478) | | | | | | (260,580) | | |
Total deferred tax liabilities
|
| | | $ | (2,548,265) | | | | | $ | (1,048,358) | | |
Total net deferred tax assets
|
| | | $ | 2,389,240 | | | | | $ | 4,893,834 | | |
|
| | |
2021
|
| |
2020
|
| ||||||
Balance as of January 1
|
| | | $ | 3,171,850 | | | | | $ | 2,268,269 | | |
Allowance made during the year
|
| | | | 581,264 | | | | | | 710,450 | | |
Effect of exchange differences
|
| | | | 82,987 | | | | | | 193,131 | | |
Balance as of December 31
|
| | | $ | 3,836,101 | | | | | $ | 3,171,850 | | |
| | |
2021
|
| |
2020
|
| ||||||
Balance as of January 1
|
| | | $ | 500,434 | | | | | $ | 387,287 | | |
Gross increases – tax positions in prior period
|
| | | | 22,905 | | | | | | — | | |
Gross increase – tax positions in current period
|
| | | | 91,012 | | | | | | 113,147 | | |
Balance as of December 31
|
| | | $ | 614,351 | | | | | $ | 500,434 | | |
| | |
For the Years Ended
December 31, |
| |||||||||
| | |
2021
|
| |
2020
|
| ||||||
Net income (loss) attributable to DiaCarta Ltd shareholders
|
| | | $ | 11,810,158 | | | | | $ | (2,183,518) | | |
| | | | | — | | | | | | | | |
Weighted average number of ordinary share outstanding
|
| | | | | | | | | | | | |
Basic
|
| | | | 28,469,472 | | | | | | 28,469,472 | | |
Diluted
|
| | | $ | 49,370,099 | | | | | | 28,469,472 | | |
Earnings per share
|
| | | | | | | | | | | | |
Basic
|
| | | | 0.41 | | | | | | (0.08) | | |
Diluted
|
| | | $ | 0.25 | | | | | $ | (0.08) | | |
| | | | | |
As of December 31, 2019
|
| |
Redeemed
|
| |
As of December 31, 2020
|
| |||||||||||||||||||||||||||||||||
Series
|
| |
Issuance date
|
| |
Shares
|
| |
Price
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| |||||||||||||||||||||
A(1) | | |
December 16, 2014
|
| | | | 7,543,978 | | | | | $ | 1.0604 | | | | | $ | 8,000,000 | | | | | | — | | | | | $ | — | | | | | | 7,543,978 | | | | | $ | 8,000,000 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
B1(2) | | |
October 26, 2018
|
| | | | 10,058,637 | | | | | $ | 2.9825 | | | | | $ | 30,000,000 | | | | | | (1,463,080) | | | | | $ | (4,363,751) | | | | | | 8,595,557 | | | | | $ | 25,636,249 | | |
B2(3) | | |
October 26, 2018
|
| | | | 3,352,878 | | | | | | 2.9825 | | | | | | 10,000,000 | | | | | | — | | | | | | — | | | | | | 3,352,878 | | | | | | 10,000,000 | | |
B3(4) | | |
October 26, 2018
|
| | | | 234,702 | | | | | | 2.9825 | | | | | | 700,000 | | | | | | — | | | | | | — | | | | | | 234,702 | | | | | | 700,000 | | |
B in total
|
| | | | | | | 13,646,217 | | | | | | | | | | | $ | 40,700,000 | | | | | | (1,463,080) | | | | | $ | (4,363,751) | | | | | | 12,183,137 | | | | | $ | 36,336,249 | | |
| | |
For the years ended
December 31, |
| |||||||||
| | |
2021
|
| |
2020
|
| ||||||
Operating lease expense
|
| | | $ | 1,282,873 | | | | | $ | 670,117 | | |
Finance lease expense
|
| | | | 53,284 | | | | | | 63,641 | | |
Short-term lease expense
|
| | | | 49,848 | | | | | | 42,514 | | |
| | | | $ | 1,386,005 | | | | | $ | 776,272 | | |
| | |
Amounts
|
| |||
2021
|
| | | $ | 1,522,194 | | |
2022
|
| | | | 1,733,753 | | |
2023
|
| | | | 1,805,393 | | |
2024
|
| | | | 1,840,913 | | |
2025
|
| | | | 1,876,433 | | |
Thereafter
|
| | | | 2,904,732 | | |
Total lease payment
|
| | | | 11,683,418 | | |
Less: imputed interest
|
| | | | (1,420,553) | | |
Present value of operating lease liabilities
|
| | | $ | 10,262,865 | | |
| | |
Amounts
|
| |||
2021
|
| | | $ | 15,266 | | |
Total lease payment
|
| | | | 15,266 | | |
Less: imputed interest
|
| | | | (463) | | |
Present value of finance lease liabilities
|
| | | $ | 14,803 | | |
| | |
As of December 31,
2021 |
| |
As of December 31,
2020 |
| ||||||
Weighted average remaining lease term (in years): | | | | | | | | | | | | | |
Operating leases
|
| | | | 6.5 | | | | | | 6.5 | | |
Finance leases
|
| | | | 0.4 | | | | | | 1.1 | | |
Weighted average discount rate: | | | | | | | | | | | | | |
Operating leases
|
| | | | 3.8% | | | | | | 4.9% | | |
Finance leases
|
| | | | 12.5% | | | | | | 10.7% | | |
Year Ended December 31, 2021
|
| |
United States
|
| |
China
|
| |
Total
|
| |||||||||
Revenue
|
| | | $ | 33,387,082 | | | | | $ | 8,114,486 | | | | | $ | 41,501,568 | | |
Depreciation
|
| | | | 56,472 | | | | | | 438,712 | | | | | | 495,184 | | |
Income (loss) from operations
|
| | | | 18,956,077 | | | | | | (1,705,856) | | | | | | 17,250,221 | | |
Net income (loss)
|
| | | | 13,391,173 | | | | | | (1,581,015) | | | | | | 11,810,158 | | |
Year Ended December 31, 2020
|
| |
United States
|
| |
China
|
| |
Total
|
| |||||||||
Revenue
|
| | | $ | 7,392,396 | | | | | $ | 7,052,683 | | | | | $ | 14,445,079 | | |
Depreciation
|
| | | | 68,121 | | | | | | 360,055 | | | | | | 428,176 | | |
Loss from operations
|
| | | | (1,052,058) | | | | | | (1,723,054) | | | | | | (2,775,112) | | |
Net loss
|
| | | | (758,813) | | | | | | (1,459,168) | | | | | | (2,217,981) | | |
Year Ended December 31, 2021
|
| |
United States
|
| |
China
|
| |
Total
|
| |||||||||
Current assets
|
| | | $ | 23,207,544 | | | | | $ | 7,962,589 | | | | | $ | 31,170,133 | | |
Total assets
|
| | | | 32,434,905 | | | | | | 13,833,175 | | | | | | 46,268,080 | | |
Total liability
|
| | | | 11,690,615 | | | | | | 7,987,206 | | | | | | 19,677,821 | | |
Year Ended December 31, 2020
|
| |
United States
|
| |
China
|
| |
Total
|
| |||||||||
Current assets
|
| | | $ | 7,823,382 | | | | | $ | 7,646,378 | | | | | $ | 15,469,760 | | |
Total assets
|
| | | | 13,408,903 | | | | | | 13,805,981 | | | | | | 27,214,884 | | |
Total liability
|
| | | | 6,007,043 | | | | | | 6,866,473 | | | | | | 12,873,516 | | |
No.
|
| |
Name of Related Parties
|
| |
Relationship
|
|
1 | | | Nanjing Dide Biomedical Technology Co. Ltd. (“Nanjing Dide”) | | | A company controlled by a shareholder of the Company, who is also the general manager, Asia Pacific of the Company | |
2 | | | Nanjing Diyang Lab Co., Ltd. (“Nanjing Diyang Lab”) | | | A company controlled by the brother of the CEO of the Company | |
3 | | | Veritas Bioscience (“BVCF”) | | | A shareholder of the Company | |
| | |
For the
year ended December 31, 2021 |
| |
For the
year ended December 31, 2020 |
| ||||||
Service revenue from Nanjing Dide
|
| | | $ | — | | | | | $ | 12,450 | | |
Interest expense paid to BVCF
|
| | | | 14,287 | | | | | | 85,724 | | |
Labor outsourcing expense to Nanjing Diyang Lab
|
| | | | 182,900 | | | | | | 143,671 | | |
| | |
As of
December 31, 2021 |
| |
As of
December 31, 2020 |
| ||||||
Loan to Nanjing Diyang Lab(i)
|
| | |
$
|
1,337,364
|
| | | | $ | 757,992 | | |
| | |
As of
December 31, 2021 |
| |
As of
December 31, 2020 |
| ||||||
Loan from BVCF(iii)
|
| | | $ | — | | | | | $ | 1,188,428 | | |
| | |
As of
December 31, 2021 |
| |
As of
December 31, 2020 |
| ||||||
Assets: | | | | | | | | | | | | | |
Amounts due from subsidiaries
|
| | | $ | 46,886,275 | | | | | $ | 47,623,817 | | |
Total assets
|
| | | | 46,886,275 | | | | | | 47,623,817 | | |
Liabilities: | | | | | | | | | | | | | |
Convertible bond payable
|
| | | | 2,152,617 | | | | | | 1,433,485 | | |
Deficit in subsidiaries
|
| | | | 18,143,399 | | | | | | 31,848,964 | | |
Total liabilities
|
| | | | 20,296,016 | | | | | | 33,282,449 | | |
Shareholders’ equity: | | | | | | | | | | | | | |
Ordinary shares (USD0.001 par value, 28,469,472 shares authorized; 28,469,472 shares issued and outstanding at December 31, 2021 and 2020, respectively)
|
| | | | 28,469 | | | | | | 28,469 | | |
Series A non-redeemable preferred shares (USD0.001 par value, 7,543,948
shares authorized; 7,543,948 shares issued and outstanding with liquidation preference of $8,000,000 at December 31, 2021 and 2020, respectively) |
| | | | 7,544 | | | | | | 7,544 | | |
Series B non-redeemable preferred shares (USD0.001 par value,
13,646,217 shares authorized; 12,183,137 shares issued and outstanding with a liquidation preference of $36,336,249 at December 31, 2021 and 2020, respectively) |
| | | | 12,183 | | | | | | 12,183 | | |
Additional paid-in capital
|
| | | | 54,019,642 | | | | | | 53,871,540 | | |
Accumulated deficit
|
| | | | (25,751,210) | | | | | | (37,561,368) | | |
Accumulated other comprehensive loss
|
| | | | (1,726,369) | | | | | | (2,017,000) | | |
Total Shareholder’s Equity
|
| | | | 26,590,259 | | | | | | 14,341,368 | | |
Total liabilities and shareholders’ equity
|
| | | $ | 46,886,275 | | | | | $ | 47,623,817 | | |
| | |
For the year ended
December 31, 2021 |
| |
For the year ended
December 31, 2020 |
| ||||||
General and administrative expenses
|
| | | $ | (737,542) | | | | | $ | (83,341) | | |
Interest expense
|
| | | | (719,132) | | | | | | (280,493) | | |
Loss before equity in losses of subsidiaries
|
| | | | (1,456,674) | | | | | | (363,834) | | |
Equity in gain (losses) of subsidiaries
|
| | | | 13,266,832 | | | | | | (1,819,684) | | |
Net Income (Loss)
|
| | | | 11,810,158 | | | | | | (2,183,518) | | |
Foreign currency translation adjustment
|
| | | | 290,631 | | | | | | 472,844 | | |
Comprehensive Income (Loss) Attributable To DiaCarta, Ltd
shareholders |
| | | $ | 12,100,789 | | | | | $ | (1,710,674) | | |
| | |
For the year ended
December 31, 2021 |
| |
For the year ended
December 31, 2020 |
| ||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | |
Net Income (Loss)
|
| | | $ | 11,810,158 | | | | | $ | (2,183,518) | | |
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
|
| | | | | | | | | | | | |
Interest and amortization of convertible note
|
| | | | 719,132 | | | | | | 280,493 | | |
Equity (gain) loss of subsidiaries
|
| | | | (13,266,832) | | | | | | 1,819,684 | | |
Changes in assets and liabilities: | | | | | | | | | | | | | |
Amounts due from subsidiaries
|
| | | | 737,542 | | | | | | 83,341 | | |
Net Cash Provided by Operating Activities:
|
| | | | — | | | | | | — | | |
Net increase in cash and cash equivalents
|
| | | | — | | | | | | — | | |
Cash and cash equivalents at beginning of year
|
| | | | — | | | | | | — | | |
Cash and cash equivalents at end of year
|
| | | $ | — | | | | | $ | — | | |
| | | | | F-79 | | | |
| | | | | F-81 | | | |
| | | | | F-82 | | | |
| | | | | F-83 | | | |
| | | | | F-85 — F-99 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
| | |
(unaudited)
|
| | | | | | | |||
Assets | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 4,243,524 | | | | | $ | 22,644,119 | | |
Short-term investments
|
| | | | 10,916,415 | | | | | | — | | |
Accounts receivable, net
|
| | | | 4,071,378 | | | | | | 6,219,331 | | |
Advances to suppliers, net
|
| | | | 20,153 | | | | | | 147,642 | | |
Inventories
|
| | | | 1,451,085 | | | | | | 1,198,578 | | |
Loan to a related party, current
|
| | | | 288,255 | | | | | | 223,219 | | |
Prepayments and other current assets, net
|
| | | | 3,103,812 | | | | | | 737,244 | | |
Total current assets
|
| | | | 24,094,622 | | | | | | 31,170,133 | | |
Non-current assets: | | | | | | | | | | | | | |
Property, plant and equipment, net
|
| | | | 2,535,658 | | | | | | 2,491,126 | | |
Intangible assets, net
|
| | | | 9,070 | | | | | | 10,529 | | |
Operating lease right-of-use assets
|
| | | | 7,432,419 | | | | | | 8,997,758 | | |
Finance lease assets
|
| | | | 22,596 | | | | | | 53,024 | | |
Deferred tax assets, net
|
| | | | 2,389,240 | | | | | | 2,389,240 | | |
Loan to a related party
|
| | | | 1,419,836 | | | | | | 1,114,145 | | |
Other assets
|
| | | | 42,125 | | | | | | 42,125 | | |
Total non-current assets
|
| | | | 13,850,944 | | | | | | 15,097,947 | | |
Total assets
|
| | | $ | 37,945,566 | | | | | $ | 46,268,080 | | |
Liabilities And Shareholders’ Equity | | | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 4,588,796 | | | | | $ | 5,339,633 | | |
Accrued liabilities and other payables
|
| | | | 281,277 | | | | | | 543,866 | | |
Operating lease liabilities, current
|
| | | | 1,224,747 | | | | | | 1,164,841 | | |
Finance lease liabilities, current
|
| | | | — | | | | | | 14,803 | | |
Income taxes payable
|
| | | | — | | | | | | 1,218,562 | | |
Advances from customers
|
| | | | 168,366 | | | | | | 145,475 | | |
Convertible bond payable, current
|
| | | | — | | | | | | 2,152,617 | | |
Total current liabilities
|
| | | $ | 6,263,186 | | | | | $ | 10,579,797 | | |
Liabilities And Shareholders’ Equity | | | | | | | | | | | | | |
Non-current liabilities: | | | | | | | | | | | | | |
Operating lease liabilities, non-current
|
| | | | 7,285,463 | | | | | | 9,098,024 | | |
Total non-current liabilities
|
| | | | 7,285,463 | | | | | | 9,098,024 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
| | |
(unaudited)
|
| | | | | | | |||
Total liabilities
|
| | | | 13,548,649 | | | | | | 19,677,821 | | |
Shareholders’ equity: | | | | | | | | | | | | | |
Ordinary shares (USD0.001 par value, 28,469,472 shares authorized;
28,469,472 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively) |
| | | | 28,469 | | | | | | 28,469 | | |
Series A non-redeemable preferred shares (USD0.001 par value, 7,543,948 shares authorized; 7,543,948 shares issued and outstanding with liquidation preference of $8,000,000 at September 30, 2022 and December 31, 2021, respectively)
|
| | | | 7,544 | | | | | | 7,544 | | |
Series B non-redeemable preferred shares (USD0.001 par value, 13,646,217 shares authorized; 12,183,137 shares issued and outstanding with liquidation preference of $36,336,249 at September 30, 2022 and December 31, 2021, respectively)
|
| | | | 12,183 | | | | | | 12,183 | | |
Additional paid-in capital
|
| | | | 55,385,930 | | | | | | 54,019,642 | | |
Accumulated deficit
|
| | | | (28,688,454) | | | | | | (25,751,210) | | |
Accumulated other comprehensive loss
|
| | | | (2,348,755) | | | | | | (1,726,369) | | |
Total Shareholder’s Equity
|
| | | | 24,396,917 | | | | | | 26,590,259 | | |
Total liabilities and shareholders’ equity
|
| | | $ | 37,945,566 | | | | | $ | 46,268,080 | | |
|
| | |
For the
nine months ended September 30, 2022 |
| |
For the
nine months ended September 30, 2021 |
| ||||||
Revenues
|
| | | $ | 18,332,240 | | | | | $ | 32,236,815 | | |
Cost of revenues
|
| | | | 10,722,756 | | | | | | 10,057,420 | | |
Gross profit
|
| | | | 7,609,484 | | | | | | 22,179,395 | | |
Operating expenses: | | | | | | | | | | | | | |
Selling and marketing expenses
|
| | | | 1,855,147 | | | | | | 1,268,160 | | |
General and administrative expenses
|
| | | | 3,889,301 | | | | | | 2,681,495 | | |
Research and development expenses
|
| | | | 4,868,430 | | | | | | 3,630,832 | | |
Total operating expenses
|
| | | | 10,612,878 | | | | | | 7,580,487 | | |
(Loss) Income from operations
|
| | | | (3,003,394) | | | | | | 14,598,908 | | |
Interest income (expense), net
|
| | | | 123,371 | | | | | | (527,078) | | |
Investment loss
|
| | | | (140,787) | | | | | | (10,370) | | |
Other (expense) income, net
|
| | | | (319,626) | | | | | | 554,597 | | |
(Loss) Income before income taxes
|
| | | | (3,340,436) | | | | | | 14,616,057 | | |
Income tax expenses
|
| | | | 403,192 | | | | | | (4,263,379) | | |
Net (Loss) Income
|
| | | | (2,937,244) | | | | | | 10,352,678 | | |
Other comprehensive (loss) income: | | | | | | | | | | | | | |
Foreign currency translation adjustment
|
| | | $ | (622,386) | | | | | $ | 59,728 | | |
Comprehensive (Loss) Income
|
| | | $ | (3,559,630) | | | | | $ | 10,412,406 | | |
Net (loss) income per ordinary share: | | | | | | | | | | | | | |
Basic
|
| | | $ | (0.10) | | | | | $ | 0.36 | | |
Diluted
|
| | | | (0.10) | | | | | | 0.22 | | |
Weighted average number of ordinary shares outstanding | | | | | | | | | | | | | |
Basic
|
| | | | 28,469,472 | | | | | | 28,469,472 | | |
Diluted
|
| | | | 28,469,472 | | | | | | 49,370,099 | | |
| | |
Ordinary
shares |
| |
Series A
Preferential shares |
| |
Series B
Preferential shares |
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Accumulated
Other Comprehensive Loss |
| |
Total
equity |
| |||||||||||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2021
|
| | | | 28,469,472 | | | | | $ | 28,469 | | | | | | 7,543,978 | | | | | $ | 7,544 | | | | | | 12,183,137 | | | | | $ | 12,183 | | | | | $ | 53,871,540 | | | | | $ | (37,561,368) | | | | | $ | (2,017,000) | | | | | $ | 14,341,368 | | |
Net income
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,352,678 | | | | | | — | | | | | | 10,352,678 | | |
Foreign currency translation adjustments
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | |
|
—
|
| | | | | 59,728 | | | | | | 59,728 | | |
Balance as of September 30,
2021 |
| | | | 28,469,472 | | | | | $ | 28,469 | | | | | | 7,543,978 | | | | | $ | 7,544 | | | | | | 12,183,137 | | | | | $ | 12,183 | | | | | $ | 53,871,540 | | | | | $ | (27,208,690) | | | | | $ | (1,957,272) | | | | | $ | 24,753,774 | | |
Balance as of January 1, 2022
|
| | | | 28,469,472 | | | | | $ | 28,469 | | | | | | 7,543,978 | | | | | $ | 7,544 | | | | | | 12,183,137 | | | | | $ | 12,183 | | | | | $ | 54,019,642 | | | | | $ | (25,751,210) | | | | | $ | (1,726,369) | | | | | $ | 26,590,259 | | |
Share based compensation
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,366,288 | | | | | | | | | | | | | | | | | | 1,366,288 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (2,937,244) | | | | | | — | | | | | | (2,937,244) | | |
Foreign currency translation adjustment
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | — | | | | | | (622,386) | | | | | | (622,386) | | |
Balance as of September 30,
2022 |
| | | | 28,469,472 | | | | | $ | 28,469 | | | | | | 7,543,978 | | | | | $ | 7,544 | | | | | | 12,183,137 | | | | | $ | 12,183 | | | | | $ | 55,385,930 | | | | | $ | (28,688,454) | | | | | $ | (2,348,755) | | | | | $ | 24,396,917 | | |
| | |
For the
nine months ended September 30, 2022 |
| |
For the
nine months ended September 30, 2021 |
| ||||||
Cash Flows From Operating Activities: | | | | | | | | | | | | | |
Net (loss) income
|
| | | $ | (2,937,244) | | | | | $ | 10,352,680 | | |
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
|
| | | | | | | | | | | | |
Depreciation and amortization expenses
|
| | | | 408,892 | | | | | | 395,148 | | |
Allowance for doubtful accounts
|
| | | | 20,366 | | | | | | — | | |
Loss on disposal of property, plant and equipment
|
| | | | 6,657 | | | | | | — | | |
Amortization of operating lease right-of-use assets
|
| | | | 859,820 | | | | | | 713,277 | | |
Amortization of finance lease assets
|
| | | | 30,428 | | | | | | 38,641 | | |
Interest on lease liabilities
|
| | | | 255,703 | | | | | | 187,672 | | |
Interest on shareholder loan
|
| | | | — | | | | | | 14,287 | | |
Interest and amortization of convertible bond
|
| | | | 425,191 | | | | | | 539,246 | | |
Share based compensation expenses
|
| | | | 1,366,288 | | | | | | — | | |
Loss on short-term investments
|
| | | | 140,787 | | | | | | — | | |
Gain on write-off of lease liability
|
| | | | (85,605) | | | | | | — | | |
Gain on forgiveness of PPP loan
|
| | | | — | | | | | | (463,238) | | |
Changes in assets and liabilities: | | | | | | | | | | | | | |
Accounts receivable, net
|
| | | | 2,127,587 | | | | | | (3,642,606) | | |
Inventory
|
| | | | (252,507) | | | | | | (75,043) | | |
Advances to suppliers
|
| | | | 127,489 | | | | | | (13,057) | | |
Prepayments and other current assets, net
|
| | | | (2,366,568) | | | | | | (103,303) | | |
Other assets
|
| | | | — | | | | | | 417,727 | | |
Accounts payable
|
| | | | (535,367) | | | | | | 1,922,741 | | |
Income taxes payable
|
| | | | (1,218,562) | | | | | | 2,844,779 | | |
Advances from customers
|
| | | | 22,891 | | | | | | (1,273,743) | | |
Operating lease liabilities
|
| | | | (1,216,770) | | | | | | (857,915) | | |
Accrued liabilities and other payables
|
| | | | (262,589) | | | | | | 244,026 | | |
Net Cash (Used In) Provided by Operating Activities
|
| | | | (3,083,113) | | | | | | 11,241,319 | | |
Cash Flows From Investing Activities: | | | | | | | | | | | | | |
Purchases of property, plant and equipment
|
| | | | (721,111) | | | | | | (197,330) | | |
Cash paid for short-term investments
|
| | | | (15,855,200) | | | | | | — | | |
Loan to a related party
|
| | | | (764,720) | | | | | | (727,052) | | |
Proceeds from maturity of short-term investments
|
| | | | 4,797,998 | | | | | | — | | |
Net Cash Used In Investing Activities
|
| | | $ | (12,543,033) | | | | | $ | (924,382) | | |
| | |
For the
nine months ended September 30, 2022 |
| |
For the
nine months ended September 30, 2022 |
| ||||||
Cash Flows From Financing Activities: | | | | | | | | | | | | | |
Principal prepayments of finance leases
|
| | | $ | (15,267) | | | | | $ | (75,285) | | |
Repayment of loan from a related party
|
| | | | — | | | | | | (1,202,715) | | |
Repayment of convertible bond
|
| | | | (2,577,808) | | | | | | — | | |
Net Cash Used In Financing Activities
|
| | | | (2,593,075) | | | | | | (1,278,000) | | |
Effect of exchange rate changes on cash and cash equivalents
|
| | | | (181,374) | | | | | | 18,047 | | |
Net (Decrease) Increase in Cash and Cash Equivalents
|
| | | | (18,400,595) | | | | | | 9,056,984 | | |
Cash and cash equivalents at beginning of year
|
| | | | 22,644,119 | | | | | | 9,595,487 | | |
Cash and cash equivalents at end of year
|
| | | $ | 4,243,524 | | | | | $ | 18,652,471 | | |
Supplemental cash flow information: | | | | | | | | | | | | | |
Cash paid for income taxes
|
| | | $ | 1,048,745 | | | | | $ | 1,418,600 | | |
Interest paid
|
| | | | 77,808 | | | | | | 347,815 | | |
Non-cash activities: | | | | | | | | | | | | | |
Right of use assets obtained in exchange for operating lease obligations
|
| | | $ | 1,048,745 | | | | | $ | 702,652 | | |
Finance lease assets obtained in exchange for finance lease
obligations |
| | | | 9,397 | | | | | | 34,885 | | |
Settlement of accounts payable with loan receivable from a related party
|
| | | | 215,470 | | | | | | 136,767 | | |
| | |
For the
Nine months ended September 30, 2022 |
| |
For the
Nine months ended September 30, 2021 |
| ||||||
Revenue | | | | | | | | | | | | | |
Service revenue
|
| | | $ | 12,509,349 | | | | | $ | 11,356,239 | | |
Product sales – kits and reagents
|
| | | | 5,822,891 | | | | | | 20,880,576 | | |
| | | | $ | 18,332,240 | | | | | $ | 32,236,815 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
Accounts receivable
|
| | | $ | 4,227,189 | | | | | $ | 6,452,444 | | |
Less: allowance for doubtful accounts
|
| | | | (155,811) | | | | | | (233,113) | | |
Total Accounts receivable, net
|
| | | $ | 4,071,378 | | | | | $ | 6,219,331 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
Beginning balance
|
| | | $ | 233,113 | | | | | $ | 227,684 | | |
Accrual
|
| | | | 77,482 | | | | | | — | | |
Reversal
|
| | | | (57,116) | | | | | | — | | |
Written off
|
| | | | (77,482) | | | | | | — | | |
Foreign currency translation difference
|
| | | | (20,186) | | | | | | 5,429 | | |
Ending balance
|
| | | $ | 155,811 | | | | | $ | 233,113 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
Test kits and reagents
|
| | | $ | 1,451,085 | | | | | $ | 1,198,578 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
Equipment
|
| | | $ | 1,927,615 | | | | | $ | 1,402,305 | | |
Leasehold improvement
|
| | | | 2,157,983 | | | | | | 2,408,877 | | |
| | | | | 4,085,598 | | | | | | 3,811,182 | | |
Less: Accumulated depreciation
|
| | | | (1,549,940) | | | | | | (1,320,056) | | |
Total Property, plant and equipment, net
|
| | | $ | 2,535,658 | | | | | $ | 2,491,126 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
Other receivables(i)
|
| | | $ | 1,250,413 | | | | | $ | 1,395,790 | | |
Prepaid Income taxes(ii)
|
| | | | 2,484,630 | | | | | | — | | |
VAT recoverable
|
| | | | 139,260 | | | | | | 244,755 | | |
Prepayments
|
| | | | 240,577 | | | | | | 248,854 | | |
Office rental deposits and other deposits
|
| | | | 239,345 | | | | | | 243,635 | | |
| | | | | 4,354,225 | | | | | | 2,133,034 | | |
Less: Provision against other receivables
|
| | | | (1,250,413) | | | | | | (1,395,790) | | |
Total prepayments and other current assets, net
|
| | | $ | 3,103,812 | | | | | $ | 737,244 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
Beginning balance
|
| | | $ | 1,395,790 | | | | | $ | 1,451,709 | | |
Collections
|
| | | | — | | | | | | (89,537) | | |
Foreign currency translation difference
|
| | | | (145,377) | | | | | | 33,618 | | |
Ending balance
|
| | | $ | 1,250,413 | | | | | $ | 1,395,790 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
Salaries
|
| | | $ | 250,367 | | | | | $ | 408,470 | | |
Other taxes payable
|
| | | | 2,207 | | | | | | 88,305 | | |
Others
|
| | | | 28,703 | | | | | | 47,091 | | |
Total accrued liabilities and other payables
|
| | | $ | 281,277 | | | | | $ | 543,866 | | |
| | |
For the Nine Months Ended
September 30, |
| |||||||||
| | |
2022
|
| |
2021
|
| ||||||
Net (loss) income attributable to DiaCarta Ltd shareholders
|
| | | $ | (2,937,244) | | | | | $ | 10,352,678 | | |
Weighted average number of ordinary share outstanding | | | | | | | | | | | | | |
Basic
|
| | | | 28,469,472 | | | | | | 28,469,472 | | |
Diluted
|
| | | $ | 28,469,472 | | | | | | 49,370,099 | | |
Earnings per share | | | | | | | | | | | | | |
Basic
|
| | | | (0.10) | | | | | | 0.36 | | |
Diluted
|
| | | $ | (0.10) | | | | | $ | 0.22 | | |
Fair value per ordinary share at grant date(1)
|
| |
Exercise
price(2) |
| |
Expected
volatility(3) |
| |
Contractual
life(4) |
| |
Risk-free
interest rate(5) |
| |
Expected
dividend(6) |
| ||||||||||||
US$
|
| |
US$
|
| | | | | | | | | | | | | | | | | | | | | | |||
4.49
|
| | | | 4.49 | | | | | | 67.1% | | | |
10 years
|
| | | | 2.91% | | | | | | Nil | | |
| | |
Number of
shares |
| |
Weighted
average exercise price |
| |
Weighted
average remaining contractual life |
| |
Aggregate
intrinsic value |
| ||||||||||||
| | | | | | | | |
US$
|
| |
Years
|
| |
US$
|
| |||||||||
Outstanding as of January 1, 2022
|
| | | | — | | | | | | | | | | | | | | | | | | | | |
Granted
|
| | | | 2,579,500 | | | | | | 4.49 | | | | | | 10 | | | | | | — | | |
Exercised
|
| | | | — | | | | | | | | | | | | | | | | | | | | |
Forfeited
|
| | | | — | | | | | | | | | | | | | | | | | | | | |
Outstanding as of September 30, 2022
|
| | | | 2,579,500 | | | | | | 4.49 | | | | | | 9.75 | | | | | | — | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
Weighted average grant date fair value of option per share
|
| | | $ | 3.37 | | | | | $ | — | | |
Twelve months ending September 30,
|
| |
Amounts
|
| |||
2023
|
| | | $ | 1,556,092 | | |
2024
|
| | | | 1,663,895 | | |
2025
|
| | | | 1,699,415 | | |
2026
|
| | | | 1,734,935 | | |
2027
|
| | | | 1,663,784 | | |
Thereafter
|
| | | | 1,346,896 | | |
Total lease payment
|
| | | | 9,665,017 | | |
Less: imputed interest
|
| | | | (1,154,807) | | |
Present value of operating lease liabilities
|
| | | $ | 8,510,210 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
Weighted average remaining lease term (in years): | | | | | | | | | | | | | |
Operating leases
|
| | | | 5.8 | | | | | | 6.5 | | |
Finance leases
|
| | | | — | | | | | | 0.4 | | |
Weighted average discount rate: | | | | | | | | | | | | | |
Operating leases
|
| | | | 3.7% | | | | | | 3.8% | | |
Finance leases
|
| | | | — | | | | | | 12.5% | | |
No.
|
| |
Name of Related Parties
|
| |
Relationship
|
|
1 | | | Nanjing Diyang Lab Co., Ltd. (“Nanjing Diyang Lab”) | | | A company controlled by the brother of the CEO of the Company | |
2 | | | Veritas Bioscience (“BVCF”) | | | A shareholder of the Company | |
| | |
For the nine
months ended September 30, 2022 |
| |
For the nine
months ended September 30, 2021 |
| ||||||
Interest expense paid to BVCF
|
| | | $ | — | | | | | $ | 14,287 | | |
Labor outsourcing expense to Nanjing Diyang Lab
|
| | | | 84,899 | | | | | | 136,767 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
Loan to Nanjing Diyang Lab(i)
|
| | |
$
|
1,708,091
|
| | | | $ | 1,337,364 | | |
| | |
As of
September 30, 2022 |
| |
As of
December 31, 2021 |
| ||||||
| | |
(unaudited)
|
| | | | | | | |||
Assets: | | | | | | | | | | | | | |
Amounts due from subsidiaries
|
| | | $ | 43,527,616 | | | | | $ | 46,886,275 | | |
Total assets
|
| | | | 43,527,616 | | | | | | 46,886,275 | | |
Liabilities: | | | | | | | | | | | | | |
Convertible bond payable
|
| | | | — | | | | | | 2,152,617 | | |
Deficit in subsidiaries
|
| | | | 19,130,699 | | | | | | 18,143,399 | | |
Total liabilities
|
| | | | 19,130,699 | | | | | | 20,296,016 | | |
Shareholders’ equity: | | | | | | | | | | | | | |
Ordinary shares (USD0.001 par value, 28,469,472 shares authorized; 28,469,472 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively)
|
| | | | 28,469 | | | | | | 28,469 | | |
Series A non-redeemable preferred shares (USD0.001 par value, 7,543,948
shares authorized; 7,543,948 shares issued and outstanding with liquidation preference of $8,000,000 at September 30, 2022 and December 31, 2021, respectively) |
| | | | 7,544 | | | | | | 7,544 | | |
Series B non-redeemable preferred shares (USD0.001 par value,
13,646,217 shares authorized; 12,183,137 shares issued and outstanding with liquidation preference of $36,336,249 at September 30, 2022 and December 31, 2021, respectively) |
| | | | 12,183 | | | | | | 12,183 | | |
Additional paid-in capital
|
| | | | 55,385,930 | | | | | | 54,019,642 | | |
Accumulated deficit
|
| | | | (28,688,454) | | | | | | (25,751,210) | | |
Accumulated other comprehensive loss
|
| | | | (2,348,755) | | | | | | (1,726,369) | | |
Total Shareholder’s Equity
|
| | | | 24,396,917 | | | | | | 26,590,259 | | |
Total liabilities and shareholders’ equity
|
| | | $ | 43,527,616 | | | | | $ | 46,886,275 | | |
| | |
For the nine
months ended September 30, 2022 |
| |
For the nine
months ended September 30, 2021 |
| ||||||
General and administrative expenses
|
| | | $ | (780,851) | | | | | $ | (493,708) | | |
Interest expense
|
| | | | (3,562) | | | | | | (539,246) | | |
Other expense
|
| | | | (421,629) | | | | | | — | | |
Loss before equity in losses of subsidiaries
|
| | | | (1,206,042) | | | | | | (1,032,954) | | |
Equity in (losses) gain of subsidiaries
|
| | | | (1,732,202) | | | | | | 11,385,632 | | |
Net (Loss) Income
|
| | | | (2,937,244) | | | | | | 10,352,678 | | |
Foreign currency translation adjustment
|
| | | | (622,386) | | | | | | 59,728 | | |
Comprehensive (Loss) Income
|
| | | $ | (3,559,630) | | | | | $ | 10,412,406 | | |
| | |
For the nine
months ended September 30, 2022 |
| |
For the nine
months ended September 30, 2021 |
| ||||||
Cash Flows from Operating Activities: | | | | | | | | | | | | | |
Net (Loss) Income
|
| | | $ | (2,937,244) | | | | | $ | 10,352,678 | | |
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
|
| | | | | | | | | | | | |
Interest and amortization of convertible note
|
| | | | 425,191 | | | | | | 539,246 | | |
Equity loss (gain) of subsidiaries
|
| | | | 1,732,202 | | | | | | (11,385,632) | | |
Changes in assets and liabilities: | | | | | | | | | | | | | |
Amounts due from subsidiaries
|
| | | | 780,851 | | | | | | 493,708 | | |
Net Cash Provided by Operating Activities:
|
| | | | — | | | | | | — | | |
Net increase in cash and cash equivalents
|
| | | | — | | | | | | — | | |
Cash and cash equivalents at beginning of year
|
| | | | — | | | | | | — | | |
Cash and cash equivalents at end of the period
|
| | | $ | — | | | | | $ | — | | |
| | |
Page
|
| |||
| | | | A-2 | | | |
| | | | A-2 | | | |
| | | | A-15 | | | |
| | | | A-16 | | | |
| | | | A-16 | | | |
| | | | A-16 | | | |
| | | | A-17 | | | |
| | | | A-17 | | | |
| | | | A-18 | | | |
| | | | A-18 | | | |
| | | | A-18 | | | |
| | | | A-20 | | | |
| | | | A-20 | | | |
| | | | A-20 | | | |
| | | | A-20 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-23 | | | |
| | | | A-23 | | | |
| | | | A-24 | | | |
| | | | A-24 | | | |
| | | | A-25 | | | |
| | | | A-25 | | | |
| | | | A-25 | | | |
| | | | A-25 | | | |
| | | | A-25 | | | |
| | | | A-26 | | | |
| | | | A-26 | | | |
| | | | A-26 | | | |
| | | | A-27 | | | |
| | | | A-27 | | | |
| | | | A-27 | | | |
| | | | A-28 | | | |
| | | | A-29 | | | |
| | | | A-29 | | | |
| | | | A-30 | | | |
| | | | A-30 | | |
| | |
Page
|
| |||
| | | | A-30 | | | |
| | | | A-32 | | | |
| | | | A-34 | | | |
| | | | A-36 | | | |
| | | | A-37 | | | |
| | | | A-37 | | | |
| | | | A-37 | | | |
| | | | A-38 | | | |
| | | | A-38 | | | |
| | | | A-39 | | | |
| | | | A-40 | | | |
| | | | A-41 | | | |
| | | | A-41 | | | |
| | | | A-41 | | | |
| | | | A-42 | | | |
| | | | A-42 | | | |
| | | | A-43 | | | |
| | | | A-43 | | | |
| | | | A-43 | | | |
| | | | A-44 | | | |
| | | | A-44 | | | |
| | | | A-44 | | | |
| | | | A-44 | | | |
| | | | A-45 | | | |
| | | | A-45 | | | |
| | | | A-46 | | | |
| | | | A-46 | | | |
| | | | A-47 | | | |
| | | | A-47 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-48 | | | |
| | | | A-49 | | | |
| | | | A-50 | | | |
| | | | A-51 | | | |
| | | | A-51 | | | |
| | | | A-51 | | | |
| | | | A-52 | | | |
| | | | A-52 | | | |
| | | | A-52 | | | |
| | | | A-52 | | |
| | |
Page
|
| |||
| | | | A-52 | | | |
| | | | A-52 | | | |
| | | | A-53 | | | |
| | | | A-53 | | | |
| | | | A-55 | | | |
| | | | A-56 | | | |
| | | | A-57 | | | |
| | | | A-57 | | | |
| | | | A-58 | | | |
| | | | A-58 | | | |
| | | | A-61 | | | |
| | | | A-61 | | | |
| | | | A-62 | | | |
| | | | A-62 | | | |
| | | | A-63 | | | |
| | | | A-63 | | | |
| | | | A-64 | | | |
| | | | A-64 | | | |
| | | | A-65 | | | |
| | | | A-65 | | | |
| | | | A-65 | | | |
| | | | A-65 | | | |
| | | | A-65 | | | |
| | | | A-65 | | | |
| | | | A-66 | | | |
| | | | A-67 | | | |
| | | | A-67 | | | |
| | | | A-67 | | | |
| | | | A-67 | | | |
| | | | A-67 | | | |
| | | | A-68 | | | |
| | | | A-68 | | | |
| | | | A-69 | | | |
| | | | A-69 | | | |
| | | | A-69 | | | |
| | | | A-70 | | | |
| | | | A-70 | | | |
| | | | A-70 | | | |
| | | | A-70 | | | |
| | | | A-71 | | | |
| | | | A-71 | | |
| | |
Page
|
| |||
| | | | A-72 | | | |
| | | | A-72 | | | |
| | | | A-72 | | | |
| | | | A-73 | | | |
| | | | A-73 | | | |
| | | | A-73 | | | |
| | | | A-74 | | | |
| | | | A-74 | | | |
| | | | A-74 | | | |
| | | | A-74 | | | |
| | | | A-75 | | | |
| | | | A-75 | | | |
| | | | A-75 | | | |
| | | | A-75 | | | |
| | | | A-75 | | |
| NEW HOLDER: | | | | | | ACCEPTED AND AGREED | | | | |
| Print Name: | | |
|
| |
DIACARTA, INC.
|
| | | |
| By: | | |
|
| | By: | | |
|
|
| | | | COMPANY SHAREHOLDER: | | ||||||
| | | | Vertias Bioscience | | ||||||
| | | | By: | | |
/s/ Zhi Yang
|
| |||
| | | | | | | Name: | | | Zhi Yang | |
| | | | | | | Title: | | | Managing Partner | |
| | | | COMPANY SHAREHOLDER: | | ||||||
| | | | Girton Water Ltd UK | | ||||||
| | | | By: | | |
/s/ Zhen Sun
|
| |||
| | | | | | | Name: | | | Zhen Sun | |
| | | | | | | Title: | | | Managing Partner | |
| | | | SPAC: | | ||||||
| | | | HH&L ACQUISITION CO. | | ||||||
| | | | By: | | |
/s/ Richard Qi Li
|
| |||
| | | | | | | Name: | | | Richard Qi Li | |
| | | | | | | Title: | | | Chief Executive Officer and Director | |
| | | | COMPANY: | | ||||||
| | | | DIACARTA, LTD. | | ||||||
| | | | By: | | |
/s/ Aiguo Zhang
|
| |||
| | | | | | | Name: | | | Aiguo Zhang | |
| | | | | | | Title: | | | Chief Executive Officer | |
| | | | DIACARTA, INC. | |
| | | |
By:
|
|
| | | | Name: | |
| | | | Title: | |
| | | | DIACARTA HOLDINGS, INC. | |
| | | |
By:
|
|
| | | | Name: | |
| | | | Title: | |
| | | | HH&L INVESTMENT CO. | |
| | | |
By:
|
|
| | | | Name: | |
| | | | Title: | |
| NEW HOLDER: | | | | | | ACCEPTED AND AGREED | | | | |
| Print Name: | | |
|
| |
DIACARTA, INC.
|
| | | |
| By: | | |
|
| | By: | | |
|
|
| | | | COMPANY SHAREHOLDER: | |
| | | | AIGUO ZHANG | |
| | | |
|
|
| | | | COMPANY SHAREHOLDER: | |
| | | | PAUL OKUNIEFF | |
| | | |
|
|
| | | | COMPANY SHAREHOLDER: | |
| | | | EFFIE HO | |
| | | |
|
|
| | | | COMPANY SHAREHOLDER: | | ||||||
| | | | VERITAS BIOSCIENCE | | ||||||
| | | | By: | | |
Name:
Title: |
| |
| | | | COMPANY SHAREHOLDER: | | ||||||
| | | | GIRTON WATER LTD. | | ||||||
| | | | By: | | |
Name:
Title: |
| |
| | | | SPAC: | | ||||||
| | | | HH&L ACQUISITION CO. | | ||||||
| | | | By: | | |
Name:
Title: |
| |
| | | | COMPANY: | | ||||||
| | | | DIACARTA, LTD. | | ||||||
| | | | By: | | |
Name:
Title: |
| |
| “Affiliate” | | | in respect of a person, means any other person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such person, and (a) in the case of a natural person, shall include, without limitation, such person’s spouse, parents, children, siblings, mother-in-law and father-in-law and brothers and sisters-in-law, whether by blood, marriage or adoption or anyone residing in such person’s home, a trust for the benefit of any of the foregoing, a company, partnership or any natural person or entity wholly or jointly owned by any of the foregoing and (b) in the case of an entity, shall include a partnership, a corporation or any natural person or entity which directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such entity. | |
| “Applicable Law” | | | means, with respect to any person, all provisions of laws, statutes, ordinances, rules, regulations, permits, certificates, judgments, decisions, decrees or orders of any governmental authority applicable to such person. | |
| “Articles” | | | means these second amended and restated articles of association of the Company. | |
| “Audit Committee” | | | means the audit committee of the board of directors of the Company established pursuant to the Articles, or any successor committee. | |
| “Auditor” | | | means the person for the time being performing the duties of auditor of the Company (if any). | |
| “Business Combination” | | | means a merger, share exchange, asset acquisition, share purchase, reorganisation or similar business combination involving the Company, with one or more businesses or entities (the “target business”), which Business Combination: (a) as long as the securities of the Company are listed on the New York Stock Exchange, must occur with one or more target businesses that together have an aggregate fair market value of at least 80 per cent of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the signing of the definitive agreement to enter into such Business | |
| | | | Combination; and (b) must not be solely effectuated with another blank cheque company or a similar company with nominal operations. | |
| “business day” | | | means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorised or obligated by law to close in New York City. | |
| “Clearing House” | | | means a clearing house recognised by the laws of the jurisdiction in which the Shares (or depositary receipts therefor) are listed or quoted on a stock exchange or interdealer quotation system in such jurisdiction. | |
| “Class A Share” | | | means a Class A ordinary share of a par value of US$0.0001 in the share capital of the Company. | |
| “Class B Share” | | | means a Class B ordinary share of a par value of US$0.0001 in the share capital of the Company. | |
| “Company” | | | means the above named company. | |
| “Company’s Website” | | | means the website of the Company and/or its web-address or domain name (if any). | |
| “Compensation Committee” | | | means the compensation committee of the board of directors of the Company established pursuant to the Articles, or any successor committee. | |
|
“Designated Stock Exchange”
|
| | means any United States national securities exchange on which the securities of the Company are listed for trading, including the New York Stock Exchange. | |
| “Directors” | | | means the directors for the time being of the Company. | |
| “Dividend” | | | means any dividend (whether interim or final) resolved to be paid on Shares pursuant to the Articles. | |
| “Electronic Communication” | | | means a communication sent by electronic means, including electronic posting to the Company’s Website, transmission to any number, address or internet website (including the website of the Securities and Exchange Commission) or other electronic delivery methods as otherwise decided and approved by the Directors. | |
| “Electronic Record” | | | has the same meaning as in the Electronic Transactions Act. | |
| “Electronic Transactions Act” | | | means the Electronic Transactions Act (2003 Revision) of the Cayman Islands. | |
| “Equity-linked Securities” | | | means any debt or equity securities that are convertible, exercisable or exchangeable for Class A Shares issued in a financing transaction in connection with a Business Combination, including but not limited to a private placement of equity or debt. | |
| “Exchange Act” | | | means the United States Securities Exchange Act of 1934, as amended, or any similar U.S. federal statute and the rules and regulations of the Securities and Exchange Commission thereunder, all as the same shall be in effect at the time. | |
| “Founders” | | | means all Members immediately prior to the consummation of the IPO. | |
| “Independent Director” | | | has the same meaning as in the rules and regulations of the Designated Stock Exchange or in Rule 10A-3 under the Exchange Act, as the case may be. | |
| “IPO” | | | means the Company’s initial public offering of securities. | |
| “Member” | | | has the same meaning as in the Statute. | |
| “Memorandum” | | | means the second amended and restated memorandum of association of the Company. | |
|
“Minimum Member”
|
| | means a Member meeting the minimum requirements set forth for eligible members to submit proposals under Rule 14a-8 of the Exchange Act or any applicable rules thereunder as may be amended or promulgated thereunder from time to time. | |
| “Nominating and Corporate Governance Committee” | | | means the nominating and corporate governance committee of the board of directors of the Company established pursuant to the Articles, or any successor committee. | |
| “Officer” | | | means a person appointed to hold an office in the Company. | |
| “Ordinary Resolution” | | | means a resolution passed by a simple majority of the Members as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting, and includes a unanimous written resolution. In computing the majority when a poll is demanded regard shall be had to the number of votes to which each Member is entitled by the Articles. | |
| “Over-Allotment Option” | | | means the option of the Underwriters to purchase up to an additional 15 per cent of the firm units (as described in the Articles) issued in the IPO at a price equal to US$10 per unit, less underwriting discounts and commissions. | |
| “Preference Share” | | | means a preference share of a par value of US$0.0001 in the share capital of the Company. | |
| “Public Share” | | | means a Class A Share issued as part of the units (as described in the Articles) issued in the IPO. | |
| “Redemption Notice” | | | means a notice in a form approved by the Company by which a holder of Public Shares is entitled to require the Company to redeem its Public Shares, subject to any conditions contained therein. | |
| “Register of Members” | | | means the register of Members maintained in accordance with the Statute and includes (except where otherwise stated) any branch or duplicate register of Members. | |
| “Registered Office” | | | means the registered office for the time being of the Company. | |
| “Representative” | | | means a representative of the Underwriters. | |
| “Seal” | | | means the common seal of the Company and includes every duplicate seal. | |
| “Securities and Exchange Commission” | | |
means the United States Securities and Exchange Commission.
|
|
| “Share” | | | means a Class A Share, a Class B Share or a Preference Share and includes a fraction of a share in the Company. | |
| “Special Resolution” | | | subject to Article 31.4, has the same meaning as in the Statute, and includes a unanimous written resolution. | |
| “Sponsor” | | | means HH&L Investment Co., a Cayman Islands exempted company, and its successors or assigns. | |
| “Statute” | | | means the Companies Act (2021 Revision) of the Cayman Islands. | |
|
“Tax Filing Authorised Person”
|
| | means such person as any Director shall designate from time to time, acting severally. | |
| “Treasury Share” | | | means a Share held in the name of the Company as a treasury share in accordance with the Statute. | |
| “Trust Account” | | | means the trust account established by the Company upon the consummation of its IPO and into which a certain amount of the net proceeds of the IPO, together with a certain amount of the proceeds of a private placement of warrants simultaneously with the closing date of the IPO, will be deposited. | |
| “Underwriter” | | | means an underwriter of the IPO from time to time and any successor underwriter. | |
|
Name:
[ ] |
| |
Address:
[ ] |
|
| | | |
[Name]
Sole Incorporator |
|
| | |
Page
|
| |||
| | | | I-1 | | | |
| | | | I-1 | | | |
| | | | I-1 | | | |
| | | | I-1 | | | |
| | | | I-1 | | | |
| | | | I-1 | | | |
| | | | I-1 | | | |
| | | | I-1 | | | |
| | | | I-4 | | | |
| | | | I-6 | | | |
| | | | I-7 | | | |
| | | | I-8 | | | |
| | | | I-8 | | | |
| | | | I-8 | | | |
| | | | I-9 | | | |
| | | | I-9 | | | |
| | | | I-9 | | | |
| | | | I-10 | | | |
| | | | I-10 | | | |
| | | | I-10 | | | |
| | | | I-11 | | | |
| | | | I-11 | | | |
| | | | I-11 | | | |
| | | | I-11 | | | |
| | | | I-11 | | | |
| | | | I-11 | | | |
| | | | I-11 | | | |
| | | | I-12 | | | |
| | | | I-12 | | | |
| | | | I-12 | | | |
| | | | I-12 | | |
| | |
Page
|
| |||
| | | | I-12 | | | |
| | | | I-12 | | | |
| | | | I-13 | | | |
| | | | I-13 | | | |
| | | | I-13 | | | |
| | | | I-13 | | | |
| | | | I-14 | | | |
| | | | I-14 | | | |
| | | | I-14 | | | |
| | | | I-14 | | | |
| | | | I-14 | | | |
| | | | I-14 | | | |
| | | | I-14 | | | |
| | | | I-14 | | | |
| | | | I-15 | | | |
| | | | I-15 | | | |
| | | | I-15 | | | |
| | | | I-15 | | | |
| | | | I-15 | | | |
| | | | I-16 | | | |
| | | | I-16 | | | |
| | | | I-16 | | | |
| | | | I-16 | | | |
| | | | I-16 | | | |
| | | | I-16 | | | |
| | | | I-16 | | | |
| | | | I-16 | | | |
| | | | I-17 | | | |
| | | | I-17 | | | |
| | | | I-17 | | | |
| | | | I-18 | | | |
| | | | I-18 | | |
| | |
Page
|
| |||
| | | | I-18 | | | |
| | | | I-18 | | | |
| | | | I-19 | | | |
| | | | I-19 | | | |
| | | | I-19 | | | |
| | | | I-19 | | | |
| | | | I-19 | | | |
| | | | I-20 | | | |
| | | | I-20 | | | |
9.11
Limitation on Indemnification
|
| | | | | | |
9.12
Indemnification of Employees and Agents
|
| | | | | | |
9.13
Primacy of Indemnification
|
| | | | | | |
| | | | I-21 | | | |
| | | | I-21 | | |
|
Exhibit
Number |
| |
Description
|
|
| 10.25^ | | | | |
| 21.1^ | | | | |
| 23.1 | | | | |
| 23.2 | | | | |
| 23.3* | | | Consent of White & Case LLP (included as part of Exhibit 5.1 hereto). | |
| 23.4* | | | Consent of White & Case LLP (included as part of Exhibit 8.1 hereto). | |
| 24.1^ | | | | |
| 99.1* | | | Form of Preliminary Proxy Card. | |
| 99.2^ | | | | |
| 99.3^ | | | | |
| 99.4^ | | | | |
| 99.5^ | | | | |
| 101.INS | | | XBRL Instance Document | |
| 101.SCH | | | XBRL Taxonomy Extension Schema Document | |
| 101.CAL | | | XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | | | XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | | | XBRL Taxonomy Extension Labels Linkbase Document | |
| 101.PRE | | | XBRL Taxonomy Extension Presentation Linkbase Document | |
| 107^ | | | |